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1 Introduction 
1.1 The Ubiquitin-Conjugating System 
  The ubiquitin-conjugating system (UCS), describes a system in which intracellular 
proteins are selectively targeted by the covalent ligation of a 76-amino acid residue called 
ubiquitin. Typically, ubiquitinated proteins are targeted for degradation by the 26S proteasome 
– a major enzyme that catalyses the degradation of intracellular proteins – in this, its main 
capacity  (in  which  the  overall  system  is  usually  referred  to  as  the  ubiquitin-proteasome 
system (UPS) (Figure 1)), the UCS plays a crucial role in a number of basic cellular events 
such as cell signalling, signal transduction, metabolism and the immune and inflammatory 
response (Pagano (1997), Ben-Neriah (2002)). It is believed that the UCS is involved in the 
rapid  degradation  of  30%  or  more  of  newly  made  proteins  within  a  cell  (Schubert  et  al. 
(2000)). However, more recently the ubiquitin signal has also been connected  with many 
other cell processes that function independently of the proteasome, including endocytosis, 
vesicle  fusion,  DNA  repair,  transcriptional  silencing  and  ribosomal  function  (Weissman 
(2001)). It has been shown that up to 20% of cellular proteins are conjugated to ubiquitin at 
any one time within a cell (under standard cellular conditions) (Welchman et al. (2005)). The 
emergence of protein modification by ubiquitin as a critical regulatory process in virtually all 
aspects of cell biology has been acknowledged by the scientific community: the 2004 Nobel 
Prize  in  Physiology  or  Medicine  was  awarded  for  the  discovery  of  Ubiquitin-mediated 
proteolysis.  The  fates  of  the  different  ubiquitinated  protein  substrates  in  all  of  these 
intracellular processes are predominantly determined by the number of ubiquitin molecules 
involved, and the ‘linkage’ that exists between them.   2
 
Figure 1 – Schematic diagram of the ubiquitin-proteasome system describing the sequential 
action of the three main enzymes – E1, E2 and E3 – in recruiting protein substrates to the 
26S proteasome. E1 – ubiquitin-activating enzyme, E2 – ubiquitin-conjugating enzyme, E3 – 
ubiquitin ligase. (Image by W. Hilt, Stuttgart University). 
  Ubiquitin  protein  ligation  is  catalysed  by  the  sequential  actions  of  three  main 
enzymes; a ubiquitin-activating enzyme (Enzyme(E)1), a ubiquitin-conjugating enzyme (E2) 
and a ubiquitin ligase (E3). The transfer of ubiquitin to a substrate protein is initiated by an E1 
activation step. The activation reaction is dependent on ATP (Adenosine TriPhosphate), the 
hydrolysis of which is catalysed by the E1 activating enzyme, to form a high-energy mixed 
anhydride intermediate - ubiquitin adenylate - between the C-terminus of ubiquitin and AMP 
(Adenosine MonoPhosphate). This is then nucleophilically attacked by a conserved cysteine 
residue of the E1 enzyme, which activates the ubiquitin through the formation of a thiolester 
linkage  (covalent  bond  formed  with  a  sulfhydryl  group  (-SH)  and  the  elimination  of  the 
elements of water) with the C-terminal glycine residue (G76) of ubiquitin (Schindelin (2005)). 
Once the ubiquitin is activated, the E1-ubiquitin thiol ester complex undergoes ‘transthiolation’ 
with the active-site cysteine residue of an E2 ubiquitin-conjugating enzyme forming an E2-  3
ubiquitin thiol ester complex (Argiles et al. (1998)). The ubiquitin can then be transferred from 
the E2 active site to the ε-amino group (ε for epsilon, describing the fifth atom in a side chain) 
of the substrate protein’s lysine residue by way of isopeptide bond formation (Hershko et al. 
(1983)), but only with the assistance of an E3 ubiquitin-protein ligase. Three major classes of 
E3  have  been  identified,  termed  the  HECT  (Homologous  to  E6-associated  protein  C-
Terminus), RING finger (Really Interesting New Gene) and U-box E3s. HECT E3s have their 
name  derived  form  the  archetypical  E3  involved  in  the  ubiquitination  (leading  to  the 
degradation) of the tumour suppressor protein p53 by the human papilloma virus’ E6 protein 
and are characterised by a central cysteine domain within the HECT motif, which acts as an 
acceptor for ubiquitin. RING finger and U-box E3 motifs, who differ only by the latter’s relative 
structural instability owed to a lack of key residues required for metal chelation, do not appear 
to  have  a  direct  catalytic  site  for  ubiquitin  (Ardley  &  Robinson  (2005),  Eddins  &  Pickart 
(2005)). Thus it follows that if the E3 involved in the particular ubiquitin conjugation cascade 
belongs  to  the  HECT  domain  family,  substrate  protein  ubiquitination  is  achieved  by  the 
ubiquitin firstly being transferred to the active site cysteine residue of the E3; whereas if the 
E3 belongs to the RING finger or U-box domain families, the ubiquitin is transferred directly to 
the substrate protein’s amino group from the E2 enzyme. 
It is important to note that the ubiquitin conjugation system described above follows a 
hierarchical organisation. Only a single E1 is responsible for the initial activation and transfer 
of activated ubiquitin, whilst the E2 family of enzymes consists of over 20 members, all with 
differing  substrate  preferences  and  subcellular  locations.  Conjugation  to  the  substrate 
proteins is in turn assisted by hundreds of E3 enzymes which fine-tune the specificity set forth 
by the E2s (Pickart (2001)). Thus it can be seen, that the combinatorial diversity of a set of 
E2s interacting with a large variety of different E3s endows the ubiquitin-proteasome system 
with an exquisite specificity in the recognition of potential substrates among thousands of 
cellular proteins. 
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1.1.1 Polyubiquitination 
Most often, substrate conjugation through the cascade of enzymes outlined above 
results in polyubiquitin chain formation. Specific lysine residues of each ubiquitin molecule in 
the extending chain serves as a site for further ubiquitination. The ubiquitin molecule itself 
contains seven lysine residues at amino acid positions 6, 11, 27, 29, 33, 48, and 63 (Figure 
2). 
 
Figure  2  –  Ribbon  structure  of  ubiquitin  showing  internal  lysine  residues  (K)  and  the  C-
terminal glycine residue (G76) (www.ks.uiuc.edu/training/tutorials/vmd/tutorial-html/img89.gif). 
Polyubiquitin chains linked throughout via lysine(K)48-glycine(G)76 isopeptide bonds 
represent  the  predominant  in  vivo  targeting  signal  for  26S  proteasomal  degradation  (a 
multicatalytic protease complex that degrades substrates into small peptides and amino acids 
– see below) of substrate proteins in the UPS (Pickart & Fushman (2004)). Work done by 
Thrower et al. elucidated that in lysine 48 (Lys
48)-linked chains the critical number of ubiquitin 
moieties  required  to  recruit  the  26S  proteasome  was  four  (tetraubiquitin)  (Thrower  et  al. 
(2000)). This is due to the spatial arrangement of hydrophobic patches located at Lys
9, Ile
44 
and Val
70 within the tetraubiquitin unit being essential for the efficient recognition  by the 
proteasome (Ulrich (2002)). As well as Lys
48-linked chains, there is evidence to support that 
atypical  chain  formation  through  Lys
29  and  Lys
11  could  also  be  competent  proteasomal   5
targeting signals, as both chains are able to bind to the 26S proteasome in vitro (Pickart & 
Fushman (2004)). In contrast, Lys
63-linked chains act as non-proteolytic signals in several 
intracellular pathways, such as DNA repair, transcriptional regulation, protein trafficking and 
ribosomal protein synthesis (Weissman (2001)). One example is the regulation of a DNA 
polymerase processivity factor called PCNA (Proliferating Cell Nuclear Antigen); PCNA is part 
of a DNA damage tolerance pathway which is crucial in the error free repair of damaged DNA. 
After initial mono-ubiquitination of PCNA, its activation requires the synthesis of a Lys
63-linked 
polyubiquitin chain – this is brought about by the Ubc13/ Mms/ Rad 5 complex, where UBC13/ 
Mms are an E2/ UEV (Ubiquitin E2 Variant – an E2 homologue minus the active site cysteine 
residue) complex and Rad 5 is the RING E3 which targets the E2/ UEV complex to PCNA to 
allow Lys
63-linked chain formation (Eddins & Pickart (2005)). The less frequently used Lys
27 
and Lys
6 polyubiquitin chains additionally provide functions that are distinct from proteasomal 
targeting.  Lys
27-linked  polyubiquitin  chains  have  shown  not  to  induce  proteasomal 
degradation directly, but specifically promote the association of BAG-1 (Bcl-2-Asscociated 
athanoGene-1)  with the 26S proteasome (Pickart & Fushman (2004)). In this case, Lys
27 
polyubiquitin chain formation allows BAG-1 to act as a coupling factor between misfolded 
proteins  bound  by  molecular  chaperone  Hsp70  and  the  26S  proteasomal  complex 
(Rechsteiner  (2005)).  Not much  work  has  been  done  on  Lys
6-linked  polyubiquitin  chains, 
though the fact their formation is catalysed by the Brca1 (Breast-cancer susceptibility gene 
1)/ Bard1 (BRCA-associated RING domain 1) E3 heterodimer, which seem to associate at 
sites of DNA double strand break repair after exposure to ionising radiation, indicates a role in 
DNA  repair (Morris  &  Solomon  (2004)). Taken together,  the  generation  of these  different 
polyubiquitin chains (6 have been discussed above) provides an important level of complexity 
to facilitate all the different roles of the UCS.  
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1.1.2 Monoubiquitination and Endocytic Trafficking 
As outlined above, the cascade of enzymes that make up the UCS usually give rise to 
polyubiquitin chain formation, the nature of which (lysine linkage) determines whether the 
proteasome  is  recruited  in  the  predominant  UPS  pathway,  or  a  non-proteolytic  signal  is 
established  in  an  alternate  intracellular  pathway.  In  addition  to  Lys
63,  Lys
27  and  Lys
6 
polyubiquitin chains, mono-ubiquitination has also been recently elucidated as an important 
non-proteolytic  signal  –  most  notably  in  the  endocytic  trafficking  of  proteins,  specifically 
mammalian growth factor receptors targeted to the lysosyme. 
In mammalian  cells, many  plasma  proteins  are  ubiquinated  in  response  to  ligand 
binding.  These  include  the  RTKs  (Receptor  Tyrosine  Kinases)  EGFR  (Epidermal  Growth 
Factor  Receptor),  PDGFR  (Platelet  Derived  Growth  Factor  Receptor),  FGF  (Fibroblast 
Growth Factor) and HGF (Hepatocyte Growth Factor – also referred to as Met) (Marmor 
&Yarden (2004)). When the ligand binds to them, their tyrosine kinase activity  is activated 
catalysing autophosphorylation which is then recognised by an E3 ligase, such as the RING 
finger c-Cbl – which is thought to be the main E3 that mediates RTK ubiquitination (Marmor 
&Yarden (2004)). For those targeted to the lysosome, this results in mono-ubiquitination at 
multiple lysine residues on the substrate RTK, which promote its internalisation by recruiting 
multiple sorting adapters which recognise two hydrophobic patches on the mono-ubiquitin 
molecules around residues Phe
4 and Ile
44, through a wide variety of ubiquitin-binding motifs, 
e.g.  UIM  (Ubiquitin-Interacting  Motif)  and  UBA  (UBiquitin-Associated)  domains  (Marmor  & 
Yarden (2004)). Once internalised these activated receptors are sorted into clathrin-coated 
pits by a multiprotein complex. The most stringent requirement of ubiquitin in the progression 
through the endocytic process is at the trafficking from early to late endosome/ MVB (Multi-
Vesicular Bodies), where Cbl sustained ubiquitination ensures that the RTK is sorted into the 
MVB and not the recycling endosome, which delivers back to the plasma membrane. The 
sorting  of  the  receptors  into  the  internal  vesicles  of  the  MVB  requires  the  sequential 
engagement  of  several  multi-protein  complexes  such  as  ESCRT  (Endosomal  Sorting 
Complex Required for Transport) and its related components, which all have the ability to bind 
ubiquitin. This then allows the ubiquitinated receptors to be passed down from one complex to 
another, which with the invagination of the limiting membrane of the MVB, secures them in   7
internal  vesicles.  Finally,  the  MVB  organelles  gradually  accumulate  lysosomal  acidic 
proteases and fuse with the lysosome, resulting in degradation of the contents of the internal 
vesicles. 
  Thence it not only can be seen that mono-ubiquitination as well as polyubiquitination 
play large roles in key cellular events, but it is also important to note that ubiquitin is a major 
player  in  the  two  major  systems  controlling  protein  degradation  within  Eukaryotic  cells: 
lysosomal and proteasomal. 
1.1.3 A Fourth UCS Enzyme? 
Very recent investigations has lent significant credence to work first done in 1999 by 
Koegl et al. which indicated the existence of a forth enzyme in the UCS enzyme cascade (E1, 
E2 and E3 being the first three – see above) termed E4 by the authors (polyubiquitin chain 
conjugation factor). It is hypothesised that E4 complexes may regulate the selection of lysine 
residues used for ubiquitin-ubiquitin linkages during polyubiquitin-chain assembly, and could 
also determine whether mono- or polyubiquitination is to be implemented. This would suggest 
that  the  fates  of  proteins  in  the  UCS  can  be  regulated  even  after  E3  ubiquitin  ligase 
involvement, which would endow the system with an extra level of complexity to control its 
wide ranging intracellular roles, at the level of ubiquitin-chain elongation. UFD2 (Ubiquitin 
Fusion Degradation model 2) defines the first identified family of E4s in humans, which is 
characterised by a conserved C-terminal U-box (refer to section 1.1). Biochemical and genetic 
studies have revealed that UFD2 binds to substrates conjugated with one to three ubiquitin 
molecules, and catalyses the addition of further ubiquitin moieties in the presence of E1, E2 
and  E3s,  yielding  polyubiquitinated  substrates  that  are  targeted  for  the  26S  proteasome 
(Hoppe et al. (2005)). In addition, work done by Saeki et al. (2004) has shown that yeast 
UFD2 (UFD-2) catalyses a ‘linkage switch’ from Lys
29, used for mono-ubiquitination, by further 
elongation of the ubiquitin chain through Lys
48. A different type of E4 enzyme is represented 
by p300 which does not contain a U-box motif, it has been shown to polyubiquitinate mono-
ubiquitinated  species  of  the  tumour  suppressor  p53  in  collaboration  with  the  E3  enzyme 
MDM2 (Murine Double Minute clone 2 oncoprotein) (Hoppe et al. (2005)).    8
Most of the evidence so far unearthed relevant to E4s tend towards ubiquitinated 
substrate  protein  modification  to  Lys
48-linked  polyubiquitin  chains  of  four  to  six  ubiquitin 
molecules – which promotes optimal binding to RAD23 and DSK2 (two well described yeast 
proteins)  -  which  are  the  key  mediators  in  the  delivery  of  the  substrates  to  the  26S 
proteasome. Thence, the extra level of complexity/ control endowed upon the UCS by E4 
polyubiquitin chain conjugation factors may only be of particular relevance to the UCS’s key 
role in recruiting the proteasome, i.e. the UPS. 
1.1.4 The Proteasome (inv. UPS) 
Almost all proteins that are damaged, abnormal or foreign (viral) are degraded by the 
26S proteasome – a single, highly conserved 2.5 MDa (MegaDalton) multisubunit enzyme 
which  is  ATP-dependent  (Glickman  (2000)).  The  26S  proteasome  (also  known  as  the 
haloenzyme) is made up of at least 45 subunits (Figure 3), which can be broken down into 
two major subcomplexes: the 20S core particle (CP), and the 19S regulatory complex (RC). 
 
Figure  3  –  Schematic  representation  of  the  26S  proteasome’s  subunits  in  S.cerevisiae  
displaying the relative positions of the six homologous ATPases (Rpts 1-6) and eleven non 
ATPase subunits of the 19S regulatory complex, as well as the two alpha (a) and beta (b) 
rings of the 20S core particle. (www.genome.ad.jp).   9
  The CP (20S) is barrel shaped structure made up of four rings of seven subunits 
each, termed a and b rings. The two inner b-rings (outer being a) realise the proteolytic active 
sites facing inwards into the sequestered proteolytic inner chamber (which can be compared 
to the size of serum albumin (Rechsteiner (2005))), while the a-rings seal off the chamber 
from  the  external  solvent  (Groll  et  al.  (1997)).  One  regulatory  particle  is  attached  to  the 
surface of either (outer) a-ring of the CP to form the complete 26S proteasome (Figure 3). It 
should  be  noted  here  that  what  has  been  deemed  the  26S  proteasome  by  conventional 
literature, could in fact exist as the 30S proteasome in vivo; with one 19S RC disassociating 
from one of the a-rings during the purification process (Dahlmann (2005)).  
The 19S RC itself can be broken down into two multisubunit substructures – a lid and 
a  base.  The  base  contains  six  homologous  ATPases  (S7,  S4,  S6,  S10b,  S6’  and  S8  - 
mammalian subunit nomenclature following the chronology of the yeast subunit nomenclature 
which  was  discovered  first  (Rpts  1-6))  which  are  thought  to  unfold  polyubiquitinated 
substrates and translocate them into the CP (Braun et al. (1999)) The remainder of the base 
is made up of three non-ATPase subunits (S2, S1 and S5a (Rpns 1,2 and 10)) which can all 
bind polyubiquitin chains or UBL (UBiquitin-Like) domains. The lid of the RP is made up of a 
further 8 non ATPase subunits, the majority of which contain PCI domains (so called for their 
occurrence in Proteasome, Cop9 signalosome, and the eukaryotic Initiation factor 3 subunits) 
which are thought to mediate subunit-subunit interactions. The most important subunit in the 
lid seems to be a metalloisopeptidase – S13/ Rpn 11 – that removes ubiquitin chains from the 
tagged substrate prior to its translocation into the inner chamber for degradation (Rechsteiner 
(2005)).   
The lid and base of the 19S RC orchestrate four of the six steps required in the 
effective proteolysis of a ubiquitinated protein: (1) polyubiquitinated substrate association with 
S1,  S2  and  S10  subunits;  (2)  substrate  unfolding  through  the  base’s  six  ATPases;  (3) 
detachment of polyubiquitin chain from the substrate by S13, and (4) translocation of the 
polypeptide  into  the  20S  central  chamber  by  threading  through  a  channel  in  the  20S 
proteasome's a-ring (a process thought to be controlled by the 19S base’s six ATPases as   10
they  progressively  unravel  substrates  –  ‘pumping’  the  substrate  in  a  C-  or  N-terminal 
direction) (Rechsteiner (2005)).  
The  fifth  and  decisive  step  in  ubiquitinated  protein  proteolysis  is  peptide  bond 
cleavage, the mechanism of which relies on the positioning of N-terminal threonine residues 
within the seven subunits of the b-rings of the 20S CP. This residue is positioned just at the 
open cleft between two layers of b-sheets (subunits within the a-rings realise an extra a-helix 
in this position), and owed to its nucleophillic ‘attacking’ properties forms the proteolytically 
active sites within the 20S CP (Dahlmann (2005)). For reasons that are unclear at present, 
only three of the seven threonine residues fully function as active sites within each of the b-
ring subunits (subunits b1, b2 and b5), each with their own cleavage site specificity: b1 – 
caspase-like; b2 – trypsin-like, and b5 – chymotrypsin-like (Groll et al. (2005)). On average, 
these three (x 2) threonine active sites allow the 20S CP to produce cleavage fragments with 
a  length  of  seven  to  eight  amino  acids,  with  a  range  in  length from  three  to  twenty-five 
(Dahlmann  (2005)).  The  peptide  products  of  the  proteasome  are  short  lived,  and  do  not 
accumulate in the cell under normal (healthy) physiological conditions. These peptides are 
most probably hydrolysed by an array of downstream proteases and aminopeptidases. The 
release  of  the  peptide  products  defines  the  final  step  (step  6)  in  effective  proteolysis  of 
ubiquitinated proteins, and includes the release of ubiquitin, polyubiquitin chains and ubiquitin 
still attached to short, residual chains of amino acids (Hershko and Ciechanover (1998)). The 
latter  two  of  these  products  are  substrates  for  certain  DeUbiquitinating  Enzymes  (DUBs) 
(S13/ Rpn 11 of the proteasome’s 19S RC belongs to this family) which are able to cleave the 
isopeptide bonds that ubiquitin forms with itself in polyubiquitin chains, and lysine residues of 
its substrate proteins. DUBs in this instance ensure that ubiquitin is recycled back into the 
cell’s free pool of monomeric ubiquitin, a process which is critical in maintaining the UCS’s 
overall efficiency and thus effective functioning. 
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1.2 Deubiquitinating Enzymes (DUBs) 
  Based on the mechanism of catalysis, the 561 proteases realised within the human 
body (Puente & Lopez-Otin (2004)) are divided into five classes – aspartic, metallo, serine, 
threonine and cysteine proteases. DUBs are generally of the cysteine variety, although there 
are  some  that  belong  to  the  metallo  class.  It  has  been  suggested  that  humans  express 
approximately 79 functional DUBs (Nijman et al. (2005)). 
  Cysteine proteases rely on a catalytic triad of residues for their hydrolase activity – a 
defining cysteine harbouring the all important thiol group, an adjacent histidine which assists 
deprotonation of the cysteine, and an aspartate residue which polarises the histidine. The 
general biochemical nature of cysteine protease catalysis can be summed up thus: (1) the 
carbonyl (carbon atom double bonded to an oxygen atom) of the scissile (a peptide bond that 
is hydrolysed by a peptidase) peptide bond between ubiquitin and the target is nucleophilically 
attacked by the DUBs cysteine; (2) the oxyanion (an oxygen containing, negatively charged 
polyatomic ion) containing intermediate is stabilised by the main chain of the catalytic cysteine 
and a glutamate, glutamine or asparagine – the so-called oxyanion hole; (3) the target protein 
is released, and a covalent ubiquitin/ DUB intermediate is formed; and (4) a water molecule 
reacts with this intermediate to separate and release the ubiquitin and DUB (Nijman et al. 
(2005)).  
  Unlike cysteine proteases, metalloproteases generally employ a Zn
2+ atom stabilised 
by two histidines and an aspartate to bind and polarise a water molecule which can form a 
(noncovalent) substrate intermediate. Proton transfer from another water molecule can then 
release the DUB (Nijman et al. (2005)). 
  DUBs have four distinct functions within the UPS (encompassing the UCS): they are 
responsible for processing inactive ubiquitin precursors, they are able to remove ubiquitin 
from  proteins  inappropriately  targeted  to  the  proteasome  (a  suggested  proofreading 
mechanism  (Lam  et  al.  (1997))  -  this  includes  small  intracellular  nucleophiles  such  as 
glutathione and polyamines which are of considerable abundance and thus have the potential 
to rapidly use up free ubiquitin, DUBs efficiently remove ubiquitin from its conjugates prior to 
proteolysis of the substrate protein – thus allowing the ubiquitin to be recycled, and they   12
disassemble unanchored ubiquitin oligomers that can compete with ubiquitinated substrates 
for the ubiquitin-binding sites within the proteasome’s 19S RC – which would hinder its protein 
turnover (Amerik and Hochstrasser (2004)). 
  DUBs specifically cleave ubiquitin-linked molecules after the terminal carbonyl of the 
final glycine residue at position 76. The target bond is generally an isopeptide bond, except 
with  ubiquitin  C-terminally  extended  precursors,  where  a  standard  peptide  bond  requires 
hydrolysis. 
  The DUBs belonging to the cysteine protease class (see above) can be further sub-
categorised into four classes based on their ubiquitin protease domains. The largest and most 
diverse  of  these  subclasses  are  the  UBiquitin-Specific  Proteases  (UBPs  (Amerik  and 
Hochstrasser (2004)) or USPs (Nijman et al. (2005))). The second ubiquitin-specific cysteine 
protease subclass is made up of the Ubiquitin Carboxyl-Terminal Hydrolases (UCHs), which 
were among the first DUBs to be described. The remaining two known subclasses have been 
discovered only recently; a bioinformatics approach led to the identification of the Ovarian 
TUmour (OTU) subclass (Makarova et al. (2000)), and the fourth cysteine protease DUB 
subclass, for which ataxin-3 is the only demonstrated member to date, is characterised by a 
domain called the Josephin domain (Amerik and Hochstrasser (2004)) or Machado-Joseph 
Disease (MJD) protein domain (Nijman et al. (2005)). DUBs belonging to the metalloprotease 
class  all  have  a  ubiquitin  protease  domain  called  JAMM  (JAB1/  MPN/  Mov34 
metalloenzyme), and is represented by the S13/ Rpn 11 subunit of the 19S RC. 
1.2.1 Ubiquitin-Specific Proteases (UBPs/ USPs) 
  It has been postulated that the reason the UBP subclass outnumber the other 4 DUB 
(sub)classes by such a large degree (UCH and MJD by around 13:1, and the OTU and JAMM 
subclasses by 4:1 (Nijman et al. (2005)) is that the UBPs coevolved in an intimate relationship 
with the ubiquitin E3 ligases, so as the number of E3s increased during evolution, so did the 
number of UBPs (Semple (2003)). 
  Crystal  structures  of  ubiquitin  and  a  human  UBP  –  the  Herpesvirus-Associated 
Ubiquitin-Specific Protease (HAUSP) – has indicated an active site in a deep cleft between   13
two of three major globular domains, harbouring the protease’s catalytic triad – a nucleophillic 
cysteine (Cys 223) and a His box containing a histidine and an aspartate (His 464 and Asp 
481). In free HAUSP, the Cys 223 and His 464 are too far apart for a ‘productive’ interaction, 
whereas ubiquitin binding causes a major change in the conformation of the catalytic cleft, 
bringing them within binding distance (Hu et al. (2002)). 
  An important example of a UBP DUB within the UPS is that of isopeptidase T (Ubp 14 
in yeast), one of the enzymologically best characterised DUBs (Wilkinson et al. (1995)). It acts 
almost  exclusively  on  unanchored  ubiquitin  chains, and  its  yeast  homologue  is  singularly 
responsible  for  the  bulk  of  ‘free’  ubiquitin  chain  disassembly  in  vivo.  Isopeptidase  T 
disassembles K
48-linked polyubiquitin chains (refer to section 1.1.1) starting at the proximal 
end  of  the  chain  (the  end  that  contains  a  free  carboxyl-terminus)  in  a  sequential  exo 
mechanism, and though K
48-linked chains are preferentially targeted, isopeptidase T can also 
cleave ubiquitin polymers in head to tail linkage, such as occurs in the polyubiquitin precursor, 
albeit less efficiently. It should be noted that isopeptidase T cannot act on polyubiquitinated 
protein  substrates  directly;  another  DUB  must  first  release  the  chain  from  the  substrate 
(Wilkinson et al. (1995)). 
  The substrate diversity within this subclass of approximately 58 DUBs (Nijman et al. 
(2005)) can be indicated by another two well known examples of UBP roles within the UCS 
and UPS. The first example is of ubiquitin retrieval within the endocytic trafficking process 
(refer  to  section  1.1.2).  Owing  to  the  relative  longevity  of  ubiquitin  in  vivo,  it  requires 
recovering from the involuting membrane proteins prior to complete vesticulation – the yeast 
DUB involved in this process is Doa4. Doa4’s localisation to the endosome can be blocked by 
the  elimination  of  factors  (‘E’  factor  mutants)  from  the  large  ESCRT  III  assembly  at  the 
endosome surface. This strongly suggests that ESCRT III helps to recruit Doa4 to the late 
endosome and direct it toward monoubiquitinated membrane proteins after they have been 
committed  to  inclusion  in  the  involuting  membrane  (Amerik  et  al.  (2000)).  The  human 
homologue  of  Doa4  is  thought  to  be  UBPY  owing  to  its  ability  to  bind  Hbp  (Hrs-binding 
protein), which is, along with Hrs, involved in endocytic trafficking in mammalian cells (Kato et 
al. (2000). The second example is of the UBP found in complex with the proteasome’s 19S 
RC component (refer to section 1.1.4) - USP 14 (Ubp 6 in yeast) (Borodovsky et al. (2001)) -   14
where it works in conjunction with S13/ Rpn 11 to deubiquitinate proteins that are destined for 
degradation. Specifically, immediately after the substrates have been unfolded by the 19S RC 
base’s  six  ATPases,  and  just  before  they  are  actively  translocated  into  the  20S  inner 
proteolytic chamber. The importance of this enzyme has also been intriguingly demonstrated 
by  the  fact  that  USP14  mutant  mice  develop  ataxia  (inability  to  coordinate  movement  ) 
(Wilson et al. (2002)).  
1.2.2 Ubiquitin C-Terminal Hydrolases (UCHs) 
  The  human  UCH  subclass  of  cysteine  protease  DUBs  consists  of  at  least  four 
mammalian  isozymes  which  all  share  close  homology  in  their  catalytic  domains.  X-ray 
crystallographic results of UCH catalytic core structures reveal a catalytic triad that matches 
very closely to that of a classical cysteine protease  (refer to section 1.2), and the three-
dimensional  folds  of  these  segments  are  nearly  indistinguishable  from  those  of  the  UBP 
subclass,  with  superimposing  catalytic  residues  (Amerik  and  Hochstrasser  (2004)).  Also, 
similarly  to  the  UBP  subclass,  active  site  residues  within  the  free  form  UCH  are  not  in 
catalytically competent conformations. Both subclasses seem to undergo a conformational 
change when bound to ubiquitin which brings the cysteine, histidine and aspartate catalytic 
residues into play by either eliminating steric (effects of atomic arrangements) obstructions in 
the active site cleft (UCH relevant – see below) or changing their relative positions (UBP 
relevant – refer to section 1.2.1) (Amerik and Hochstrasser (2004)). The obvious biological 
advantage of UCHs and UBPs being dependent upon ubiquitin binding for their hydrolase 
activity, is that they will be proteolytically inactive against non-substrate cellular proteins. 
  UCHs active site nucleophile cysteine is positioned at the bottom of a narrow groove 
in the enzyme’s surface. When in free form (not ubiquitin-bound), a specific UCH residue 
aliphatic (noncyclic) side chain occupies part of this groove by arcing over it (Johnston et al. 
(1999)). This so called active site ‘crossover loop’ becomes ordered when the UCH binds to 
ubiquitin,  which increases  the  diameter  of  the loop  allowing  access  to  the  catalytic  triad. 
However, even at its maximally open state, the diameter is no greater than 15Ǻ (Johnston et 
al. (1999). Biochemical studies have shown that the UCH subclass of DUBs preferentially 
cleave small adducts or unfolded polypeptides from the C-terminus of ubiquitin. This seems to   15
be directly owed to the 15Å size restriction of the 21 residue arcing peptide segment (loop) 
over the active site, which is much smaller than the majority of folded proteins. In addition to 
the  active  site  obstruction  which  enhances  UCH  substrate  selection  there  are  extensive, 
highly specific interactions realised between the UCH subclass and ubiquitin. These include 
numerous van de Waals interactions, twenty hydrogen bonds, and a salt bridge (electrostatic 
bond) between Arg(arginine)
72 of ubiquitin and an aspartate residue (Johnston et al. (1999)). 
  Despite  this  biochemical  data  (and  being  the first  described  DUBs),  their  specific 
functions within the UCS/ UPS remain poorly understood. They are thought to mainly cleave 
ubiquitin from inappropriately ubiquitinated polypeptides such as intracellular nucleophiles like 
glutathione and polyamines (Larsen et al. (1998)). They have also been shown to be involved 
in the processing of the ubiquitin precursors, which are translated fused to ribosomal protein 
precursors or head-to-tail ubiquitin-linked multimers with an additional amino acid on the last 
ubiquitin (Larsen et al (1998)). Though the vast majority of work on the UCH subclass points 
to a substrates no longer than 20-30 amino acids in length (Amerik and Hochstrasser (2004)), 
recent work by Misaghi et al. (2005) proposes a catalytic model for UCH-L3 which would 
allow the hydrolysis of larger ubiquitin conjugates.  
Four  mammalian  isozymes  have  so  far  been  established  (Mayer  and  Wilkinson 
(1989), Osawa et al. (2001)), whose expression is tissue specific (Wilkinson et al. (1992)) and 
developmentally regulated (Schofield et al. (1995)). UCH-L1 is predominantly expressed in 
the cytoplasm of neural and neuroendocrine cells, where its malfunction is thought to bring on 
the symptoms of Parkinson’s disease (refer to section 1.3 and 1.5 for advanced discussion). 
UCH-L3 is localised in the haematopoietic tissues, whereas UCH-L2 is widely expressed, but 
at much lower levels than either UCH-L1 or UCH-L3 (Wilkinson et al. (1992)). Very little is 
known of the fourth isozyme – UCH-L4 – though its high sequence similarity with UCH-L3 
does give some insight (Osawa et al. (2001)).  
Additionally, recent work has highlighted a potential specific function of a UCH within 
the UPS. Wicks et al. (2005) has identified a UCH in the 19S RC (also recently referred to as 
the PA700 activator complex) of the bovine 26S proteasome. This UCH, originally named 
UCH37, but also known as UCH-L5 (Nijman et al. (2005)), has shown the ability to cleave 
‘branched’ ubiquitin chains from the distal end, it does not however display activity toward   16
linear ubiquitin dimers. Though a ubiquitin editing function has been postulated (Wicks et al. 
(2005)),  whereby  it  deubiquitinates  proteins  that  have  been  mistakenly  ubiquitinated 
(recognised by having shorter ubiquitin chains) to halt their degradation; compelling evidence 
is yet to be provided.  
1.2.3 The Ovarian Tumour (OTU)- Related Proteases 
  The otu gene is involved in the development of the Drosophila melanogaster ovary, 
where it is thought to help regulate the translation of certain RNA transcripts (Goodrich et al. 
(2004)). Sequence similarities were originally found between the Drosophila otu gene and 
those encoding viral cysteine proteases (Makarova et al. (2000)).  
  A member  of  the  OTU family  of  DUBs  –  human  otubain  2  –  has  had  its  crystal 
structure  unveiled  (Nanao  et  al.  (2004)).  It  realised  a  five-stranded  β-sheet  positioned 
between two helical domains, in which amino residues Cys
51, His
224 and Asn(asparagine)
226 
appear to form the unorthodox catalytic triad. Despite the lack of sequence similarity, the 
active site of otubain 2 displays almost identical geometries to those of the UBP and UCH 
subclass,  though  a  critical  hydrogen  bond  between  the  His
224  and  Asn
226  is  required  to 
stabilise this unorthodox cysteine protease catalytic triad (Nanao et al. (2004)). Similar to the 
UCH and UBP free enzyme conformations, otubain 2 may also be in a self-inhibited state 
owed  to  the  helix  α3  loop  spatially  restricting  the  active  site  (Amerik  and  Hochstrasser 
(2004)). 
  Recent  work  has  confirmed  that  proteins  containing  the  OTU  domain  have  DUB 
activity.  In  one  study,  a  100-KDa  cytoplasmic  protein  called  Cezanne  which  negatively 
regulates  NF-kB  (Nuclear  Factor-kappa  B),  displayed  in  vitro  DUB  activity  upon  linear 
polyubiquitin translation products, isopeptide-linked polyubiquitin chains and ubiquitin-protein 
conjugates (Evans et al. (2003)). 
 
 
   17
1.2.4  Machando-Joseph  Disease  Proteins  (or  Josephin)  Domain  Protease 
(MJDs) 
  A bioinformatics search for other classes of DUB cysteine proteases identified ataxin-
3. Instability of a CAG (glutamine coding) nucleotide repeat within the ataxin-3 gene leads to 
Machando-Joseph  Disease  –  a  hereditary  neurological  condition.  Expansion  of  the  tri-
nucleotide repeat leads to protein misfolding, which results in aggregation and cellular toxicity 
(Nijman et al. (2005)). 
  ataxin-3 displays three typical DUB properties: (1) it deubiquitinates ubiquitin-AMC 
(ubiquitin-7-amido-4-methylcoumarin);  (2)  it  is  able  to  disassemble  ubiquitin-lysosyme 
conjugates; and (3) ubiquitin aldehyde (Ubal) – a potent DUB inhibitor – is readily bound by it 
(Burnett et al (2003)). Very recent work also shows that the characteristic cysteine protease 
catalytic  triad is  conserved  within  ataxin-3  (Nicastro  et  al.  (2005)).  In  evolutionary  terms, 
MJDs are likely to be relatively late additions to the UCS/ UPS, as no yeast homologues have 
been uncovered. 
1.2.5 JAMM Motif Proteases (Metalloprotease Subclass) 
  The S13/ Rpn 11 subunit (also known as POH1) of the 20S proteasome’s 19S RC 
(refer to section 1.1.4) represents this class of DUBs. Mutation studies have revealed that 
DUB activity is almost completely attributable to POH1 (Nijman et al. (2005)). The sequence 
of the distinct motif typified by POH1 was named the JAMM domain to distinguish it from a 
broader group of proteins which contain an MPN motif, of which JAMM is a subtype (Maytal-
Kivity et al. (2002)). 
  This metalloprotease motif realises two conserved His residues and an Asp residue 
that coordinate a zinc ion in the active site. Additionally, there is a conserved Ser (Serine) 
residue positioned between the two histidines which hydrogen bonds to a Glu (Glutamate) 
residue, which is thought to function in general JAMM acid-base catalysis (Maytal-Kivity et al. 
(2002)). 
  Cytidine deaminase is a well characterised metalloenzyme whose overall structure 
superimposes well onto that of the AF2198 JAMM domain protein, and also utilises a zinc ion   18
in  catalysis,  and  thus  presents  clues  into  the  mechanism  of  isopeptide  bond  hydrolysis 
employed by POH1. Cytidine deaminase catalysis proceeds thus: the zinc ion polarises a 
water molecule which then nucleophilically attacks a carbon atom in the cytidine pyrimidine 
ring. This results in the formation of a tetrahedral intermediate that rapidly collapses due to 
instability, releasing the reaction products. It is likely that JAMM proteases including POH1, 
use a similar zinc dependent mechanism in bond hydrolysis (Snider et al. (2002)). Unlike 
most other proteases described, AF2198 lacks peptide-binding site elements (Amerik and 
Hochstrasser (2004)), which lends credence to the contention that POH1 is only active when 
incorporated into the larger heteromeric 19S RC complex. Indeed, neighbouring 19S subunits 
are known to participate in ubiquitin-protein conjugation binding. 
 
 
 
  All  the  main  subclasses  of  DUBs  within  mammalian  cells  have  been  generally 
discussed with specific examples where appropriate. Ubiquitin carboxyl-terminal hydrolase L-
1 (UCH-L1) of the UCH subclass of cysteine proteases DUBs is the main focus of this study, 
and will now be considered in detail. 
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1.3 Ubiquitin Carboxyl-Terminal Hydrolase L1 (UCH-L1) 
Ubiquitin  C-terminal  hydrolase  L1  (UCH-L1),  previously  known  as  protein  gene 
product 9.5 (PGP 9.5), is a cysteine protease of the UCH subclass (refer to section 1.2.2). 
UCH-L1 is one of the most abundant proteins in the brain (accounting for 1-5% of total soluble 
protein), with immunohistological experiments demonstrating its exclusive localisation within 
neurons (Wilkinson et al. (1989)). The UCH-L1 gene maps to 4p14 (chromosome four, petit 
(short)  arm, major  band fourteen)  (Edwards  et  al.  (1991)),  containing  nine  exons  (coding 
sequences) and eight introns (intervening non-coding sequences), that span approximately 
10kb (kilobase = 1000 nucleotide bases) in this genomic region (Leroy et al (1998a), Day et 
al. (1990)) – to be discussed in greater detail later (refer to section 1.8). Northern blot analysis 
(primary electrophoresis of ribonucleic acid) revealed a 1.3kb transcript broadly represented 
in all the brain tested, with higher levels evident in the substantia nigra (Leroy et al. (1998a)). 
UCH-L1 is a 223 amino acid cysteine protease that contains a classical active site catalytic 
triad composing of cysteine, histidine and aspartate residues which are only activated once 
ubiquitin is bound, inducing a conformational change within the enzyme that eliminates a 
steric  obstruction  over  the  active  site  residues  (refer  to  section  1.2.2).  However,  this  21 
residue arcing peptide ‘loop’ once ordered by the ubiquitin-induced conformational change, 
still  restricts  potential  UCH-L1  substrates  to  a  15Ǻ  size  (up  to  20-30  amino  acids).  This 
biochemical  data  (Johnston  et  al.  (1999),  Amerik  and  Hochstrasser  (2004))  seems  to 
supplement the early work done by Larsen et al. (1998), who showed that UCH-L1 rapidly 
and preferentially cleaves small ‘leaving groups’ such as amino acids and oligopeptides from 
the C-terminus of ubiquitin in vitro, but not larger ‘leaving groups’ such as proteins. These 
findings indicate a physiological role of UCH-L1 in the recycling of ubiquitin; to hydrolyse 
inappropriately conjugated intracellular nucleophiles such as  glutathiones and polyamines, 
which  are  abundant  by-products  of  cellular  metabolism  (Pickart  and  Rose  (1985)). 
Additionally, Larsen et al. (1998) also  showed that  ubiquitin gene products could also be 
hydrolysed (very slowly) by UCH-L1, indicating a further possible physiological role in the 
generation  of  free  monomeric  ubiquitin  from  ubiquitin  precursors  (proproteins).  The  size 
restriction placed upon UCH-L1 substrates by the active site 15Ǻ ‘crossover loop’, seems to   20
prohibit  deubiquitination  of  ubiquitin-protein  conjugates  or  disassembling  of  polyubiquitin 
chains. 
1.3.1  UCH-L1’s  Isoleucine93Methionine  Mutation  (Ile93Met)  and  Parkinson’s 
Disease 
  Parkinson’s disease is the most prevalent neurodegenerative disease in the world 
affecting 1 in 500 people (Clough et al. (2003). It is characterised by four main disabling 
symptoms  –  paucity  of  movement,  rigidity,  rest  tremor  and  postural  instability  (the 
pathophysiology and epidemiology of Parkinson’s disease is discussed in greater detail in 
section 1.5). 
  Heritability of Parkinson’s disease has come to the forefront with the identification of 
rare  gene  mutations  in  familial  Parkinson’s  disease  and  common  genetic  risk  factors  for 
idiopathic Parkinson’s disease. Ten regions of the genome are now linked/ associated with 
the phenotype (Table 1). Of these ten regions, the genes associated with the UCS – namely 
UCH-L1, a-synuclein and Tau – were of the first to be uncovered; most prominent of these 
was UCH-L1 in a study carried out by Leroy et al. in 1998(b). 
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Chromosome  Locus  Gene 
Range of Age (years) 
at Onset (mean) 
Reference 
AD 
1p36 
2p13 
4p14-15 
4p15 
4q21 
12p11.2-q13.1 
12q23-24.1 
14q32.1 
17q21-22 
19q13 
AR 
1p35-36 
1p36 
6q25.2-27 
 
PARK9 
PARK3 
PARK5 
PARK4 
PARK1 
PARK8 
SCA2 
SCA3 
FTDP-17 
DYT12 
 
PARK6 
PARK7 
PARK2 
 
Unknown 
Unknown 
UCH-L1 
Unknown 
a-synuclein 
Unknown 
Ataxin-2 
Ataxin-3 
Tau 
Unknown 
 
Unknown 
Unknown 
Parkin 
 
N/A (65) 
36-89 (58) 
49-51 (50) 
24-48 (30) 
20-85 (46) 
38-68 (53) 
19-61 (39) 
31-57 (42) 
25-76 (49) 
12-45 (23) 
 
32-48 (41) 
27-40 (33) 
6-58 (26) 
 
Hicks et al. (2001) 
Gasser et al. (1998) 
Leroy et al. (1998b) 
Farrer et al. (1999) 
Polymeropoulos et al. (1997) 
Funayama et al. (2002) 
Gwin-Hardy et al. (2000) 
Gwin-Hardy et al. (2001) 
Hutton et al. (1998) 
Kramer et al. (1999) 
 
Valente et al. (2001) 
Van Duijn et al. (2001) 
Kitada et al. (1998) 
Table  1  –  Indicates  the  main  reported  mutations  or  genetic  loci  associated  with  familial 
Parkinson’s disease (taken and modified from Skipper & Farrer (2002)). 
- Abbreviations: AD, autosomal dominant; AR, autosomal recessive; FTDP-17, frontotemporal 
dementia and Parkinsonism linked on chromosome 17; LRRK2, leucine rich repeat kinase 2; 
N/A, data not available; PINK, PTEN induced putative kinase 1. 
The  majority  of  the  work  now  being  done  on  UCH-L1  was  initiated  by  this 
investigation. The coding region of the UCH-L1 gene was sequenced in probands from 72 
families with Parkinson's disease, and consequently identified a missense mutation in one 
proband of German pedigree. It was realised in the fourth exon of the UCH-L1 gene, and took 
the  form  of  an  isoleucine  to  methionine  amino  acid  substitution  at  position  93  –  this 
corresponds  to  a  C  to  G  change  at  nucleotide  position  277  in  exon  4.  Further mutation 
analysis revealed that the affected brother of the proband also carried the Ile93Met mutation. 
The group’s control study comprised of 500 chromosomes with 204 originating from German 
backgrounds; none carried the Ile93Met change. This mutation was however not seen to be 
100%  penetrant;  the  father  of  the  two  affected  individuals,  and  the  presumed  carrier  of   22
Ile93Met,  did  not  develop  Parkinson's  disease  (Figure  4).  The reason  for  this  incomplete 
penetration will be postulated later (refer to section 1.3.2). 
 
Figure 4 – The family in which the Ile93Met mutation was discovered (taken from Leroy et al. 
(1998b)), demonstrating the Ile93Met’s penetrance (squares = males, shaded = Parkinson's 
disease). Note the unaffected father, presumed to be the carrier of Ile93 Met. Genotypes were 
only available from the most recent generation, with the results shown.  
  In  the  same  investigation,  the  catalytic  activity  of  the  mutant  protein  was  then 
compared  to  that  of  the  wild-type  (Wt)  on  standard  substrates  (ubiquitin  ethyl  ester  and 
ubiquitin-7-amido-4-methycoumarin  (Ub-AMC)).  Results  obtained  indicated  a  roughly  50% 
reduction  in the  Ile93Met  protein’s  VMAX  (maximum velocity  of  enzymic  reaction),  with  no 
difference in Km (Michaelis’ constant – a substrate affinity measurement). This indicated a 
50% reduction in the catalytic activity of the Ile93Met protein. 
  Though in the early stages of the understanding of the biochemistry of the UPS and 
UCH-L1’s role within it, the potential significance of the results obtained in this investigation 
were appreciated; an abundant protein in the brain, with a significant role in the ‘ubiquitin-
dependent proteolytic pathway’ (as the authors referred to it) had realised a coding region 
mutation,  resulting  in  reduced  enzymatic  activity,  indicating  a  causative  role  in  the 
pathogenesis of autosomal dominant Parkinson's disease - which it was strongly associated 
with. Leroy et al. postulated that the reduced catalytic activity could affect the cleavage and 
turnover of the unknown substrate(s), leading to aggregation of the substrate(s) over time, 
causing severe aberration in the processing and degradation of proteins, which would then 
bring about the neuronal degeneration apparent in Parkinson's disease.     23
  Once  Leroy  et  al.  had  reported  these  findings,  several  groups  around  the  world 
(Harhangi et al. (1999), Maraganore et al. (1999), Wintermeyer et al. (2000), Zhang et al. 
(2000)) initiated work to uncover further Parkinson's disease patients carrying the UCH-L1 
Ile93Met amino acid substitution. None of these groups, or any group since, has identified the 
mutation in any Parkinson's disease cases (or any other individual). This indicates that though 
the mutation is a highly penetrant one (~80% - from what can be assumed – refer to Figure 4) 
that seriously affects UCH-L1’s hydrolase activity, it is an extremely rare cause of autosomal 
dominant Parkinson's disease. 
  Furthermore, more recent work done by Nishikawa et al. (2003) has verified the early 
enzyme kinetic work done by Leroy et al. (1998b). Using the same substrate that Leroy et al. 
had employed in part of their work – Ub-AMC (ubiquitin-7-amino-4-methylcoumarin) – this 
group observed the hydrolase activity of the Ile93Met mutant was 45.6% of that of the Wt 
UCH-L1. This confirms UCH-L1’s considerable loss of hydrolase activity when harbouring the 
Ile93Met amino acid substitution. Structural model analysis of the UCH-L1 enzyme suggests 
a highly plausible reason for the mutant’s substantial loss in hydrolase activity (Figure 5); it 
clearly shows that residue 93 is proximal to the active site nucleophile – Cys90 – and is thus 
in a good position to affect the active site’s catalytic activity. 
   24
 
Figure 5 – A structural model for the UCH-L1-ubiquitin complex. The sequence of UCH-L1 is 
shown, mapped onto the determined structure of the highly homologous (52% identity) UCH-
L3, complexed to the inhibitor ubiquitin aldehyde (SwissPdbViewer V.3.7b2) (Johnson et al. 
(1997), Johnston et al. (1999)). Residue 93 is proximal to the active site nucleophile (Cys90), 
while Ser18 (refer to section 1.3.2) is distal from the active site and from the ubiquitin binding 
site (Johnston et al. (1997), Johnston et al. (1999)). 
  It is postulated that (as discussed above) UCH-L1’s critical function to catalyse the 
hydrolysis of C-terminal esters and amides of ubiquitin (Larsen et al. (1998)), which allows 
ubiquitinated intracellular nucleophiles and ubiquitin proproteins to be processed, maintains 
cellular levels of ‘free ubiquitin’ (i.e. ligatable to further substrate proteins at the C-terminus) 
(Larsen  et  al.  (1998)).  This  decreased  hydrolase  activity  of  the  Ile93Met  UCH-L1  could 
therefore result in reduced levels of free ubiquitin, that may well have adversely affected the 
normal degradation of certain proteins in the brains of the two German sibs, particularly in the 
substantia nigra region, where UCH-L1 is transcribed at higher levels (Leroy et al. (1998b)). 
  Parkin-associated endothelin receptor-like receptor (Pael-R) and O-glycosylated α-
synuclein are two such proteins whose degradation could be affected; as they have both been   25
identified as substrates for parkin (Imai et al. (2001)) – which is a UPS E3 enzyme (refer to 
section 1.1). Without normal levels of free ubiquitin, parkin (discussed below – refer to section 
1.4.2)  would  no  longer  be  able  to  remove  misfolded  proteins  such  as  Pael-R  from  the 
endoplasmic reticulum (ER), and thus protect neurons from ER-mediated stress induced cell 
death (Imai et al. (2001)); a possible route that could generate the stresses realised upon the 
brain  of  a  Parkinson's  disease  sufferer,  specifically  in  the  dopaminergic  neurons  of  the 
substantia  nigra  where  UCH-L1  is  transcribed  at  higher  levels  (Leroy  et  al.  (1992)).  The 
degradation of O-glycosylated α-synuclein, as a parkin substrate, would also be affected by a 
reduction in the availability of monomeric ubiquitin – leading to its build up and deposition. 
Intriguingly α-synuclein (discussed below – refer to section 1.4.1 and 1.5.3) has been found to 
be  a  major  component  of  Lewy  Bodies  (the  major  pathological  hallmark  of  Parkinson's 
disease - refer to section 1.5.3) in Parkinson's disease patients (Spillantini et al. (1990)), as 
has UCH-L1 itself (Doran et al. (1983)).  
1.3.2  UCH-L1’s  Serine18Tyrosine  Polymorphism  (Ser18Tyr)  and  Parkinson’s 
Disease 
  As mentioned earlier, the fact that Leroy et al. (1998) reported a missense mutation 
(Ile93Met) in exon 4 of the UCH-L1 gene in a case of familial Parkinson's disease, spurred a 
series  of  similar  investigations  which  failed  to  uncover  further  individuals  carrying  this 
mutation. However, a more common sequence variation in exon 3 of the UCH-L1 gene was 
uncovered (Maraganore et al. (1999), Gasser et al. (1999), Wintermeyer et al. (2000), Zhang 
et al. (2000)).  
  Maraganore et al. (1999) were the first group to uncover this sequence polymorphism 
in a study which was initiated as a linkage analysis on a large well-documented family with 
Parkinson’s disease. Their early data from this scan strongly suggested a locus for autosomal 
dominant  familial  Parkinson's  disease  on  chromosome  4p  –  a  region  containing  many 
candidate genes (Farrer et al. (1999)). However, knowing that the gene for UCH-L1  was 
located on the short arm of chromosome 4, and that Leroy et al. (1998b) had very recently 
reported a Parkinson's disease-associated mutation within this gene, they undertook a cDNA 
sequencing  strategy  of  UCH-L1  in  four  individuals,  and  identified  a  coding  region  and   26
expressed polymorphism - Ser18Tyr. They subsequently found that the novel polymorphism 
occurred on ~20% of Caucasian chromosomes, and determined it was outside their ‘obligate 
candidate  region’.  Further  investigation  into  this  polymorphism  was  halted  in  the  study. 
However, importantly the group had uncovered a novel polymorphism in exon 3 of the UCH-
L1  gene  –  a  C-to-A  transition  at  nucleotide  54  –  which  results  in  a  serine  to  tyrosine 
substitution at amino acid position 18 (Ser18Tyr).  
  Where  Farrer  et  al.  (1999)  had  left  off,  several  investigations  (Maraganore  et  al. 
(1999), Gasser et  al. (1999), Wintermeyer et al. (2000), Zhang et al. (2000))  went on to 
confirm the Ser18Tyr polymorphism’s prevalence in various populations, but also investigated 
its association with sporadic and familial Parkinson's disease. A reduced risk was observed 
for  carriers  of  the  Tyr  allele  in  an  American  population  in  which  half  the  controls  and 
Parkinson's  disease  cases  reported  having  at  least  one  parent  of  German  origin  (PD 
(Parkinson’s  disease)  cases  –  n  =  139,  Controls  –  n  =  113.  OR  (odds  ratio)  =  0.53) 
(Maraganore  et  al.  (1999)).  This  protective  effect  was  subsequently  replicated  in  two 
Japanese populations (PD cases – n = 160, Controls – n = 160. OR = 0.73) (Zhang et al. 
(2000), Satoh et al. (2001)) and one German (PD cases – n = 229, Controls – n = 200. OR = 
0.57) (Wintermeyer et al. (2000)). Though three other studies could not reproduce this effect 
in Australian (PD cases – n = 142, Controls – n = 142. OR = ns (not significant)) (Mellick et al. 
(2000)), Italian (Savettieri et al. (2001)) and French (PD cases – n = 114, Controls – n = 93. 
OR = ns) (Levecque et al. (2001)) Caucasian populations. The lack of association consistency 
of the  Ser18Tyr  polymorphism’s  Tyr  allele  protection  against  Parkinson's  disease  can  be 
explained if the results from the studies above are related to sporadic and familial Parkinson's 
disease, and ethnic origin is taken into account. 
  The protective effect of the Tyr allele was only found among German and Japanese 
sporadic cases (Wintermeyer et al. (2000), Zhang et al. (2000), Satoh et al. (2001)), and also 
in  an  American  group  where  nearly  half  the  studied  patients  has  at  least  one  parent  of 
German origin (Maraganore et al. (1999)) – indicating a possible German founder effect (a 
change in the American population’s Ser18Tyr frequency directly owed to the establishment 
of  a  German  subpopulation).  Moreover,  the  fact  that  all  the  studies  which  observed  a 
protective influence only involved sporadic cases suggests that this polymorphism has no   27
impact on familial Parkinson's disease. This has led to the hypothesis that the full effect of 
another major UPS gene in the potential pathology of familial cases, may obscure the more 
moderate impact of the Ser18Tyr protective effect (Levecque et al. (2001)). Additionally, as 
one may expect, Parkinson's disease protection does seem to be dependent on the Tyr allele 
dosage;  that  is,  homozygotes  are  at  significantly  lower  risk  (relative  risk  0.31)  than  are 
heterozygotes (relative risk between 0.55 and 0.81) (Levecque et al. (2001), Maraganore et 
al. (1999), Satoh and Kuroda (2001)). Furthermore, two other studies have shown that the Tyr 
allele is inversely associated with early onset sporadic Parkinson's disease (PD cases – n = 
209. p = 0.03) (Elbaz et al. (2002)), (PD cases – n = 160. p = 0.043) (Wang et al. (2002)), i.e. 
as well as protecting against sporadic Parkinson's disease outright, the UCH-L1 Ser18Tyr 
polymorphism is also indicated in the more discreet effect of delaying the age of onset. 
  The predicted location of residue 18 on UCH-L1’s surface (refer to Figure 5) indicates 
that it is not situated near either the active nor ubiquitin binding site (Johnson et al. (1997), 
(1999)).  This  discounts  the  simple  explanation  for  Ser18Tyr’s  protective  influence;  that  it 
opposes the Ile93Met reduction in hydrolase activity. Additionally, residue 18 is only one of a 
few amino acids which are not conserved between and human and other mammals (horse, 
mouse, and rat have Ala at position 18), which indicates non-involvement in UCH-L1 normal 
hydrolysis activity, and suggests the existence of a distant pathological UCH-L1 activity. This 
pathological activity seems to have recently been uncovered (Liu et al. (2002)). 
  Liu et al. (2002) discovered a novel in vitro ubiquityl ligase activity of the UCH-L1 
dimer, that does offer a simple mechanistic explanation for the observation that the Ser18Tyr 
polymorphism reduces susceptibility to sporadic Parkinson's disease. This ligase activity was 
an  unexpected  outcome  from  cell  culture  experiments  which  indicated  that  UCH-L1  was 
responsible  for  the  ubiquitination  of  α-synuclein-ubiquitin  conjugates.  Other  predominantly 
hydrolytic enzymes have been seen to have a ligation mechanism that catalyses amide bond 
formation, though usually only under extreme conditions in vitro. This, as the study indicates, 
may  be  the  first  example  of  catalysis  (by  a  hydrolase)  of  amide  bond  formation  under 
physiologically reasonable conditions – which strongly supports its occurrence in vivo. UCH-
L1’s  dimerisation  dependent  ubiquityl  ligase  activity  is  mechanistically  reasonable,  and 
importantly is still dependent on its hydrolase activity; once a substrate ubiquitin C-terminal   28
amide or ester (for instance) has been hydrolysed, a ubiquitin/ UCH-L1 intermediate is formed 
(refer to section 1.2) which then, instead of reacting with water (step 4 in cysteine protease 
catalysis), react directly with a nucleophillic lysine of another ubiquitin to produce a ubiquitin-
ubiquitin  amide  bond  (Liu  et  al.  (2002)).  In  this  process,  ubiquitin  does  not  have  to  be 
activated  using  ATP  (which is  ordinarily required in the  UCS  enzyme cascade  –  refer  to 
section 1.1), as the ubiquitin will already be bound post C-terminal amide/ ester hydrolysis. 
  Liu et al. (2002) go on to report the Ser18Tyr (serine being the major allele) mutant as 
bringing about a five-fold reduction in UCH-L1’s ligase activity at high concentrations, this 
linked to the fact that the variant displayed comparable ligase activity to that of the Wt enzyme 
at  lower  levels,  does  indeed  indicate  a  protective  route  for  the  Ser18Tyr  mutant.  It  is 
postulated that the Ser18Tyr variant’s observed five-fold decrease in ligase activity (at high 
concentrations), would not elevate the concentration of cytoplasmic α-synuclein as much as 
the  Wt  protein;  whose  higher  ligase  activity  would  inhibit  its  ‘normal’  degradation  by  the 
potential production of undegradable, Lys
63 linked polyubiquitin chains, which act as a non-
proteolytic  signal  inhibiting  the  proteasome’s  activity  upon  α-synuclein.  In  order  to  avoid 
Parkinson's disease, it has become accepted that α-synuclein levels are required to be kept 
under the ‘critical concentration’ for oligomerisation (Rochet and Lansbury (2000)), owed to its 
accumulation resulting in synaptic damage and neurotoxicity via amyloid-like fibril formation 
and  mitochondrial  dysfunction,  leading  to  apoptotic-like  changes  (Giasson  et  al.  (2000), 
Hashimoto  et  al.  (1999), Irizarry  et  al.  (1998),  Tompkins  et  al.  (1997), van  Duinen  et  al. 
(1999)). The Ser18Tyr variant’s comparable ligase activity to that of the Wt at low levels could 
also be important, as the basal ligase activity of UCH-L1 would not be disturbed, which may 
have an important as yet unknown physiological function. The novel ligase activity uncovered 
by  Liu  et  al.  (2002)  is  an  attractive  hypothesis;  for  it  would  suggest  that  UCH-L1  is  not 
produced solely for its relatively weak hydrolase activity (200-fold less than UCH-L3). It was 
also suggested by the authors that UCH-L1’s dimerisation-dependent ligase activity could 
have  evolved  to  be  regulated  posttranslationally  and  could  be  regulated  by  a  number  of 
cytoplasmic events such as synaptic vesicle binding, which would be expected to promote 
dimerisation.   29
  It is also important to note that Liu et al. (2002) also investigated the possibility of an 
indirect interaction between the Ser18Tyr polymorphism and the Ile93Met mutation (refer to 
section 1.3.1), to help explain the incomplete penetrance of the latter. An explanation was 
realised in the fact that a 1:1 Wt/ Ile93Met mixture (a model of the affected heterozygotes) 
showed  significantly  much  higher  ligase  activity  to  a  1:1  Ser18Tyr/  Ile93Met  mixture  (a 
potential model of the unaffected father). Thus, if ligase activity confers susceptibility, then the 
Ser18Tyr polymorphism could protect against Ile93Met. 
  In a very recent study (Naito et al. (2006), the large five-fold decrease in UCH-L1’s 
dimerisation dependent ligase activity compared to that of the wildtype protein, is seen to 
have  a  morphological  basis  in  enzyme  dimer  configuration.  Using  a  small-angle  neutron 
scattering  (SANS)  approach,  this  group  found  that  the  UCH-L1  dimer  was  a  rotating 
ellipsoidal,  contrasting  to  the  Ser18Tyr  dimer,  which  exhibited  a  much  more  globular 
appearance. This pronounced change in shape lends credence to the fact that the Ser18Tyr 
enzyme can bring about such a reduction in ligase activity.  
1.3.2.1 UCH-L1’s Ser18Tyr Polymorphism and Alzheimer’s Disease 
  Alzheimer’s disease is the most prevalent neurodegenerative disease in the world, 
making up over half of all dementia cases in the elderly (Small et al. (1997)). The clinical 
progression of Alzheimer’s disease is made up of three main features – progressive memory 
impairment,  progressive  cortical  dysfunction  and  neuropsychiatric  disturbances  (the 
pathophysiology and epidemiology of Alzheimer’s disease is discussed in greater detail in 
section 1.6). 
  Recent work done by Xue and Jia (2006) tested the hypothesis that the Tyr allele of 
the Ser18Tyr polymorphism may also confer protection Alzheimer’s disease, specifically in 
the Chinese Han population. After examining the UCH-L1 Ser18Tyr polymorphism genotypes 
in  116  sporadic  Alzheimer’s  disease  patients  and  123  healthy  subjects,  the  data 
demonstrated,  after  stratification  by  gender, that female  Alzheimer’s  disease  patients  had 
significantly less frequencies of the Tyr allele (the Ser18Tyr polymorphism) than the female 
controls (p = 0.003). From these results, the study does seem to indicate that the Tyr allele 
confers  protection  towards  sporadic  Alzheimer’s  disease  in  female  subjects  within  the   30
Chinese  population,  however,  similar  studies  are  now  required  in  other  populations  to 
ascertain  the  level  of  importance  this  polymorphism  actually  has  in  the  pathogenesis  of 
Alzheimer’s disease globally.    
1.3.2.2 UCH-L1’s Ser18Tyr Polymorphism and Huntington’s Disease 
  In addition to Parkinson's disease and Alzheimer’s disease, the UCH-L1’s Ser18Tyr 
polymorphism has also been implicated in Huntington’s disease (refer to section 1.6.3) (Naźe 
et al. (2002)). The study indicated that the Ser18Tyr variant could have a moderate effect in 
delaying the age-at-onset of Huntington’s Disease , though due to the vast majority of these 
cases being governed by the expansion size of a triplet CAG repeat mutation in the ’HD’ 
gene, the group was left with only a small proportion (seven) of the initial 138 Huntington's 
disease-diagnosed patients available for Ser18Tyr association work. Therefore, much larger 
studies are required if a Ser18Tyr Huntington's disease age-at-onset association of any real 
significance is to be unveiled. 
1.3.3  UCH-L1’s  Methionine124Leucine  Mutation  (Met124Leu)  and Parkinson’s 
Disease 
  In addition to the highly penetrant familial Parkinson's disease Ile93Met mutation, and 
the protective Ser18Tyr polymorphism, one other UCH-L1 mutation has been identified – an 
A371C UCH-L1 single nucleotide polymorphism (SNP) in exon 5 - leading to a Met124Leu 
amino acid substitution (Farrer et al. (2000)). This mutation was discovered in two individuals 
with  ‘probable’  Parkinson's  disease,  and  although  this  amino  acid  is  conserved  across 
species  (Equus  caballus  (wild  horse)  and  Rattus  norvegicus  (brown  rat)  species  have  a 
leucine at this position), the Met 124Leu variant does not seem to completely segregate with 
familial Parkinson's disease in this German family. Farrer et al. thus concluded that this UCH-
L1 variant is unlikely to be pathogenic, but without association data or functional analysis of 
the Met124Leu substitution, the pathogenic potential must remain a possibility. 
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1.3.4 UCH-L1 and Dementia With Lewy Bodies 
  In addition to the association of UCH-L1’s Ser18Tyr polymorphism with Alzheimer’s 
disease (through the potentially protective influence of the Tyr allele), the influence of UCH-L1 
on the pathogenesis of another dementia – dementia  with Lewy bodies – has also been 
investigated. Dementia with Lewy bodies (refer to section 1.6.2) is the second commonest 
form of dementia and is characterised by the widespread distribution of Lewy bodies (refer to 
section  1.5.3)  and  α-synuclein-containing  neuritis  in  the  cerebral  cortex  (Spillantini  et  al. 
(1998)). With this pathological feature of dementia with Lewy bodies in mind, a study was 
initiated by Barrachina et al. (2005) to test for UCH-L1 mRNA and protein levels in post 
mortem frontal  cortex  of  dementia  with  Lewy  bodies  cases,  compared  with  age  matched 
controls. Their findings demonstrated down-regulation of UCH-L1 frontal cortex mRNA and 
protein, which could indicate that reduced UCH-L1 expression contributes to the abnormal 
protein aggregation seen in dementia with Lewy bodies.  
1.3.5 Gracile Axonal Dystrophic  Mouse - UCH-L1 Intragenic Deletion 
  Further to the UCH-L1 single point mutations discussed above, an in-frame deletion 
of UCH-L1 has been reported in a mammalian model of neurodegeneration (Saigoh et al. 
(1999)). The deletion includes exons 7 and 8, and has been realised within the UCH-L1 gene 
of the gracile axonal dystrophic (gad) mouse, which is an autosomal recessive mutant that 
exhibits sensory ataxia at an early stage, followed by motor ataxia at a later stage. This was 
pathologically characterised by ‘dying-back’ type axonal degeneration, and accumulation of 
ubiquinated deposits along the sensory and motor nervous systems. The gad allele encodes 
a truncated UCH-L1 lacking a segment of 42 amino acids containing the His161 residue – the 
general  base  involved  in  UCH-L1’s  hydrolysing  catalysis.  This  strongly  supports  the 
hypothesis  that  an  abnormal  expression  or  function  of  UCH-L1,  particularly  effecting  the 
active  site  residues  –  as  with  the  Ile93Met  mutation  –  can  accelerate  the  formation  of 
ubiquitinated protein inclusions (comparable to Lewy bodies) that disrupt cellular homeostasis 
in neural cells, leading to neurodegeneration. Though this study is generally very applicable to 
UCH-L1  and  the  pathological  deterioration  seen  in  neurodegenerative  diseases,  i.e. 
Parkinson’s disease, Alzheimer’s disease and dementia with Lewy bodies; the mice do not   32
specifically exhibit the pathological and clinical features consistent with any of these diseases, 
however, with such a large portion of the UCH-L1 enzyme having been truncated, it is difficult 
to  draw  any  specific  cross  species  comparisons  (of  neurological  features)  with  any  real 
confidence. 
  The  gad  mouse  was  also  used  in  another  UCH-L1  relevant  study  (Osaka  et  al. 
(2003)) in which the authors deemed it analogous to a UCH-L1 null mutant using polyclonal 
antibody immunoblotting techniques of brain lysates (no compensatory UCH-L3 isozyme up 
regulation was identified). Concordant accumulation of UCH-L1 substrates was not detected, 
though  a  decrease  in  mono-ubiquitin  was  -  specifically  in  the  neurons.  Furthermore, 
overexpression  of  UCH-L1  in  the  transgenic  mice,  as  well  as  cultured  mouse  embryonic 
fibroblast (MEF) cells, showed a proportional increase in mono-ubiquitin levels. The authors 
eliminated  ubiquitin  transcriptional  activation  in  the  cells  transfected  with  adeno-UCH-L1 
(UCH-L1 expressed by the adenovirus vectors), and catalysed release of mono-ubiquitin from 
potential UCH-L1 substrates was also ruled out (though by no means definitely). Using an 
immunoreactivity  approach  within  neuronal  dopamine  producing  cells,  and  his-tagged 
wildtype and two UCH-L1 mutants – one lacking hydrolase activity (UCH-L1
C90S) and one with 
a disrupted ubiquitin binding domain (UCH-L1
D30K) - UCH-L1 affinity for ubiquitin was asserted 
as the critical factor in maintaining these ubiquitin levels. Moreover, further work in this study 
showed that ubiquitin half life of control MEF cells could be increased to a level comparable to 
those expressing transfected adeno-UCH-L1 if a lysosome inhibitor was added (2,3-trans-
epoxysuccinyl-L-leucylamide-3  methyl  butane  ethyl  ester  (EST)).  This  led  to  the  authors’ 
conclusion that UCH-L1’s ability to bind ubiquitin is potentially critical in sequestering it from 
lysosomal degradation, which in turn maintains its intracellular levels.  
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1.3.6 Ubiquitin Carboxyl-Terminal Hydrolase-L1 - Discussion 
  Neuron  specific  UCH-L1  was  one  of  the  first  DUBs  to  be  described,  though  its 
specific  functioning  still  has  to  yet  to  be  clearly  illuminated.  Leroy  et  al.  uncovered  the 
Ile93Met  mutation  within  a  Parkinson's  disease  sufferer  in  1998,  and  together  with  the 
associated loss in hydrolase function of this mutant (around fifty percent), firmly established 
UCH-L1 as a critical DUB of the brain. Almost disappointingly (to those in the UCH-L1 field), 
Larsen et al. (1998) confirmed the in vitro substrate specificity of UCH-L1, in which only small 
C-terminal adducts (amides or esters) of ubiquitin could be rapidly cleaved. The ubiquitin 
proprotein, though generally described in the literature as a UCH-L1 substrate, was shown to 
be  cleaved  only  very  slowly,  perhaps  indicating  an  evolutionary  redundant  role.  Though 
deubiquitinating the abundant by-products of cellular metabolism did endow UCH-L1 with a 
very important physiological role in maintaining cellular levels of ‘free’ ubiquitin, the fact that 
its hydrolase activity was over 200-fold less than other UCH subclass members, meant that 
its perceived hydrolase function (or disturbance there of) was probably not enough on its own 
to warrant the pathological decay seen in the German proband. 
  The breakthrough required came in 2002, when Liu et al. reported the novel in vitro 
ubiquityl-ligase  activity  of  the  UCH-L1  dimer.  Suddenly,  UCH-L1  had  become  a 
multifunctional  enzyme,  with  an  E3-like  ligase  activity  which  was  mechanistically  still 
dependent  on  its  hydrolase  activity.  (This  is  generally  understated  in  DUB/  UCH(-L1) 
literature, but the only biochemically reasonable proposition for its dimerisation dependent 
ligase  activity  to  date,  depends  on  its  ability  to  form  a  ubiquitin/  UCH-L1  intermediate 
(sometimes  referred  to  as  an  acyl  enzyme  due  to  the  loss  of  a  hydroxyl  group),  after 
hydrolysis of a C-terminal ubiquitin bond). The Ser18Tyr variant’s observed five-fold reduction 
in this ligase activity was presented as the physiological rationale for the Tyr allele’s observed 
protective effect (with respect to Parkinson's disease) in Japanese and German populations 
(possibly  indicating  a  protective  environmental  cofactor),  and  could  also  be  the  main 
biochemical  factor  contributing  to  the  allele’s  observed  protective  effect  seen  in  female 
Alzheimer’s disease patients in China, along with its proposed delayed age-at-onset effect 
seen in Huntington’s disease patients.   34
  UCH-L1’s ability to ubiquitinate such substances as α-synuclein, opened up a vast 
array of possibilities for its actual physiological role. Only in the past two to three years has 
the true versatility of the UCS (briefly summarised in section 1.1) been uncovered, with much 
yet still to be learned (Mayer & Layfield (2005)). UCH-L1 is thought to promote the formation 
of K
63-linked polyubiquitin chains (Liu et al. (2002)), which would point towards a role in the 
UCS away from the UPS and 26S proteasome recruitment. 
  The work done by Osaka et al. (2003) with the gad mouse has clouded UCH-L1’s 
overall  picture,  as  it  demonstrated  the  apparent  ability  of  UCH-L1  to  raise  and  maintain 
ubiquitin levels independent of its hydrolase activity, and thus potentially (from what can be 
inferred to date) its ligase activity. However, no study of this nature has been reported since, 
and it should be noted that this investigation was far from exhaustive in ruling out gad mouse 
UCH-L1  substrate  hydrolysis.  Nevertheless,  it  certainly  threw  open  to  conjecture  the  true 
nature of UCH-L1’s physiological role. With this in mind, it is worth indicating that a very 
recent  study  by  Manago  et  al.  (2005)  has  uncovered  the  first  evidence  of  a  relationship 
between  UCH-L1  and  a  neurotransmitter  receptor  -  specifically  P2X  -  which  are  widely 
distributed in the brain, and involved with various biological activities including neurosecretion. 
The results from this study showed that UCH-L1 overexpression in PC12 cells (Rat adrenal 
pheochromocytoma (adrenal gland tumour) cell line) potentiated ATP-induced currents due to 
the activation of these receptors, though again, somewhat perplexingly, through the use of a 
C90S mutant (refer to section 1.3.4) these effects were deemed to be independent of UCH-
L1’s  hydrolase  activity.  However,  work  in  vitro  on  one  neuronal  precursor  cell line is  not 
sufficient to pass judgement on the biochemical mode of UCH-L1’s effect, though the effect 
realised on the PX2 receptors does allow speculation that UCH-L1 may play an important role 
in synaptic activity. 
  This  finding  could  eventually  be  seen  as  a  turning  point,  for  so  far  no  specific 
neurological role has been put forward for UCH-L1. Its loss of hydrolase function, which is 
most probably linked mechanistically to its ligase activity, has certainly been shown to be 
pathogenic (Ile93Met), but the current state of knowledge on UCH-L1 goes no further than it 
as  a  general  ‘hydrolyser’  of  ubiquitinated  glutathiones  and  polyamines  to  ‘prime’  its  yet 
unknown E3-like ubiquityl-ligase activity.   35
  In 2002, when Liu et al. first uncovered UCH-L1’s ligase activity, they also found that 
UCH-L1 coimmunoprecipitated with α-synuclein in synaptic vesicle fractions. At that time α-
synuclein’s specific biological role was completely unknown, apart from that it was a major 
substrate of Parkin – a well documented E3 ligase. However, very recently, an illuminating 
study done by Chandra et al. (2005) revealed that α-synuclein acts as a dualistic molecular 
chaperone with cysteine-string protein • (CSP•) at the synapse, assisting in the folding and 
refolding of SNARE proteins which are essential in neurotransmitter release, vesicle recycling 
and synaptic integrity. When this is borne in mind with the fact that overexpression of UCH-L1 
causes  an  accumulation  of  α-synuclein  (Liu  et  al.  (2002)),  and  can  also  activate  P2X 
receptors (Manago et al. (2005)) whose subunits have been shown to be located proximal to 
proteins of the SNARE complex (Barden et al. (1999)), an intriguing new role for UCH-L1 at 
the  synapse,  in  my  opinion,  begins  to  unveil  itself.  Perhaps  its  ability  to  ubiquitinate  α-
synuclein  could  provide  an  extra level  of control to α-synuclein’s  role  at  the  synapse,  or 
perhaps it straightforwardly inhibits proteasomal degradation of α-synuclein (with K
63-linked 
polyubiquitin chains) which allows its beneficial presynaptic generation to continue. 
  This  potential  role  of  UCH-L1  could  explain  the  results  obtained  by  Osaka  et  al. 
(2003) in the gad mouse – where overexpression of UCH-L1 led to increased levels of mono-
ubiquitin. UCH-L1 could regulate α-synuclein at the synapse through K
63-linked ubiquitination: 
after each facilitating interaction in the folding/ refolding cycle of the SNARE proteins, post 
neurotransmitter release, the α-synuclein could be deubiquitinated by a yet unidentified DUB 
that  associates  within  the  SNARE  complex,  ready  to  be  incorporated  again  into  another 
‘neurotransmitting cycle’. This would probably cause a proportional amount of ubiquitin to be 
present at the synapse, dependent upon how much UCH-L1 dimer there is present, governing 
the amount of α-synuclein being ubiquitinated, and thus deubiquitinated after each cycle. In 
this hypothetical model, it could also be speculated that UCH-L1 concentration at the synapse 
(and thence its dimerisation dependent ligase activity) could be a rate-limiting step, in view of 
α-synuclein potential activation, in neurotransmitter release at the synapse.  
  Further to this, though the increased ligase activity (five-fold) of the UCH-L1 wildtype 
dimer may lead to increased susceptibility of sporadic Parkinson's disease and Alzheimer’s 
disease,  and  possibly  an  earlier  age-at-onset  of  Huntington’s  disease,  in  later  life  (with   36
reference  to  the  Ser18Tyr  variant’s  in  vitro  activity  and  its  protective  effect  in  certain 
populations), what would be very interesting to elucidate, is whether individuals carrying the 
Ser18Tyr allele realise a reduced level of neurotransmitter activity throughout life, caused by 
reduced UCH-L1 α-synuclein ubiquitination/ activation. This could then lead to a reduced build 
up of protein aggregates and their attributable cytoplasmic stresses (refer to section 1.5.3) in 
later life (depending on certain apparent environmental influences), when protein turnover and 
degradation pathways become less efficient, thus explaining the potential protective effect. 
  This  potential  synaptic  role  for  UCH-L1  also  provides  a  model  to  help  explain 
Ile93Met pathogenesis in familial Parkinson's disease. As the current model determines (Liu 
et  al.  (2002)),  UCH-L1’s  hydrolase  activity  is  necessary  to  form  the  UCH-L1/  ubiquitin 
intermediate which is required for ubiquityl-ligase activity. Because hydrolysis of ubiquitin C-
terminal amides and esters by UCH-L1 is so rapid (Larsen et al. (1998)), a reduction in this 
activity of around fifty percent, which the Ile93Met mutant exhibits, should not effect synaptic 
α-synuclein turnover ordinarily – the fact that the German proband harboured this mutation 
free of illness till 51 years of age strongly supports this (Leroy et al (1998)). However, it is very 
possible that later in life this hydrolysis step could become rate limiting, if it realised such a 
decrease in enzymatic kinetics. Once a threshold is reached, where α-synuclein cannot be 
(K
63) ubiquitinated by UCH-L1 as quickly as it is deubiquitinated by the ‘SNARE complex 
DUB’,  then  α-synuclein  would  start  to  accumulate,  reaching  the  ‘critical  concentration’ 
described by Rochet and Lansbury (2000) (refer to section 1.3.2), and overload the UPS 
pathways. This would in turn lead to aggregation of α-synuclein and related proteins (e.g. 
parkin and synphilin-1 – discussed below), especially within neurons of the substantia nigra 
where UCH-L1 is transcribed at higher levels (Leroy et al. (1992)), causing synaptic damage 
and  neurotoxicity  to  this  region  (in  the  first  instance) via  amyloid-like fibril formation  and 
mitochondrial  dysfunction,  leading  to  the  symptoms  observed  in  Parkinson’s  disease. 
Incomplete penetrance (eighty percent from what can be ascertained – see Figure 4) of this 
mutation in the family of the German proband, as also speculated by Liu et al. (2002), could 
be owed to the protective Ser18Tyr allele. The Ser18Tyr:Ile93Met UCH-L1 dimer model of the 
unaffected heterozygote showed a significantly reduced ligase activity in vitro compared to 
that  of  the  Wt:Ile93Met  dimer  model  (Liu  et  al.  (2002)).  This  translated  in  vivo,  could   37
potentially have maintained α-synuclein levels at tolerable levels within the UPS owed to the 
reduction in general α-synuclein recruitment to the synaptic SNARE complex throughout life, 
brought about by UCH-L1’s lower ligase activity in this instance. 
  Whatever the specific function and mechanisms of UCH-L1 at the synapse/ in the 
brain, it is fairly clear that UCH-L1’s hydrolase/ ligase function, and the variation there of, is 
intimately  linked  to  Parkinson’s  disease  pathogenesis.  A  recent  study  (Barrachina  et  al. 
(2005)) not only indirectly supports this statement further, but it also correlates with a novel 
hypothesis  put  forward  describing  Lewy  bodies  (the  pathological  hallmark  of  Parkinson’s 
disease) as a protective attempt by the neuron to sequester α-synuclein from the cytoplasm – 
to maintain levels below the critical concentration (refer to section 1.5.3), which results in a 
further  refined  hypothesis.  The  study  clearly  showed,  through  post  mortem  analysis  of 
Parkinson’s  disease  sufferers’  brains,  that  UCH-L1  protein  levels  were  reduced  in  the 
substantia nigra (where UCH-L1 is potentially expressed at higher levels compared to the rest 
of the brain (Leroy et al. (1992)) of only those Parkinson’s disease cases exhibiting Lewy 
body pathology. This does suggest that that Lewy body formation is an active process in the 
neuron  to  regain  control  of  cytoplasmic  α-synuclein  concentration,  for  it  is  coupled  with 
apparent UCH-L1 down regulation - an effective route, bearing in mind UCH-L1 as a probable 
α-synuclein  ubiquitinator,  to  curb  any  further  cytoplasmic  α-synuclein  neuronal  build  up. 
Moreover, together with a down regulation of other deubiquitinating enzymes in response to 
Lewy body build up – especially those potentially realised in the SNARE complex involved in 
α-synuclein deubiquitination at the synapse (discussed above) – indicates a physiological 
response that can viably explain how an individual can survive with Lewy body pathology 
without ever presenting a disease phenotype. 
  The very fact that UCH-L1 is ordinarily transcribed at higher levels in the substantia 
nigra, seems to be one of the primary reasons why any variation in its functioning affects the 
neural pathways involved with voluntary movement – as seen in Parkinson’s disease – in the 
first  instance.  However,  variation  in  UCH-L1  function  also  seems  to  be  associated  with 
dementias  whose  pathological  features  are  concentrated  elsewhere  in  the  brain,  i.e. 
Alzheimer’s disease and dementia with Lewy bodies. In these cases, UCH-L1’s variation in   40
proteasome.  Most  in  vitro  studies  indicate  that  a-synuclein  is  degraded  by  the  26S 
proteasome (Bennett et al. (1999)). In one study it was shown that the proteasome degrades 
both wild type and Ala53Thr (familial) mutant a-synuclein, but the mutant a-synuclein was 
degraded more slowly, indicating a disturbed protein degradation which could give rise to 
Lewy body formation (Stefanis et al. (2001)). In another study (genetic), it was shown that a 
complex dinucleotide repeat in the promoter region of the a-synuclein gene was associated 
with sporadic Parkinson's disease (Kruger et al. (1999)). It has been  shown in luciferase 
reporter assays that certain allele variations of this dinucleotide repeat enhances expression 
of the gene (Touchman et al. (2001)). If this is borne in mind with other studies which have 
shown a decreased 26S proteasome activity induced by a-synuclein over-expression in vitro 
(Lee et al. (2001)), possibly due to an inhibitory interaction of a-synuclein with a subunit of the 
19S regulatory complex (19S RC) as seen in rats (Stefanis et al. (2001)) – accumulation, 
aggregation  and  disrupted  degradation  of  a-synuclein  leading  to  Lewy  body  formation  is 
certainly a possibility.  
  This fits in well with UCH-L1’s newly hypothesised control (through its dimerisation 
dependent  ubiquityl-ligase  activity)  of  α-synuclein’s  recently  uncovered  function  at  the 
synapse  (refer  to  section  1.3.6),  which  could  readily  be  overwhelmed  by  α-synuclein 
overexpression  –  leading  to  the  detrimental  effects  on  the  26S  proteasome  complex 
described  above.  Furthermore,  this  also  lends  credence  to  the  hypothesised  pathological 
model for UCH-L1’s highly penetrant Ile93Met familial Parkinson's disease mutation (refer to 
section 1.3.6), as it involves the build up of α-synuclein within the UPS (in later life), which 
would concordantly bring about the proteasomal pathological routes discussed. 
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Kawamata  et  al.  (2001)),  which  is  further  backed  up  by  the  fact  that  synphilin-1  is  a 
component  of  Lewy  bodies  in  the  brains  of  sporadic  Parkinson's  disease  patients 
(Wakabayashi et al. (2000)).  
  One group Holzmann et al., unpublished data) has identified an Arginine(Arg)642Cys 
mutation  in  two  independent  sporadic  Parkinson's  disease  patients  (whilst  not  in  healthy 
controls). Whether or not this sequence variation disrupts  synphilin-1’s interaction with a-
synuclein at the synapse, or interferes with parkin’s potential ‘K
63 regulation’ of synphillin-1, is 
the subject of ongoing research. 
 
 
 
  The  synaptic  localisation  of  UCH-L1,  α-synuclein,  parkin  and  synphilin-1,  their 
association  with  the  UCS  and  individual  implication in  Parkinson's  disease,  underlies  the 
importance of determining the true nature and function of their individual interactions with one 
another. Current state of knowledge in the field alludes to a role for UCH-L1 in controlling α-
synuclein’s  facilitation  in  neurotransmitter  release  (hypothesised  in  section  1.3.6),  and 
establishes a dual-function for parkin in ‘ubiquitin-tagging’ a modified form of α-synuclein for 
26S proteasome degradation, as well as a contrasting regulatory ubiquitin modification role 
with synphillin-1, presumably in its intriguing, but yet unknown association with α-synuclein. 
These  series  of  interactions  within  neuronal  cells,  as  well  as  the  individual  enzymes 
themselves, will need to be studied much further to fully elucidate the true nature of the UCS/ 
UPS in synaptic neurotransmission pertaining to the pathology of Parkinson's disease. 
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1.5 Parkinson's Disease 
  Neurodegenerative diseases are becoming increasingly prevalent with the aging of 
the  general  population;  a  significant  demographic  change  in  the  human  population  was 
realised  in  the  twentieth  century,  which  shifted  life expectancy  to  the  upper  age  ranges. 
Arguably,  the  main  determinant  of  ‘quality  of  life’  for  this  aging  population  is  the  normal 
process  of  neuronal  aging  in  the  central  nervous  system,  especially  diseases  which  can 
accelerate this neuronal loss. Neurodegenerative diseases (as they are collectively known) 
are amongst the most important contributors to human disability and disease in the world 
today, with Alzheimer’s disease being the most prevalent (refer to section 1.6.1), followed by 
Parkinson’s disease. There is also a large number of rarer neurodegenerative diseases, such 
as  dementia  with  Lewy  bodies  (refer to  section  1.6.2)  and  Huntington’s  disease  (refer  to 
section 1.6.3), and though they each only effect a small number of patients, taken together 
they certainly have a detrimental impact on the aging population. 
1.5.1 Physiological Characteristics of Parkinson's Disease  
Parkinson’s disease is so called owed to the fact that James Parkinson first clinically 
described the neurological disorder in 1817 in an essay titled “Shaking Palsy” – which literally 
means ‘loss of voluntary movement with tremors’. Parkinson’s disease is characterised by 
four main neurological features (which are also known as the cardinal symptoms or signs): 
paucity of movement, rigidity, tremor and postural instability. Paucity of movement is one of 
the most disabling features of the disease (Lyons et al. (1997)) and consists of three main 
entities:  slowness  of  movement  (bradykinesia),  reduced  movement  (hypokinesia)  and  an 
inability to initiate movement (akinesia). Rigidity is defined as the increase in resistance to 
passive movements around a joint, but this is mainly considered a sign rather than a symptom 
of Parkinson’s disease, owed to the patient’s feeling of ‘stiffness’ often being attributable to 
bradykinesia  (Jankovic  (1992)).  Around  75  percent  of  patients  with  Parkinson’s  disease 
realise rest tremor (Gelb et al. (1999)), and this is the symptom that usually causes the patient 
to seek medical counsel. The rest tremor associated with Parkinson’s disease is relatively 
slow (around four to six hertz (Hz)), and is most prominent in the hands, with it also effecting   45
the feet and jaws (Sawle (1999)). Postural instability is usually the last of the core symptoms 
to be realised, though it is deemed the most disabling (Lyons et al. (1997)) owing to the 
danger of the patient falling. As well as these four main symptoms of Parkinson’s disease, 
there are less common associated features which include autonomic dysfunction, cognitive 
disturbance and dysphagia (difficulty in swallowing) (Dunnet and Bjorklund (1999)). 
1.5.2 Parkinson's Disease Epidemiology 
As  indicated  above,  Parkinson’s  disease  is  the  second  most  common  form  of 
neurodegenerative disease. Estimates of the number of new Parkinson’s disease cases in a 
year, or its incidence (generally thought of as the best measure of disease frequency as it is 
not modified by factors effecting survival (Korell & Tanner (2005)), are in the range of 4-20/ 
100’000 per year (Twelves et al. (2003), (Rosati et al. (1980), (Rajput et al. (1984)). This 
variability is most probably down to a difference in the age distribution of the populations, and 
varied  Parkinson’s  disease  diagnostic  criteria  between  the  groups,  rather  than  a  true 
difference in disease frequency. Incidentally, there are around 15’000 new cases in the UK 
each year (Krugger et al. (1998)). The prevalence (total number of cases at one time) of 
Parkinson’s disease in the UK is about one in two hundred people (Krugger et al. (1998)), 
though a widely accepted figure world wide is 200/ 100’000 population (Clough et al. (2003)). 
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1.5.3 Pathology of Parkinson’s Disease 
The  main  pathological  feature  of  Parkinson’s  disease  is  the  degeneration  of 
dopaminergic (dopamine containing) neurons in the substantia nigra (refer to Figure 6), which 
biochemically leads to the loss of dopamine, as well as its metabolites (including homovanillic 
acid  (HVA)  and  3,  4-dihydroxyphenylacetate  (DOPAC)),  its  biosynthetic  enzyme  (tyrosine 
hydroxylase (TH)) and the dopamine transporter (DAT) (Jenner and Olanow (1998)). The 
dopaminergic neurons of the substantia nigra is one of two closely related midbrain groups of 
dopamine producing cells that make up the brain’s dopaminergic diffuse modulatory systems, 
the other being the ventral tegmental area (Figure 6). The dopamine cells of the substantia 
nigra projects axons to the striatum, specifically the caudate nucleus and the putamen - which 
are both part of the basal ganglia in the basal forebrain - crucial in the normal control of 
voluntary and involuntary movement.  
 
Figure 6 – The dopaminergic diffuse modulatory systems arising from the substantia nigra 
and the ventral tegmental area in the midbrain (Bear et al. (1996)). 
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Dopamine  influences  the  activity  of  two  main  motor  pathways  within  the  basal 
ganglia. The function of these pathways is to control the activity of the globus pallidus interna, 
through an excitatory (indirect pathway) and an inhibitory (direct pathway) effect. The globus 
pallidus  interna  has  inhibitory  connections  to  the  thalamus,  which  in  turn  has  excitatory 
connections to the motor cortex which facilitate movement. Dopamine increases the direct 
pathway’s inhibitory activity, whilst decreasing the indirect pathway’s excitatory activity, to 
give rise to a net reduction in the inhibitory effect of the globus pallidus interna upon the 
thalamus, allowing the facilitation of movement (Lang & Lozano (1998a), (Lang & Lozano 
(1998b)). 
The progressive loss of dopamine in Parkinson's disease results in an imbalance of 
normal activity within the basal ganglia’s two main pathways: there is a reduction in the direct 
pathway’s inhibitory activity, and an increase in the indirect pathway’s excitatory activity. An 
increase in globus pallidus interna activity is the overall net effect, which consequently inhibits 
the thalamo-cortical outflow – inhibiting movement (Lang & Lozano (1998a), (Lang & Lozano 
(1998b)). Though this archetypic schema is currently generally accepted in the field as the 
basic  role  of  dopamine  in  facilitating  movement,  some  inconsistencies  exist,  which  have 
prompted  continual  modifications  and  resultant  modifications  (Blandini  et  al.  (2000), 
Rodriquez et al. (2000)). 
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As  well  as  dopaminergic  loss  within  the  substantia  nigra,  the  presence  of  Lewy 
bodies  (Figure  7)  in  areas  of  neuronal  degeneration  is  the  pathological  hallmark  of 
Parkinson's disease. 
 
Figure  7  –  A  substantia  nigra  neuron  with  a  Lewy  body  inclusion 
(www.akronchildrens.org/neuro (2004)) 
  Lewy bodies  were first described by Friedrich Lewy in 1912 in the brain  stem of 
patients with ‘paralysis agitans’ (Parkinson’s disease) and are typically spherical inclusions 
that have a diameter of approximately 4-30 m, with a hyaline eosinophillic core and a pale 
peripheral halo (Figure 7). They are typically found in the substantia nigra, though they can be 
widespread, being found in other areas of the brain such as the hypothalamus, sympathetic 
ganglia,  as  well  as  the  mesolimbic  and  mesocortical  dopaminergic  neurons,  where 
Parkinson's disease neuronal loss also occurs (Gibb and Lees (1988)).   
  As already described/ discussed above (refer to sections 1.3.1, 1.3.6 and 1.4.1), α-
synuclein is a major constituent of Lewy bodies (Spillantini et al. (1998)). Furthermore, other 
UCS α-synuclein-interacting proteins such as UCH-L1 and synphillin-1 have also been shown 
to be present within Lewy body filaments (Wakabayashi et al. (2000), Doran et al. (1983)). 
Towards the end of the last century, Lewy bodies were generally described in the literature as 
the intracellular pathological structures which were directly responsible for the lethal stresses 
realised  within the  dopaminergic  neurons  of  the  substantia  nigra.  However,  as  discussed 
above (refer to section 1.4.2), the fact that Parkinson's disease sufferers carrying mutations in 
the parkin gene did not exhibit Lewy bodies, and that only an accumulation (as opposed to 
aggregation of parkin’s substrates as seen in Lewy bodies) is required to induce neuronal cell 
Lewy Body 
Nerve cell 
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death (Imai et al. (2001)), led to an alternative hypothesis. This hypothesis proposed that 
Lewy  bodies  arise  in  a  protective  capacity,  sequestering  ubiquitinated  α-synuclein  in  an 
attempt to reduce its cytoplasmic concentration before it reaches the ‘critical levels’ described 
by  Rochet  and  Lansbury  (2000),  which  overload  the  UPS  pathways  and  give  rise  to the 
synaptic damage and neurotoxicity which causes Parkinson's disease associated neuronal 
decay. Thence, the protective capacity of Lewy bodies has been overwhelmed in Parkinson's 
disease  cases  that  exhibit  them.  Moreover,  this  protective  hypothesis  explains  why 
occasionally normal healthy individuals harbour Lewy bodies in the brain which are unearthed 
during autopsy. Furthermore, it is important to note that parkin’s ligase activity is probably 
intimately involved in Lewy body formation, owed to the fact that a fully functioning parkin is 
required for their formation. 
  Although Lewy bodies are the pathological hallmark of Parkinson's disease, it is worth 
mentioning  that they  are  not  restricted  to these  disorders.  They  are  also  the  hallmark  of 
dementia with Lewy bodies, and have also been described as a secondary pathology in a 
number  of  other  disorders,  including  progressive  supranuclear  palsy,  corticobasal 
degeneration, multiple system atrophy, motor neuron disease, Hallervorden-Spatz disease, 
sporadic and familial Alzheimer’s disease, subacute sclerosing panencephalitis, and Down’s 
syndrome (Jellinger (2001)). The significance of these associations remains to be formally 
determined, though similarly to Parkinson's disease, Lewy body formation could arise in all 
these neurological disorders as a physiological protective strategy in areas of the brain that 
are sensitive (such as the substantia nigra in Parkinson's disease) to the particular stresses 
generated by the relevant intraneuronal impairment. 
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1.5.4 Environmental Factors in Parkinson's Disease 
  Presently there is clearly very good evidence that several different highly penetrant 
gene mutations can initiate abnormalities in the function or structure of three main proteins, 
which are all involved with the UCS at the synapse, which are capable of inducing stresses on 
the  dopaminergic  cells  in  the  substantia  nigra,  leading  to  Parkinson's  disease.  It  must 
however be borne in mind that from what is currently known, the vast majority of these cases 
give rise to autosomal dominant or recessive Parkinson's disease, i.e. familial Parkinson's 
disease, which only make up a small proportion of those people diagnosed – there is a subset 
of about 5 to 15% of families with more than one affected family member (Gasser (2001)). 
The highly penetrant gene mutations  which give rise to familial Parkinson's disease have 
allowed elucidation of the UPS and its saturation as central to the aetiology and pathology of 
sporadic, as well as familial Parkinson's disease, whose general pathology seem identical, i.e. 
stresses upon the dopaminergic neurons of the substantia nigra. 
  Though studies have shown that the UCS genes identified in monogenically inherited 
forms  of  Parkinson's  disease  can  also  harbour  polymorphisms  associated  (positively  or 
negatively) with sporadic forms of the disease (i.e. UCH-L1’s Ser18Tyr polymorphism and α-
synuclein’s promoter dinucleotide repeat), no consistent findings in every population studied 
have  emerged,  and  to  date  no  specific  gene  polymorphism  has  been  unequivocally 
associated with sporadic Parkinson's disease (Gasser (2001), Tan et al. (2000)) (synphilin-1’s 
Arg642Cys mutation still awaits confirmation). Nevertheless, the substantial role for genetic 
factors in sporadic Parkinson's disease has been clearly demonstrated in monozygotic twin 
studies (Piccini et al. (1997), Burn et al. (1992)). Not including genes involved with the UCS, 
polymorphisms  within  eleven  other  genetic  loci  have  been  associated  with  sporadic 
Parkinson's  disease  (Table  1),  including  genes  encoding  proteins  involved  in  dopamine 
metabolism,  xenobiotic  metabolising  hepatic  enzymes  (that  are  thought  to  protect  from 
environmental toxins – i.e. debrisoquine-4-hydroxylase – discussed later) and more recently, 
neuronal survival genes (Gasser (2001), Momose et al. (2002)). 
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Other Genes Associated with Sporadic 
Parkinson's Disease  Locus 
Dopaminergic 
Dopaminergic transporter 
Dopamine D2 receptor 
Catechol-O-methyltransferase 
Monoamine oxidase B 
Involved in Detoxification of Metabolites 
Debrisoquine-4-hydroxylase 
N-acetyltransferase 
Heme oxygenase 1 
Quinone oxidorductase 2 
Lipoproteins 
Apolipoprotein E 
Neuronal Survival 
Nurr 1 
Brain-derived neurotrophic factor 
 
5p15.3 
11q22-23 
22q12.1 
Xp11.3 
 
22q13 
8p23.1-21.3 
22q12 
6p25 
 
19q13.2 
 
2q22-q23 
11p13 
Table  3  –  Indicates  genes  (UCS  unrelated),  and  their  respective  genetic  loci,  that  are 
associated with sporadic Parkinson's disease (taken and modified from Gasser (2001)).   
  The fact that none of these numerous genes, nor those discussed from the UCS, 
have been unequivocally associated with sporadic Parkinson's disease, and that many of 
these  genes  are  involved  in  the  detoxification  of  metabolites  from  environmental  toxins, 
seems to suggest that sporadic Parkinson's disease cases might well be the result of an 
interaction  between  one  or  more  ‘susceptibility  genes’  (genetically  predisposing  these 
individuals) with other non-genetic causes, i.e. environmental influences. 
  Several  epidemiological  studies  have  been  undertaken  to  determine  which 
environmental factors may be important in the onset of sporadic Parkinson's disease. Rural 
living has been identified by several surveys to increase the relative risk of the development 
of Parkinson's disease, although this observation has not been seen consistently (Barbeau et 
al. (1987), Gorrel et al. (1996), Fall et al. (1999), Semchuk (1992)). The agricultural industry is 
certainly associated with rural living, and work in this environment has also been suggested 
as a risk factor for Parkinson's disease (Seidler et al. (1996)). These observations have raised 
the issue as to whether pesticide use may contribute to the increased risk of Parkinson's 
disease for those in rural areas. An organochloride pesticide – Dieldrin – was found to be a 
risk factor in one case-control study in Germany, and in another investigation, was found to   52
be present in 6 out of 20 Parkinson's disease  brains and in no controls (Semchuk et al. 
(1991)). Another widely available and commonly used pesticide – Rotenone – which is often 
used to control fish stocks in reservoirs, has been shown to induce selective dopaminergic 
cell death, intraneuronal ubiquitin rich protein inclusions (Lewy body-like structures) and a 
motor deficit in rats (Betarbet et al. (2000)). 
  The work carried out on both of these pesticides is of great significance to the idea 
that environmental agents may contribute to Parkinson's disease. Furthermore, perhaps the 
most important  observation  that  has  supported  the  possibility  of  this  environmental factor 
hypothesis,  is  the  fact  that  inadvertent  exposure  to  1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) can induce parkinsonism (generic term referring to slowness and 
mobility problems that look like Parkinson's disease, but not referring to the disease itself) in 
humans within 7 to 14 days (Langston et al. (1983)). This study clearly established that an 
‘environmental’ agent could, through specific uptake and conversion mechanisms, target the 
neurons  of  the  substantia  nigra  and  cause  degeneration  and  a  Parkinson's  disease-like 
picture. MPTP is now routinely used as a toxin to model Parkinson's disease in rodents and 
primates. Importantly, only a small fraction of these individuals exposed to MPTP went onto 
develop Parkinson's disease-like symptoms, which could indicate that only certain people are 
genetically predisposed to MPTP toxicity. 
  The fact that this ’environmental’ agent which is a proven cause of parkinsonism in 
humans  does  not  always  bring  about  its  pathological  effect,  suggests  that  certain  people 
could  be  genetically  predisposed  to  MPTP  toxicity,  i.e.  certain  people  could  harbour 
mutations/  polymorphisms  within  specific  genes  involved  in  MPP+  dopaminergic  uptake 
(active toxin which MPTP is converted to by monoamine oxidase B – refer to Table 1), which 
could protect or cause susceptibility.  
  This obviously lends credence to the hypothesis that sporadic Parkinson's disease 
cases are the result of the interaction of one or more ‘susceptibility genes’ with environmental 
influences. What also lends credence to this hypothesis is the fact that one of the most widely 
studied candidate genes for Parkinson's disease (before those involved in the UCS were 
concentrated on) was the gene for debrisoquine-4-hydroxylase (CYP2D6) – a member of the 
cytochrome  P-450  family  of  mixed  function  oxygenases  –  which  is  involved  in  the   53
detoxification of a number of xenobiotic compounds. Several DNA-sequence variations are 
associated with a decreased (or in some cases enhanced) metabolic activity, and were seen 
to be more common in patients with Parkinson's disease (Armstrong et al. (1992), Smith et al. 
(1992)). 
  Work  uncovering  the  relative  importance  of  certain  genes  in  the  susceptibility  of 
Parkinson's disease, will no doubt give us an even clearer understanding of the causes and 
pathogenesis  involved.  This  will  in  turn  provide  us  with  more  specific  targets  for  future 
treatments that will aid Parkinson's disease modification and neuroprotection. 
1.5.5 Parkinson’s Disease Therapy 
The mainstay of current Parkinson’s disease therapy is standard oral administration 
of  L-dopa  (a  substance  that  crosses  the  blood-brain  barrier  and  is  transformed  into  the 
neurotransmitter dopamine) which can significantly improve motor functioning during the first 
years  of  treatment.  However,  higher  doses  are  required  as  the  neurodegeneration 
progresses,  which  leads  to  deleterious  side  effects  such  as  dyskinesia  (involuntary 
movements). Overall, L-dopa (and other related drugs) can indeed prevent the apparition of 
symptoms such as tremor, rigidity, etc, but it does not treat the progress or underlying cause 
of the disease. However, electrical deep brain stimulation of the subthalamic nucleus reduces 
dyskinesia and the amount of drugs needed by 50% (Sarkis & Mallet (2005)). 
An ideal treatment would be that of gene therapy, which could be administered once 
and work for a long period of time; both restorative and protective gene therapy strategies 
have  been  investigated.  The  restorative  approach  consists  of  a  sustained  and  focused 
delivery of L-dopa (or dopamine) into the striatum, by transfer of genes encoding the L-dopa 
(and/  or  dopamine)  synthetic  enzymes.  Protective  strategies  are  however  the  preferred 
solution, as they prevent the death of the dopaminergic neurons prior to disease onset, but 
also protect functioning neurons post diagnosis. 
Protective strategies include genes that protect against neuronal cell death, including 
those coding for neurotrophic factors such as GDNF. The genetic transfer of GDNF has been 
studied  in  many  animal  models  of  Parkinson’s  disease,  and  the  results  have  been  very   54
encouraging  (Sarkis  &  Mallet  (2005)).  GDNF  can  not  only  prevent  neuronal  death  of 
dopaminergic neurons when expressed directly in the neurons of the substantia nigra, but it 
can also prevent axonal degeneration through ‘sprouting’, when expressed in the projection 
area of the degenerating neurons, compensating for any deficit. Recently, in a study carried 
out by Kordower et al. (2005), young adult nonlesioned rhesus monkeys which were treated 
one  week  prior  with  MPTP,  had  a  lentiviral  vector  expressing  GDNF  injected  into  their 
respective  striatum  and  substantia  nigra.  This  treatment  was  seen  to  reverse  functional 
deficits and completely prevent against nigrostriatal degeneration. An added benefit of GDNF 
use,  is  that  it  can  be  secreted  and  subsequently  captured  by  the  dopaminergic  neuron 
terminals, i.e. it does not need to be expressed inside the neurons themselves.  
Both  restorative  and  protective  approaches  described  are  viable  therapeutic 
strategies for Parkinson’s disease patients. 
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1.6  Basic  Overview  of  other  Neurodegenerative  Diseases  (Dementias) 
Associated with UCH-L1 
1.6.1 Alzheimer’s Disease 
  As  already  discussed  above,  Alzheimer’s  disease  is  the  most  common  form  of 
dementia. 
  The clinical progression of Alzheimer’s disease can be divided into three categories:- 
1.) Progressive memory impairment, 
2.) Progressive cortical dysfunction – separable into three main features:- 
  i.) Aphasia – loss of the ability to use and understand language (speaking, writing and  
                                  listening). 
  ii.) Apraxia – inability  to  perform  purposeful  movements  in  spite  of  being  able  to 
                                  demonstrate normal muscle function. 
  iii.) Visuospatial dysfunction – geographical and environmental disorientation. 
3.) Neuropsychiatric disturbances – separable into four main features:-  
  i.) Mood disturbance. 
  II.) Delusions and hallucinations. 
  iii.) Personality change. 
  iv.) Disorders of behaviour 
  The typical clinical scenario of Alzheimer’s disease is the gradual, insidious onset of 
amnesia with difficulties experienced in learning and recall. In the initial stages of the disease 
the memory impairment is for newly acquired information with recall of remote events being 
relatively unaffected. This early progression of memory and cognitive compromise is generally 
not realised by the individual (anosagnosia). 
  As the disease evolves, cognitive deficits progressively worsen over time, advancing 
from a relatively benign ‘word finding difficulty’ (anomia – precursor to aphasia) to an inability 
to  carry  out  the  more  demanding  tasks  of  daily  living,  such  as  driving  and  finance 
management, as abstract reasoning, executive functions and visuospatial skills all become   56
disrupted,  before  cognitive impairment finally  reaches  a  point  where  the  patient  becomes 
dependent for feeding and hygiene. 
  In  respect  to  neuropsychiatric  symptoms,  personality  change  is  usually  the  first 
clinical change seen in Alzheimer’s disease, and occurs in three quarters of sufferers. As the 
disease progresses delusions, hallucinations and other psychotic behaviours may develop, 
which are often exacerbated by verbal and physical aggressive tendencies. 
  It is worth noting that motor abnormalities are typically absent in Alzheimer’s disease 
patients until the last few years of the disease; patients  with Alzheimer’s disease usually 
survive seven to ten years after the onset of initial symptoms. 
  As  indicated  above,  Alzheimer’s  disease  is  predominantly  an  age-related 
phenomenon and accounts for more than half of all dementia cases in the elderly (Small et al. 
(1997)). In 1998 it was estimated that there will be 360,000 new cases of Alzheimer’s disease 
each year, a figure that is expected to rise to 1.14 million incidences by 2048 (Brookmeyer et 
al.  (1998)).  Reflecting  the  greater  longevity  of  women,  there  is  a  greater  prevalence  of 
Alzheimer’s disease in women than in men (1.2 - 1.5: 1) (Gao et al. (1998)). As expected for a 
disease  whose  most  important  risk  factor  is  increasing  age,  both  the  incidence  and 
prevalence of Alzheimer’s disease increases dramatically with age – exponentially increasing 
after the age of 65 (Kukull & Ganguli (2000)). 
  The  major  pathological  features  found  in  Alzheimer’s  disease  are  generalised 
cerebral atrophy with widespread neuritic amyloid plaques and neurofibrillary tangles – both 
of  which  are  believed  to  be  central  to  the  pathogenesis  of  Alzheimer’s  disease  and  its 
associated degenerative cascade. 
  The pathogenesis of Alzheimer’s disease was once thought to be (and still is by a few 
researchers)  entirely  due  to  the  abnormal  processing  or  disposition  of  amyloid  (Selkoe 
(2000)). The amyloid precursor protein (βAPP) is a transmembrane protein composed of an 
extracellular amino terminal and an intracellular carboxyl terminus. It is initially cleaved by β-
secretase at amino acid 671, which then allows γ-secretase to further cleave the protein 
forming  either  Aβ40  or  Aβ42  depending  on  whether,  respectively,  residue  713  or  711  is 
targeted. This differential proteolytic cleavage of βAPP is normal, however, the Aβ40 species   57
is more often detected in plasma and cerebral spinal fluid, with Aβ42 ordinarily making up 
only  a  small  component.  In  the  Alzheimer’s  disease  state  it  is  the  Aβ42  species  which 
becomes  more  prominent,  which  causes  in  vitro  fibrils  to  be  formed  more  rapidly  (those 
composed of Aβ40 form relatively slower). Owed to this property of the Aβ42 species, it is 
thought that it may become deposited earlier in the genesis of an insoluble senile plaque, 
which is then believed to initiate the cascade of events that result in cell destruction through 
inflammatory responses (Selkoe (2000)). 
  As  well  as  widespread  neuritic  amyloid  plaques,  the  other  primary  pathological 
feature of Alzheimer’s disease is neurofibrillary tangle formation, which is thought to involve 
the abnormal processing of the axonal phosphoprotein tau. Alternative splicing of the mRNA 
for tau gives rise to six isoforms within the central nervous system, with either three tandem 
repeat sequences (3R-tau) or four tandem repeat sequences (4R-tau) in a normal 1: 1 ratio in 
the human adult brain (van Slegtenhorst et al. (2000)). These tandem repeat sequences are 
essential in tau’s main function as a microtubule stabiliser – as they bind the microtubules 
(Lee  et  al.  (2001)).  Alternative  splicing  of  tau’s  mRNA,  together  with  tau’s  degree  of 
phosphorylation, are thought to be key regulators of microtubule binding, and this has led to 
the hypothesis that neurodegeneration and pathology ensue when either or both of these 
mechanisms are disrupted, through mutations or other mechanisms, resulting in abnormal 
aggregation  of  tau.  In  support  of  this,  paired  helical  fragments  which  make  up  the 
neurofibrillary tangles found in Alzheimer’s disease have been shown to be composed  of 
hyperphosphorylated tau (Lee et al. (2001)). Additionally, the normal 1: 1 ratio of 3R- and 4R-
tau is disrupted in several neurodegenerative disorders, including corticobasal degeneration, 
progressive supranuclear palsy and argyrophilic grain disease, where 4R-tau is predominant 
(Dickson (1999)). 
  There  are  only  two  types  of  pharmacological  treatment  of  Alzheimer’s  disease 
currently in use; one is a disease modifying approach using antioxidants, and the second is 
symptomatic treatment with the use of cholinesterase inhibitors (AChEIs). 
  Acetylcholine  is  involved  in  many  aspects  of  cognition,  including  memory  and 
attention. Patients with Alzheimer’s disease have a cholinergic deficit owed to a reduction in 
choline acetyltransferase, and a loss of cholinergic neurons in the basal forebrain through   58
damage caused by the deposition of plaques and tangles. In careful, double-blind, placebo-
controlled studies, AChEI administration has been shown to significantly improve memory in 
Alzheimer’s disease patients. However, all AChEIs have similar side effect profiles including 
increased  bowel  frequency,  nausea  and  vomiting.  Nonetheless,  AChEIs  do  appear  to 
enhance cognitive function in subjects with Alzheimer’s disease, and are recommended for 
the treatment of patients with mild to moderate Alzheimer’s disease (Tang-Wai et al. (2005)). 
  The disease modifying approach to Alzheimer’s disease treatment is mainly focused 
on alpha-tocopherol (vitamin E). In a two-year double-blind study, 341 moderately severe 
Alzheimer’s disease patients participated in a placebo-controlled study comparing placebo 
with alpha-tocopherol. The study showed that there was a significant delay in the treatment 
group reaching the primary endpoints of death, institutionalisation, loss of basic activities of 
daily  living,  or  severe  dementia  –  compared  to that  of  the  placebo  group. The  American 
Academy of Neurology has indicated that vitamin E can be considered in an attempt to slow 
the progression of Alzheimer’s disease (Tang-Wai et al. (2005)). 
  There  are  also  other  potential  medications  which  are  currently  undergoing 
randomised,  blinded  trials  to  evaluate  their  efficacy;  these  include  cholesterol  lowering 
agents,  memantine  and  non-steriodal  anti-inflammatory  drugs  –  which  have  all  shown  an 
association to slow or delay disease onset (Tang-Wai et al. (2005)). 
1.6.2 Dementia with Lewy Bodies 
    Parkinsonism  is  a  major  feature  of  several  dementing  diseases  whose 
features are characteristic of Parkinson’s disease. This movement disorder is characterised 
by  rigidity  and  bradykinesia,  with  rest  tremors  and  gait  instability  also  sometimes  being 
realised. Dementia with Lewy bodies is commonly referred to as a ‘parkinson-plus’ syndrome, 
which are neurodegenerative disorders characterised by parkinsonism and at least one other 
nonparkinsonian  neurological  manifestation;  these  can  be  ‘frontal-subcortical’  cognitive 
deficits  such  as  mental  slowness,  inertia  and  lack  of  initiative,  forgetfulness,  decreased 
executive  functions,  visuospatial  deficits  or  mood  disturbances.  Other  ‘parkinson-plus’ 
syndromes  include  progressive  supranuclear  palsy,  corticobasal  degeneration,  multiple 
system atrophy and amyotrophic lateral sclerosis/ parkinsonism-dementia complex of Guam.   59
Dementia with Lewy bodies is by far the most common of these, as it is now the preferred 
term  for  a  variety  of  clinical  diagnoses,  including  diffuse  Lewy  body  disease,  dementia 
associated with cortical Lewy bodies, the Lewy body variant of Alzheimer’s disease, senile 
dementia of Lewy body type and Lewy body dementia. 
  Dementia with Lewy bodies describes a parkinsonian dementia with a widespread 
distribution of Lewy bodies – eosinophillic cytoplasmic inclusions (refer to section 1.5.3). In 
addition  to  the  parkinsonian  movement  disturbance,  typical  features  are  visuospatial  and 
executive function cognitive impairments that fluctuate over time (lasting minutes and hours, 
rather  than  days),  and  neuropsychiatric  symptoms  such  as  fixed  delusional  visual 
hallucinations. The order of emergence of these cognitive disturbances and parkinsonism are 
variable, though they usually appear within a year of one another. Dementia with Lewy bodies 
parkinsonism includes rigidity, bradykinesia and disturbances of posture and equilibrium, with 
the absence of resting tremor being typical. The cognitive fluctuations seen in dementia with 
Lewy bodies are most commonly realised in marked variations in attention, as well as periods 
of confusion, inattention or decreased responsiveness. 
  The neuropsychiatric manifestations of dementia with Lewy bodies are among the 
most fascinating aspects of the disease, and are extremely helpful in conveying clues for its 
correct diagnosis. The majority of dementia with Lewy bodies patients experience psychiatric 
disturbances  involving  visual  hallucinations,  which  are  most  commonly  fully  formed  and 
animate, and often involve deceased relatives, complete strangers or animals. 
  Depression,  apathy,  anxiety,  insomnia,  paranoia  and  paramnestic  phenomena 
(dreams confused with reality) also frequently occur in dementia with Lewy bodies, which 
often prove very difficult to manage owing to the characteristic pharmalogical sensitivities 
exhibited by dementia with Lewy bodies patients. Furthermore, a number of other features, 
which are variable in occurrence, have also been associated with Dementia with Lewy bodies. 
These include orthostatic hypotension (low blood pressure when standing), unexplained falls 
or syncopy (unconsciousness through a fall in blood pressure) and Rapid Eye Movement 
Sleep  Behaviour  Disorder  (REMSBD)  –  a  disorder  characterised  by  vocalisation  and 
gesticulations with patients acting out their dreams while asleep.   60
  Dementia  with  Lewy  bodies  is  third  most  common  cause  of  dementia  after 
Alzheimer’s disease and vascular dementia, accounting for about fourteen to twenty percent 
of patients (McKeith et al. (1999)). Two thirds of dementia with Lewy bodies patients are male 
(Barber et al. (2001), Klatka et al. (1996)), though it is unclear whether this is due to increased 
male susceptibility to the disease or reduced male survival. Classical epidemiological studies 
to ascertain age and sex variation and potential risk factors for dementia with Lewy bodies 
have yet to be reported.  
  Dementia with Lewy bodies may realise Lewy bodies that are widely distributed – 
they can occur in the substantia nigra, locus ceruleus, dorsal motor nucleus of the vagus, 
nucleus basalis, cholinergic neurons in the basal ganglia, hypothalamus, cerebellar cortex, 
spinal  cord  intermediolateral  cell  column,  and  autonomic  ganglia  including  submucosal 
ganglia of lower esophagus. Dependent upon the distribution of the Lewy bodies, dementia 
with Lewy bodies can be categorised into three types – Type A (involving the brainstem and 
cortex), Type B (limbic or transitional predominant), or Type C (brainstem predominant). The 
severity of cognitive impairment in dementia with Lewy bodies has been shown to correlate 
with Lewy body densities in the frontal and temporal neocortex, as well as Lewy neuritis in the 
hippocampus  (Haroutunian  et  al.  (2000),  Mattila  et  al.  (2000)).  Furthermore,  visual 
hallucinations seem to correlate with the presence of Lewy bodies in the parahippocampal 
and inferior temporal cortices (Harding et al. (2002)). The hippocampus also shows significant 
atrophy and pathology in dementia with Lewy bodies, involving spongiform (sponge-like) and 
vacuolar  changes  (Harvey  et  al.  (1999)).  Moreover,  magnetic  resonance  imaging  (MRI) 
discloses whole brain atrophy with disproportionate atrophy of the temporal lobes (located on 
the side of the cerebrum), although not to the extent seen in Alzheimer’s disease (McKeith et 
al. (1999), Barber et al. (2001)). In addition to the characteristic Lewy bodies, the majority of 
dementia with Lewy bodies patients exhibit senile plaques and neurofibrillary tangles – both 
characteristic features of Alzheimer’s disease pathology (Londos et al. (2002), McKeith et al. 
(1998)).  Dementia  with  Lewy  bodies  brains  have  also  been  shown  to  have  decreased 
concentrations  of  various  neurotransmitters  in  the  putamen  and  neocortex,  including 
dopamine, serotonin and norepinephrine.   61
  The  treatment  of  dementia  with  Lewy  bodies  presents  the  clinician  with  several 
challenges; as although the pathological features have become increasingly well described, 
there is still controversy in the interpretation of the histological features, i.e. do they indicate a 
variety of Alzheimer’s disease, a variety of Parkinson’s disease, a separate distinct entity, a 
coexistence  between  the  two,  or  indeed  a  spectrum  disorder?  A  recent  proposal  for  the 
reclassification of neurodegenerative disorders into synucleinopathies (or tauopathies) may 
help clarify its nosological (medical classification) status. 
  Though this nosological uncertainty must be borne in mid when discussing dementia 
with Lewy bodies, the treatment of established dementia with Lewy bodies will now be briefly 
discussed. One main approach in the current treatment of dementia with Lewy bodies, similar 
to that of Alzheimer’s disease, is the use of cholinesterase inhibitors (AChEIs) to counter the 
severe  cholineacetyltransferase  deficiency,  which  is  more  profound  than  that  seen  in 
Alzheimer’s  disease.  Second  generation  AChEIs  are  beginning  to  be  used,  and  in  one 
randomised trial of 120 patients, significant differences in neuropsychiatric symptoms were 
found in favour of the treated group over the placebo at 20 weeks. Many similar studies show 
a comparable benefit of treatment (Byrne et al. (2005)). Other putative therapeutic agents 
aimed  at  enhancing  cholinergic  function  in  dementia  with  Lewy  bodies  are  muscarinic 
agonists and nicotinic agonists.  
  Although dopamine levels are reduced in post-mortem studies in dementia with Lewy 
bodies, and CSF homovanillic acid levels are reduced in autopsy-confirmed cases, there has 
been little systematic enquiry into the effects of L-dopa therapy in dementia with Lewy bodies. 
Early studies however, found little or no L-dopa response in those that were treated, plus 
acute confusional states (delirium) and other adverse effects which are associated with L-
dopa therapy, may all account towards the lack of enthusiasm to use these drugs in dementia 
with Lewy bodies therapy (Byrne et al. (2005)). 
  Psychiatric symptoms, especially visual hallucinations, are common and troublesome 
in dementia with Lewy bodies,  which are caused by increased  sensitivity to neuroleptics. 
Although neuroleptic sensitivity is not an inevitable consequence of neuroleptic medication in 
dementia  with  Lewy  bodies,  it  is  certainly  common  and  commonly  severe  (Byrne  et  al. 
(2005)). Treatment of psychotic symptoms in dementia with Lewy bodies include the use of   62
GABAergic  agents  such  as  chlormethiazole,  which  reduce  or  even  obviate  visual 
hallucinations,  help  in  associated  sleep  disorders  and  also  has  neuroprotective  effects. 
(GABA has been suggested as an important transmitter in delirium, and also has an important 
function in motor control). (Byrne et al. (2005)). 
1.6.3 Huntington’s Disease 
  Huntington’s  disease  is  an  autosomal  dominant  disorder  that  is  clinically 
characterised by a triad of symptoms and signs:- 
1.) A prominent movement disorder, i.e. chorea – rapid, jerky, ‘dance-like’ movements   
.                of the body. 
2.)  Behavioural and emotional alterations 
3.)  Cognitive decline. 
Huntington’s  disease  is  characterised  by  both  extrapyramidal  motor  abnormalities 
and an impairment of voluntary movements that effects gait, speech and swallowing. Choreic 
movements, which are the major symptom of Huntington’s disease, are involuntary, abrupt, 
irregularly timed and randomly distributed movements of the body – with typical accentuation 
in  the  fingers  and  toes  (Yang  et  al.  (1996)).  Choreic  severity  over  time  ranges  from 
restlessness, hand fidgeting and an unstable ‘dance-like’ gait, to a continuous flow of violent 
movements that are severely disabling and exhausting to the patient. After this first phase of 
the disease, typically lasting around ten years, the  severity of chorea tends to  decrease, 
progressively becoming replaced by bradykinesia and rigidity (core features of parkinsonism) 
and dystonia (involuntary spasms of muscle contraction that causes abnormal movements/ 
postures) (Young et al. (1986)). 
In Huntington’s disease, cognitive and intellectual function typically start to slow soon 
after the chorea begins (Paulsen et al. (2001)). As the disease progresses, patients become 
significantly impaired in an array of cognitive areas  including attention and concentration, 
memory, speech and language, visuospatial skills and frontal executive functions (Snowden 
et  al.  (2001)).  Memory  deficits  occur  in  retrieval  and  procedural  learning  (Bylsma  et  al. 
(1991)), and in contrast to Alzheimer’s disease, Huntington’s disease patients seem to have a   63
greater difficulty retrieving both recent and remote information, with less difficulty in actually 
storing memories (Rohrer et al. (1999)). Speech and language changes include dysarthria (a 
disturbance in the strength and coordination of speech muscles), a decreased verbal fluency, 
and  a  decreased  speech  output  which  ultimately  progresses  to  mutism  (Murray  &  Lenz 
(2001)). The frontal-executive deficits in Huntington’s disease are prominent, and interfere 
with a patient’s ability to perform tasks that require organisation, planning and/ or sequential 
arrangement  of  information  (Zakzanis  (1998)).  As  the  disease  advances,  all  intellectual 
abilities deteriorate to the point where patients are mute and intellectually devastated in the 
final stages. 
Huntington’s disease is equally common in men and women, and effects three to ten 
people per 100’000 (Folstein (1989)). The disease usually begins in the fourth to fifth decade 
(in 90-95% of patients), and typically has a 13- to 16-year course (Folstein (1989)). 
On  autopsy,  macroscopic  inspection  of  advanced  Huntington’s  disease  patients’ 
brains reveal a weight reduction of 10-20% compared with age matched controls. Much of this 
weight loss can be attributed to the shrunken neostriatum, the main neuropathological feature 
in  Huntington’s  disease,  with  gross  atrophy  of  the  putamen  and  especially  the  caudate 
nucleus – which is reduced from a robust structure to a thin ribbon of tissue as little as two or 
three  millimetres  thick  (Myers  (1988)).  At  the  microscopic  level,  histological  changes  are 
concordantly most prominent in the neostriatum, i.e. caudate and putamen, where there is a 
loss of small spiny neurons, which is hypothesised to have the inhibitory effect on movement 
mechanisms through a 70-90% reduction in g-amino butyric acid (GABA) production – an 
inhibiting  neurotransmitter.  The  striatum  also  realises  shrunken  larger  neurons,  with  a 
conspicuous increase in glial cells (Myers (1988)). It is this striatal pathology which likely 
underlies the involuntary movements of Huntington’s disease chorea and dystonia, as well as 
the disordered planning, impulsive behaviours, diminished emotional control and some of the 
other  Huntington’s  disease  symptoms  (Albin  et  al.  (1989)).  While  the  hippocampus  also 
displays moderate neuronal loss, the cerebellum, brainstem and spinal cord are little affected 
in Huntington’s disease (Albin et al. (1989)). The extent of the striatal pathology forms the 
basis of the grading severity of the disease (grades naught to four), which clearly correlates 
with the clinical progression of Huntington’s disease (Myers et al. (1988)).   64
The  Huntington’s  disease  gene  contains  67  exons  (Huntington’s  Disease 
Collaborative Research Group (1993)) and encodes  a 350 KDa protein called Huntingtin. 
Huntington’s disease has been shown to be caused by an expanded CAG repeat located 
within the first exon (+36 to 120bp), which is translated into a polyglutamine tract. The number 
of CAG repeats in the Huntington’s disease gene correlates with a younger age of onset and 
an increased DNA fragmentation in the striatum (Butterworth et al. (1998)). It is hypothesised 
that the abnormal Huntingtin protein aggregates within neurons and glia to form abnormal 
intracytoplasmic inclusions/ filaments (Lunkes et al. (1998)). Furthermore, cysteine aspartate-
specific  proteases  (caspase)  may  cleave  the  mutant  huntingtin,  generating  toxic  protein 
fragments that lead to abnormal metabolism, oxidative stress and mitochondrial dysfunction in 
the cells of the caudate and putamen (Wellington & Hayden (2000)). 
Current treatment of Huntington’s disease is aimed at the symptomatic control of the 
motor and psychiatric aspects of the disorder. Neuroleptics such as haloperidol, which is a 
dopamine antagonist, are used to suppress abnormal movements, though in the later stages 
of the illness as dopamine receptors are destroyed, this medication will gradually become less 
useful and may aggravate dystonia, bradykinesia & dysphagia, gait and balance problems 
(Chua & Chiu (2005)). 
The depression in Huntington’s disease responds to the same treatments as it does 
in the general population, but Huntington’s disease sufferers may become more sensitive to 
the side effects such as  sedation and anticholinergic-induced cognitive decline. Psychotic 
symptoms, irritability or behavioural disturbance all respond to neuroleptics (Chua & Chiu 
(2005)). 
Specific treatments which theoretically target the disease process to slow functional 
decline in disease manifestation, such as antioxidants and other neuroprotective drugs, are 
under trial. Drugs which may slow progression or improve the chorea whilst being tolerated 
include antioxidant coenzyme Q, and remacemide, a non-competitive N-methyl-D-aspartate 
(NMDA) receptor antagonist (Chua & Chiu (2005)). 
Clinical  research  determining  the  early  onset  and  progressive  symptoms  of 
Huntington’s  disease  is  currently  being  undertaken  by  an  international  collaboration  of   65
researchers in Huntington’s disease – the Huntington Study Group. Part of their remit is to 
research  and  develop  new  restorative  therapies  that  rejuvenate  or  replace malfunctioning 
neurons in order to restore functions. 
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1.7 Basic Relevant Molecular Overview 
1.7.1 Eukaryotic Transcription Regulation 
  Regulation  of  gene  expression  is  fundamental  to  biological  systems.  Precise  and 
timely expression of genes is of paramount importance for the proper development of all 
organisms  and  correct  functioning  of  all  cell  types.  Control mechanisms  have  evolved  to 
regulate gene expression according to physiological demands and in response to various 
stimuli. There are multiple levels of control that determine and influence the expression of a 
gene into a functional mature protein. Regulatory systems for the control of gene expression 
exist  at  various  levels,  including  transcription,  precursor-RNA  processing,  translation  of 
mRNAs, degradation of the mature mRNAs, and degradation of the protein products (Lewin 
(1997)). However, it is generally accepted that gene expression is predominantly regulated at 
the level of transcription (Hames (1988)).  
  Transcriptional activation is a two-step process because most genes exist at some 
time in an inert state tightly packaged with histones into chromatin (Lewin (1997)). Before 
transcription  can  commence  this  inert  structure  must  be  decondensed  so  transcriptional 
control  sequences  are  made  available  to  regulatory  proteins.  The  exact  mechanisms  for 
decondensing chromatin are not yet fully elucidated but result in the appropriate topology of 
the  DNA  helix  which  will  expose  the  relevant  sequences  (Hames  (1988)).  Following 
decondensation  the  second  activation  step  takes  place  which  involves  the  interaction  of 
regulatory proteins known as transcription factors (TFs) with specific DNA sequences (Tjian 
and Maniatis (1994)). 
  In  the  majority  of  cases,  the  regulatory  sequences  immediately  adjacent  to  the 
encoding region constitute the core promoter region. The core promoter region and additional 
regulatory sequences situated either upstream or downstream, in close proximity or not to the 
encoding  region,  offer  binding  sites  for  transcription  factors  that  influence  the  proper 
positioning and function of the transcription machinery, and can up-regulate or completely 
silence the transcription of the particular gene.    67
  Eukaryotic genes are transcribed by one of three polymerases, RNA polymerase I, II 
or III, with the aid of transcription factors that direct the appropriate polymerase to the start 
site, unwind the DNA, and perform a range of other tasks without which the polymerase would 
not be able to function properly.  
  UCH-L1 belongs to the class of genes transcribed by RNA polymerase II. The typical 
eukaryotic  class  II  gene includes  three  kinds  of  transcriptional  control  elements: the  core 
promoter, upstream regulatory elements, and distant regulatory elements. Additionally, more 
recent  work  has  elucidated  DNA  methylation  as  another  important  control  factor  in 
mammalian gene transcription. 
1.7.1.1 The Core Promoter 
  The core promoter for every gene is situated immediately adjacent to the transcription 
start site and is characterised by two key genetic elements: The TATA box and the initiator 
(Inr) element (Smale and Baltimore (1989)). In experimental in vitro systems core promoter 
sequences  were  shown  to  be  the minimal  sequence  elements  necessary  to  nucleate  the 
promoter and recruit RNA polymerase II in order to initiate transcription (Novina et al. (1996)). 
  The  TATA  box  is  an  adenine-thymine  rich  (AT  rich)  stretch  of  sequence  usually 
situated  25-30  nucleotides  upstream  from  the  transcription  start  site  (Breathnach  and 
Chambon (1981)). It forms a binding site for a protein factor, the TATA box Binding Protein 
(TBP). TBP is one of the most highly conserved proteins in eukaryotic evolution and probably 
one  of  the  most  intensively  studied  (Buratowski  (1994)).  TBP  alone  cannot  mediate 
transcription regulation; this activity requires the entire transcription factor D complex (TFIID), 
which consists of TBP and the TBP-associated factors (Tjian and Maniatis (1994)). In the 
absence of a TATA box element, components of the TFIID complex can bind either directly or 
indirectly to the other key core promoter genetic element, the Initiator (Inr) element. The Inr 
element is defined as sequences spanning a transcription start site that can autonomously 
function as a promoter (Buratowski (1994)). 
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usually  associated  with  gene  promoters  and  extend  further  downstream  into  transcribed 
regions (Bird (1987)). 
  Methylation of CpG islands can result in gene silencing (Cedar (1998), Gaston & 
Fried  (1995)),  and  direct  effects  of  CpG  methylation  on  binding  and  activity  for  various 
transcription factors has been observed (Gaston & Fried (1995)). Furthermore, demethylation 
is  a  well-known  mechanism  for  the  developmental  activation  of  tissue-specific  gene 
expression (Cedar (1998)). 
1.7.2 Genome Variation 
  The  human  genome  comprises  of  nuclear  (23  chromosomes)  and  mitochondrial 
(several to several thousand copies of the circular molecule) genomes, with a total of 3,300 
million nucleotides for the haploid cell. Only 30% of the human genome sequence contains 
genes and 3% encodes for proteins. It is estimated that there are about 35,000 in the human 
genome, 58% of them have been annotated, and the rest do not have a known function. The 
average size of a gene is ~27kb with considerable variation.  
  There are no two individuals (except identical twins) that are exactly the same. This 
difference in phenotypic traits is the result of sequence variations found within an individual’s 
genes.  This  ‘nucleotide  diversity’  varies  greatly  across  the  genome,  and  although  these 
variations are found on all chromosomes, their distribution is not uniform. 
  Two major types of nucleotide sequence variation exist in human genomes; these are 
single nucleotide polymorphisms (SNPs) and variable number of tandem repeats (VNTRs). 
SNPs are much more prevalent with over 4 million having so far been discovered, compared 
to  a  VNTR  number  approaching  120,000.  Other  sequence  variations  are  attributable  to 
insertions/ deletions and rearrangements. SNP classification is dependent on the variant rarer 
allele’s  frequency  in  the  population  being  greater  than  1%  occurrence.  Typically  base 
changes that have a frequency of less than 1% are termed mutations. About half to two thirds 
of SNPs are shared between two populations, and the rest are ethnic specific. SNPs which 
are located in genes not only attribute to trait difference between individuals, but it is now 
becoming apparent that SNP combinations play an important role in disease susceptibility.     71
  Numerous studies have been performed to estimate the sequence variation within the 
human genome. Screening of a 9.7kb region of the human lipoprotein lipase gene from three 
diverse populations gave a total of 88 sites showing sequence variation, of which 79 were 
SNPs and 9 were insertion/ deletion variations (Nickerson et al. (1998)). Another study on a 
4Mb high density SNP based map around the human apolipoprotein E gene detected a SNP 
frequency of one SNP per 1.1kb of genomic sequence (Lai et al. (1998)). A further study, 
which took into account all publicly available SNPs spanning the whole genome sequence, 
indicated a SNP frequency of one every 1.9kb (Sachidanandom et al. (2001)). From these 
three studies a wide range of values are evident, though as briefly mentioned above, the area 
chosen to evaluate would have had a large impact on the sequence variation realised. The 
most commonly cited value for the single base variation between two non-related individuals 
is one SNP every 1kb on average. This figure equates to a 0.1% chance of any base being 
heterozygous in an individual, and indicates a 99.9% homology among human genomes – the 
0.1% variation giving rise to individual phenotypic difference. This 0.1% variation translates 
into several million sequence variations between two non-related individuals, which results in 
approximately 100,000 amino acid differences between their proteomes (Brookes (1999)). 
  Nearly  every  variable  site  results  from  a  single  historical  mutational  event;  this 
statement is supported by the fact that the mutation rate at a given site is of the order of 10
-8 
per generation, which is relatively very low contrasted to the number of generations (in the 
order of 10
4) that divides any two humans from a single common ancestor (The International 
HapMap Consortium (2003)). Each new allele which arises on a particular chromosomal block 
is initially associated with the other alleles, and this specific set of alleles is referred to as a 
haplotype. 
  Coinheritance of SNP alleles on a particular haplotype leads to these alleles being 
associated  in  the  population,  which  is  referred  to  as  linkage  disequilibrium.  These 
associations however decline with distance, as the likelihood of the maternal and paternal 
chromosomes  undergoing  recombination  (exchanging  corresponding  segments  of  DNA) 
between two SNPs increases with nucleotide length (The International HapMap Consortium 
(2003)).   72
1.7.2.1 Hardy-Weinberg Equilibrium 
  The Hardy-Weinberg equilibrium was named after G. H. Hardy & W. Weinberg, and 
its underlying principle states that genotype allele frequencies remain constant – or are in 
equilibrium  –  from  generation  to  generation,  unless  specific  influences  are  introduced. 
Disturbing influences can take the form of mutations, gene flow, random genetic drift, non-
random mating, (natural) selection and limited population size. 
  The Hardy-Weinberg principle can be used as a Punnett square (a cross/ breeding 
diagram outcome predictor) for populations (Figure 8). It can be used to predict the probability 
of an offspring’s genotype based on the parents’ genotype, and vice versa. Furthermore, the 
Hardy-Weinberg  formula  can  be  employed  to  calculate  whether  the  observed  genotype 
frequency  data  for  a  given  population  is  within  a  normal  distribution  pattern,  by  way  of 
calculating  the  deviation  from  the  expected  genotype  frequencies  through  (typically)  chi-
squared test application. 
 
Figure 8 – The Hardy-Weinberg principle for two alleles. The x-axis shows the two allele 
frequencies p and q, the y-axis displays the genotype frequencies, and the different glyphs 
represent the three possible genotypes.                                                                          . 
(http://content.answers.com/main/content/wp/en/thumb/b/b7/320px-Hardy-Weinberg.gif). 
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cords, preceding peak production of motor neurons, and in the dorsal root and cranial nerve 
ganglia,  where  it  appears  before  the  differentiation  of  sensory  neurons  (Schofield  et  al. 
(1995)). It is also worth noting that this study indicated UCH-L1 as one of the earliest neural-
specific genes to be expressed in the developing nervous system. 
  UCH-L1’s neuronal cell type specificity has been supported by UCH-L1 expression 
work in vitro (Mann et al. (1996)). UCH-L1 mRNA was seen to be absent in three different 
types  of  nonneuronal  cell  types,  while  the  UCH-L1  protein  was  clearly  observed  in 
neuroblastoma cell lines using an immunoreactivity strategy. This study also observed that 
the  UCH-L1  promoter  was  threefold  more  active  than  the  SV40  promoter/  enhancer  in 
neuroblastoma  cells,  and  in  contrast,  was  tenfold less  active in  comparison  to  the  SV40 
promoter/ enhancer in nonneuronal cells. This suggests that there are elements within the 
1kb promoter that contribute to UCH-L1s neural-specific expression. However, this study also 
revealed, though at lower activity, that the UCH-L1 promoter is also active in nonneuronal 
cells. This linked to the complete absence of UCH-L1 mRNA in nonneuronal cells above, 
indicates that an additional regulatory element, located outside the 1kb promoter may also be 
required for achieving neural-restricted expression of UCH-L1, which could then also play a 
role in its spatial and temporal (CNS) developmental expression.  
  Such  additional  regulatory  elements  could  take  the  form  of  a  ‘distant  regulatory 
silencer element’, or alternatively a mechanism of gene regulation such as DNA methylation 
may operate (refer to section 1.6.1.4).  
  DNA methylation within the 1kb promoter may also play a role in UCH-L1 expression. 
Analysis of the CpG content of the 5’ end of the UCH-L1 gene showed the presence of a 
complete CpG island region of at least 400bp that  spans the transcriptional initiation site 
(Mann et al. (1996)). Interestingly, this region also coincides with the 5’ end of the minimal 
promoter. 
  Mann  et  al.  also  elucidated  a  further  655bp  of  upstream  UCH-L1  sequence,  in 
addition to the ~340bp that was already known, which then allowed a 1kb human UCH-L1 
promoter  sequence  to  be  further  analysed  with  the  use  of  the  ‘signal  scan  programme’ 
(HGMP  database),  which  used  mammalian,  bird,  amphibian,  insect,  plant  and  yeast   75
databases to identify known regulatory sequence elements. The results were then aligned 
with the results also obtained for Monodelphis domestica to give a sequence conservation 
perspective (Figure 10). 
  The  optimal  alignment  of  the  human  and  Monodelphis  UCH-L1  5’  flanking  DNA 
revealed  the  presence  of  a  perfectly  conserved  12bp  sequence  (PSN)  within  the  59bp 
activator region (Figure 10), and its similarity to sequences in the promoters of human and rat 
synapsin 1 and neurone-specific enolase genes (Sauerwald et al. (1990), Oliva et al. (1991)), 
indicates a potentially powerful regulatory element. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   76
 
Figure  10  –  Comparison  of  the  nucleotide  sequences  at  the  5’  ends  of  the  human  and 
Monodelphis UCH-L1 genes by optimal sequence alignment. The Monodelphis sequence (M) 
is displayed on the top line, with the human (H) sequence displayed below it. Spacings (-) are 
used  where  appropriate  to  achieve  optimal  alignment,  and  those  nucleotides  seen  to  be 
conserved are highlighted (*). Sequences are numbered in the 5’ to 3’ direction from the 
major transcription initiation sites, which are numbered +1 and +5 for the Monodelphis gene 
and  +1  for  the  human  gene  (positions  marked  by  arrows).  Sequences  for  the  known 
transcription factor binding sites TATA, AP1, AP2, SP1, and Oct, the metal binding factor 
(MBF-1),  the  heat  shock  transcription factor  (HSTF),  the  glucocorticoid  response  element 
(GRE), the antennapaedia homeobox binding site (ANT HBS), and Pax 8 are shown by the 
use of lines under the appropriate nucleotides. The PSN and motif 5 sequences conserved 
between human and Monodelphis are highlighted by double lines (one above and one below 
the sequence), as is a third unnamed conserved motif that contains an inverted GATA factor 
binding sequence and the ATTA core of the homeobox binding sites (Mann et al. (1996)).   77
1.9 This Study’s Importance 
  This study will be mainly focusing on UCH-L1’s promoter sequence variants in the 
Caucasian population. UCH-L1, as already discussed above (refer to section 1.3), has critical 
roles as a hydrolyser and a ubiquityl-ligase within the UCS. 
  What also makes UCH-L1 such a good candidate gene for further study in reference 
to neurodegenerative disease susceptibility, is the fact that it has revealed three documented 
coding region variants associated with neurological disorders: one mutation directly implicated 
in familial Parkinson's disease  with high penetrance (Ile93Met), another mutation possibly 
with low penetrance (Met124Leu), and a polymorphism (Ser18Tyr) which seems to protect 
against sporadic Parkinson's disease and Alzheimer’s disease in certain populations, whilst 
also possibly delaying the onset of Huntington’s disease. 
  No work has yet investigated UCH-L1’s promoter/ 5’ untranslated region, specifically 
the potential neurodegenerative disease-association of sequence variants within this region, 
which  could  alter  UCH-L1’s  expression.  Sequence variation  within  α-synuclein’s  promoter 
(complex  dinucleotide  repeat  –  refer  to  section  1.4.1)  has  already  been  associated  with 
sporadic Parkinson's disease, and a UCH-L1 pathological route towards Parkinson's disease 
susceptibility has been established encompassing Rochet & Lansbury’s ‘critical concentration 
of α-synuclein’ hypothesis (2000). UCH-L1 has an intimate relationship with α-synuclein at the 
synapse which may even involve its regulation (refer to section 1.3.6), thence unveiling of any 
common  promoter  haplotypes  which  could  alter  its  expression,  should  be  seen  as  a 
potentially  very  important  step  in  uncovering  primary  risk  factors  in  the  pathogenesis  of 
sporadic Parkinson's disease and dementia. 
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2 Materials & Methods 
2.1 Polymorphism Identification 
2.1.1 DNA Arrays 
2.1.1.1 x26 Control DNA Array 
  Comprised of 26 unrelated healthy genomic DNA samples at a concentration of 7ng/ 
 l. DNA was extracted from annonymised blood samples (taken with permission from people 
working  in  the  Human  Genetics  department  in  Southampton  General  Hospital  in  2001); 
thence, no data on age, gender, etc is available. Samples had the following nomenclature: 
B1-B5; L1-L6, L12, L15, L18-L21 and L23-L30.  
2.1.1.2 x64 Control DNA Array 
  Comprised  of  31  unrelated  healthy  Caucasian  genomic  DNA  samples  at  a 
concentration of 7ng/  l. DNA was extracted from annonymised blood samples (taken with 
permission from people working in the Human Genetics department in Southampton General 
Hospital in 2003); thence, no data on age, gender, etc is available. The array was made up of 
30 samples in duplicate and 1 in quadruplicate; how this corresponded within the actual 64 
well array is outlined below:- 
A1 – B2  B1 – A7  C1 – H3  D1 – D6  E1 – B6  F1 – H6  G1 – F2  H1 – H2 
G6 – G8 
A2 – F4  B2 – A1  C2 – C4  D2 – C6  E2 – E7  F2 – G1  G2 – G3  H2 – H1 
G6 – G8 
A3 – F8  B3 – C5  C3 – A6  D3 – G4  E3 – G5  F3 – H7  G3 – G2  H3 – C1 
A4 – C7  B4 – A5  C4 – C2  D4 – B7  E4 – H5  F4 – A2  G4 – D3  H4 – F7 
A5 – B4  B5 – C8  C5 – B3  D5 – F6  E5 – G7  F5 – D7  G5 – E3  H5 – E4 
A6 – C3  B6 – E1  C6 – D2  D6 – D1  E6 – E8  F6- D5  G6 – G8 
H1 – H2  H6 – F1 
A7 – B1  B7 – D4  C7 – A4  D7 – F5  E7 – E2  F7 – H4  G7 – E5  H7 – F3 
A8 – H8  B8 – D8  C8 – B5  D8 – B8  E8 – E6  F8 – A3  G8 – G6 
H1 – H2  H8 – A8 
Table 4 – Indicates the sample duplicity and quadruplicity in the x64 control DNA array.   80
2.1.1.3 x480 DNA Array with Cognitive Function Data 
The sample comprised of 480 Caucasian unrelated men and women, aged 66–75 
years, who had been born in the Jessop Hospital for Women, Sheffield, UK. The participants 
had been traced using the National Health Service Central Register and were still living in 
Sheffield. The study was approved by the North Sheffield Research Ethics Committee, and 
all participants gave written informed consent. The investigation conforms with the principles 
outlined in the Declaration of Helsinki. Participants were interviewed by a fieldworker who 
administered the cognitive function tests (refer to section 2.5.2). The field worker also took a 
fasting venous blood sample which was then stored at -80° C. Genomic DNA extracted was 
from the blood sample and diluted to a final concentration of 7ng/ µl. An aliquot of the DNA 
samples was used in this study to determine the subjects’ respective UCH-L1 genotypes. 
2.1.2 Polyacrylamide MADGE Gels 
  In this study, all PCR products and PCR endonuclease digestions were visualised by 
way of Microplate Array Diagonal Gel Electrophoresis (MADGE) on horizontal polyacrylamide 
(H-PAGE) gels (Day et al. (1994)). 
2.1.2.1 MADGE Background 
  Microplate  Array  Diagonal  Gel  Electrophoresis  was  invented  at  the  Division  of 
Cardiovascular  Genetics,  Department  of  Medicine,  University  College  Medical  School  in 
1994. 
  The advantages of the MADGE system is that it uses the same 96 well format as is 
employed in most PCR reactions – a 9mm pitch between wells – which ensures compatibility 
with existing 96-well arrays and rapid loading with a multichannel pipette. Cubic wells are 
2mm and the array is rotated by 71.6°  to extend the track length to 26.5 to 50mm (Figure 11) 
(Gaunt et al. (2003)), thus ensuring good resolution of DNA bands and rapid interpretation of 
results.   81
 
Figure 11 – 96-well MADGE gel showing track ‘A1’ with direction of electrophoresis (71.6° ) 
(Gaunt et al. (2003)). 
2.1.2.2 MADGE Gel Preparation 
  All horizontal polyacrylamide MADGE gels used in this study were 5% gels and were 
prepared using the following protocol:- 
- Glass plate was cleaned using methanol (BDH Laboratory Supplies), and then wiped over 
lightly with sticky silane (refer to appendices). 
-  8.3ml  30%  acrylamide  (Severn  Biotech)  was  measured  into  a  measuring  cylinder,  5ml 
10xTBE was added, and was filled to 50ml with deionised water and poured into a beaker. 
- 150 l of 25% APS (refer to appendices) and TEMED were then individually added. 
- The gel mixture was then poured into the former, and the glass plate was placed over the 
former and left for 20 minutes to set. 
- Once set, the gel was prised apart with the MADGE gel adhering to the glass plate.   82
- The gel was then stained in an ethidium bromide (Sigma) solution (20 l per 200ml 1xTBE) 
for 20 minutes. 
2.1.2.3 MADGE Gel Loading and Running 
- 2 l of MADGE loading dye (refer to appendices) was added to 5 l PCR/ digest product and 
mixed well. 
- 5 l of required samples were loaded into corresponding gel wells. 
- Once samples were loaded, the gel was transferred into the ‘gel running pack’, and anode 
and cathode connections were secured. 
-  Gels  were  typically  run  between  8-15  minutes  at  150  volts  (0.02  amps).  Time  was 
dependent on size of DNA fragment (larger fragments take longer to run through gel matrix). 
- Once gels had been run, they were visualised in a Fluorimager 595 (Molecular Dynamics) 
using ultra-violet to elucidate required DNA bands. 
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2.1.2.4 DNA Ladders 
  In this study, two different DNA ladders were used to decipher the size of DNA bands 
visualised on polyacrylamide and agarose gels – they were both sourced from Invitrogen and 
are displayed below:-  
2.1.2.4.1 - 100bp DNA Ladder  2.1.2.4.2 - 1kb DNA Extension Ladder 
 
Figure 12 – The 100bp ladder consists of 15 
blunt-ended fragments ranging in length from 
100  to  1,500bp,  at  100-bp  increments,  and 
an additional fragment at 2,072bp. 
 
Figure 13 – The 1kb DNA extension ladder 
consists of 8 fragments ranging in length from 
1,018  to  8,144-bp  increments,  as  well  as 
bands of 506bp, 517bp, 1,636bp, 10kb, 15kb, 
20kb, and 40kb. 
2.1.3 Polymerase Chain Reaction  
(to amplify relevant UCH-L1 DNA for dHPLC analysis) 
2.1.3.1 Theory 
  Polymerase Chain Reaction (PCR) refers to a process for amplifying one or more 
specific DNA sequences contained in a nucleic acid or mixture of nucleic acids. It utilises two 
primers complementary to the ends of each specific sequence to be amplified – referred to as 
the ‘sense’ and ‘anti-sense’ primers. Extension of each primer creates a DNA strand including 
a sequence complementary to the opposite primer.   84
  PCR is a cyclic procedure in which; 1) the relevant DNA strand is denatured; 2) the 
primers  are  allowed  to  anneal  with  the  DNA  strand;  and  3)  the  primers  are  extended, 
synthesizing DNA complementary to the sequence to be amplified. These steps are repeated 
many times and result in an exponential amplification of the specific sequence. Each cycle 
doubles the amount of the specific DNA sequence being amplified (Figure 14). 
  The PCR method used in this study utilized a thermostable DNA polymerase to effect 
primer  extension.  This  allowed  the  steps  to  be  repeated  by  simple  adjustment  of  the 
temperature  and  MgCl2  concentration  to  affect  denaturation,  primer  annealing,  and 
polymerisation. 
 
Figure 14 – Basic outline of the PCR reaction (Newton and Graham (1994)). 
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2.1.3.2 Protocol 
  The following quantities were used in preparation of all PCR reactions carried out (all 
reagents used were sourced form Invitrogen):- 
-  DNA (Genomic ~7ng/  l/ Plasmid ~0.3 g/  l) - 1 l 
-  PCR Buffer (x 10) (200mM Tris-HCl, 500mM KCl) – 2.5 l 
-  dNTPs (8 mM) – 0.625 l 
-  MgCl2 (25 mM) – 1.0- 3.0 l (depending on PCR optimisation results) 
-  Sense Primer (1 l/  g) – 0.1 l 
-  Anti-sense Primer (1 l/  g) – 0.1 l 
-  DNA Taq Polymerase (5 units/  l) – 0.2 l 
-  Deionised Water – 19.475- 17.475 l (depending on MgCl2 required) 
  The following PCR reaction programme was employed for all PCR reactions (on a 
‘PTC DNA Engine Tetrad’ (gradient cycler) – MJ Research):- 
95° C for 5 mins 
50- 70° C for 2 mins 
72° C for 2 mins 
95° C for 1 min 
50- 70° C for 1 min 
72° C for 2 mins 
72° C for 6 mins 
END 
  The  specific  temperatures  used  between  50  and  70° C  f or  each  DNA  sequence 
amplified in this study, were determined in PCR optimisation reactions, in which the above 
reaction programme was employed. 
 
 
x 34   86
 
 
2.1.3.3 Polymerase Chain Reaction + Betaine 
2.1.3.3.1 Theory 
  Betaine  improves  the  amplification  of  certain  DNA  sequences  by  reducing  the 
formation of secondary structure caused by GC-rich regions, and is thus generally applicable 
to ameliorate the amplification of GC-rich DNA sequences (Henke et al. (1997)). 
2.1.3.3.2 Protocol 
  PCR + betaine protocol remained the same as the ‘normal’ ‘PCR protocol (refer to 
section 2.1.3), except the following quantities were always modified in preparation of the PCR 
reaction:- 
-  Addition of Betaine (5M) – 6.5 l (1.3mM in final 25 l reaction concentration) 
-  Volume of deionised water was thus also reduced by 6.5 l 
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2.1.4 denaturing High Performance Liquid Chromatography 
(to identify UCH-L1 regions harbouring potential mutations/ polymorphisms) 
2.1.4.1 Basic HPLC Theory 
  High-Performance (or High Pressure) Liquid Chromatography (HPLC) is a form of 
column chromatography used to separate, identify and quantify. HPLC employs a column that 
holds chromatographic packing material (the absorbent or stationary phase), a pump that 
moves the mobile phases (sample being analysed and the solvent that moves it through the 
column (the most common are methanol and acetonitrile, but the choice is dependent on the 
nature of the stationary phase and the sample), and a detector that measures the retention 
times of the molecules. 
  In HPLC the sample to be analysed (or analyte) is introduced in small volume to the 
stream  of  solvent  (mobile  phase)  and  is  retarded  by  specific  chemical  and  physical 
interactions with the stationary phase as it transverses the column length. The nature of the 
analyte,  stationary  phase  and  the  mobile  phase  composition  all  effect  the  degree  of 
retardation. One of the fundamental principles of HPLC is the fact that the time it takes for a 
specific  analyte  to  elute  from  the  mobile  phase  (retention  time)  is  a  unique  identifying 
characteristic of said analyte. The use of pressure in HPLC increases linear velocity through 
the column, thus giving the component s less time to diffuse, leading to improved resolution in 
the resulting chromatogram. 
  Varying the mobile phase composition during the analysis is typically employed and is 
known as ‘gradient elution’, in which the gradient separates the analyte mixtures as a function 
of the affinity for the current mobile phase composition relative to the stationary phase (e.g. in 
a water/ methanol gradient, the more hydrophobic components will elute under relatively high 
methanol  conditions  (hydrophobic),  whereas  the  more  hydrophilic  components  will  elute 
relatively low methanol (high water) conditions).  
  Optimum HPLC methods for a given analyte are those which give the best separation 
of peaks on the resulting chromatogram. 
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2.1.4.2 dHPLC Theory 
  Individuals who are heterozygous in a mutation or polymorphism have a 1:1 ratio of 
wild-type and mutant DNA. A mixture of hetero- and homoduplexes is formed when the PCR 
product is hybridised by heating to 95° C and slowly cool ed. After this treatment, a sample will 
contain a mixture of hetero- and homoduplexes (Figure 15). 
 
Figure 15 – Creation of a mixture of hetero- and homoduplexes through hybridisation (Taylor 
et al. (1999)). 
  Mutations are visualised as a characteristic pattern of peaks corresponding to the 
mixture of heteroduplexes and homoduplexes formed when wild-type and mutant DNA are 
hybridised. 
  Figure 16 (refer below) shows the behaviour of four hybridised species in response to 
a range of temperature regimes used in an experiment. Under the non-denaturing conditions 
used for separating the DNA fragments (51° C), all f our species have the same retention time. 
As the temperature increases to 54° C, the heterodupl ex DNA fragments start to denature in 
the region either side of the mismatched bases and begin to emerge ahead of the still intact 
homoduplexes. At 56° C the homoduplexes start to denature, with the A-T homoduplex being 
marginally more denatured than the C-G homoduplex. Optimum separation is seen to be at 
57° C.   90
 
Figure 16 – Temperature-dependent resolution of heteroduplexes from homoduplexes. In the 
absence of the mutation, only one peak, that of the wild-type homoduplex, would be observed 
(Taylor et al. (1999)). 
2.1.4.3 Setting up a dHPLC Method in ‘Wavemaker
TM’ (Transgenomic, Inc) 
- Required DNA sequence was inserted into the DNA sequence panel.   
- A helical fraction vs. temperature graph could then be calculated. From this graph, the 
optimum temperature for each major melting domain (segment of DNA with a difference in 
helical fraction vs. temperature characteristic) of the DNA sequence was identified – between 
75 and 99% helical fraction. 
- Method(s) could then be built for each respective melting domain of each DNA sequence to 
be  dHPLC  scanned  (entire  DNA  sequences  could  be  realised  within  75  and  99%  helical 
fraction at the same temperature). 
- The oven temperature was set to that calculated above.   91
-  The  ‘Gradient Template’,  which  creates  the  gradient  of  Buffer  A  and  Buffer B  (refer to 
appendices); critical in the differing elution of heteroduplexes from homoduplexes, and thus 
their resolution, was then modified in the ‘Gradient Parameters’ panel as follows:- 
 
Drop for Loading – 5% 
-  Allows  non-retained  components  such  as  dNTPs, 
primers  and  buffers  to  pass  through  the  separation 
cartridge when the PCR products are injected, so they 
do not influence the separation. 
 
Loading Duration – 0.1 mins 
Sets  the  time  over  which  the  ‘Drop  for  Loading’ 
increases  (%  Buffer  B),  to  the  start  of  the  linear 
gradient. 
 
Gradient Duration – 4 mins 
Length of time over which the % Buffer B increases 
linearly  at  a  %  Buffer  B  per  minute.  (Selected  by 
‘Slope’ option – default of 2% used) 
 
Clean Duration – 0.5 mins 
Length  of time  at  which  the  %  Buffer  B  remains  at 
100%  to  clean  high molecular  weight  DNA  such  as 
genomic DNA and contaminants from the cartridge.  
 
Equilibration Duration - 20 mins 
Length  of  time  that  the  %  Buffer  B  remains  at  the 
initial ‘Drop for Loading’ percentage, to equilibrate for 
the next injection. 
- The rest of the gradient parameters were left at the default values, as they were not deemed 
important in the dHPLC application used. 
- Finally the ‘Acquisition Time’ (time of individual dHPLC scan) was set to 6.8 mins. 
-  The  ‘Wavemaker’  method  was  then  saved  and  exported  for  running  into  ‘HSM’  (main 
operating software for the dHPLC apparatus – Transgenomic, Inc). 
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2.1.4.4 dHPLC Protocol 
  Before the samples could be placed into the ‘auto-sampler’ for the dHPLC mutation 
scanning run to commence, the following preparatory steps had to be carried out:- 
- Buffers A, B and the Wash Solution (Buffer D) were made up fresh every 7 days. Buffer C 
(75% acetonitrile (Sigma)) was renewed every 3-4 weeks. 
- Pumps A, B, C and D were purged for 3-4 minutes to remove any air build up from the 
system. 
- Autosampler line was washed 5 times to remove any air build up. 
- Column equilibration took place for 10 minutes at a flow rate of 0.9ml/ minute. 
-  ‘Rack  Parameters’  (dimensions  of  sample  well  plate)  for  96  well  plate  containing  PCR 
products were checked in ‘HSM System Manager’ software. 
- Sample table was prepared according to PCR products to be scanned and ‘Wavemaker’ 
methods required. 8 l was entered as amount of sample to be injected, and a 3 minute 
equilibration time was also entered after each different method to be used in the sample table. 
- A 75% acetonitrile (Aldrich) wash to clean the separation cartridge, followed by a low flow 
(0.05ml/ minute – ‘sleep mode’) method were always entered into the sample table to end a 
dHPLC scanning run. 
- In the ‘Autosampler Set Up’ the ‘needle down speed’ was set to ‘Fast’, the ‘injection method’ 
was set to ‘Cut’, and the ‘lead’ and ‘rear volumes’ were set to 1.0 l. 
  Once the preparatory steps above had been completed, the samples (in a 96 well 
plate), which had been heated to 95° C and slowly cooled to allow heteroduplex formation in 
any samples with a mutation/ polymorphism, were then placed in the autosampler in the pre-
specified positions. The dHPLC run was then initialised. 
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2.1.5 DNA Sequencing 
(to characterise specific nature of mutations/ polymorphisms) 
2.1.5.1 Underlying Theory 
  DNA sequencing is the determination of the precise sequence of nucleotides in a 
sample  of  DNA.  The  method  used  in  this  study  is  referred  to  as  the  ‘dideoxy’  or  ‘chain 
termination’ method. 
  DNA is synthesised from four deoxynucleotide triphosphates. Figure 17 shows one of 
them – deoxythymidine triphosphate (dTTP). 
 
Figure 17 – Chemical structure of deoxythymidine triphosphate. 
  The  ‘dideoxy  method’  gets  its  name  from  the  critical  role  played  by  synthetic 
nucleotides  that  lack  the  OH  at  the  3’  carbon  atom  (red  arrow  in  Figure  18)  –  the 
dideoxynucleotide dideoxythymidine triphosphate (ddTTP) is shown in Figure 18. 
 
Figure 18 – Chemical structure of dideoxythymidine triphosphate. Lack of a OH group on the 
3’ carbon atom is indicated with a red arrow.   94
  When a dideoxynucleotide is added to the ‘growing’ DNA strand, chain elongation 
stops because there is no 3’ OH for the next nucleotide to be added to. For this reason, the 
‘dideoxy method’ is also called the ‘chain termination method’. 
2.1.5.2 Theory 
  The DNA to be sequenced is prepared  as  a single strand. This template DNA is 
supplied  with a mixture of all four normal (deoxy) nucleotides in ample quantity – dATP, 
dGTP, dCTP and dTTP. A mixture of all four dideoxynucleotides are also supplied in limiting 
quantities, and each labelled with a fluorescent tag that fluoresces a different colour – ddATP, 
ddGTP, ddCTP, and ddTTP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19 – Pictorial summary of the dideoxy DNA sequencing method.   95
Because all four normal nucleotides are present, chain elongation proceeds normally 
until, by chance, DNA polymerase inserts a dideoxy nucleotide (shown as coloured letters in 
Figure 19) instead of the ‘normal’ deoxynucleotide (shown as vertical lines in Figure 19). If the 
ratio of normal nucleotide to the dideoxy versions is high enough, some DNA strands will 
succeed in adding several hundred nucleotides before insertion of the dideoxy version halts 
the elongation process. 
  At the end of the ‘incubation period’, the fragments are separated by length from 
longest to shortest on a gel. The resolution is so good that a difference of one nucleotide is 
enough to separate a particular strand from the next shorter/ longer strand. Each of the four 
dideoxynucleotides fluoresces a different colour when illuminated by a laser beam, and an 
automatic scanner provides a printout of the sequence. 
2.1.5.3 Shrimp Alkaline Phosphatase/ Exonuclease I Sample Preparation 
(PCR Products Only) 
  Shrimp alkaline phosphatase (SAP) and exonuclease 1 (Exo I) were used to prepare 
PCR products for sequencing. SAP removes the phosphate groups from the excess dNTPs 
left over from the PCR reaction, and Exo I digests the single stranded PCR primers into 
dNTPs. 
  The following quantities were used in preparation of all SAP/ Exo I reactions carried 
out on PCR products (all reagents used were sourced form USB):- 
-  PCR Product (~ 50ng/  l) - 5 l 
-  SAP - 1 l (1 unit) 
-  Exo I – 0.1 l (1 unit)  
-  SAP Buffer (x10) – 0.9 l 
  The  following  SAP/  Exo  I  reaction  programme  was  employed  for  all  SAP/  Exo  I 
reactions (on a ‘PTC DNA Engine Tetrad’ (gradient cycler) – MJ Research):- 
37° C for 30 mins 
80° C for 15 mins 
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2.1.5.4 Sequencing Reaction Protocol 
  The following quantities were used in preparation of all sequencing reactions carried 
out (all reagents were sourced from Applied Biosystems):- 
-  DNA Template – 3.5 l for PCR products from SAP/ Exo I  clean-up reaction, 
         1.0 l of plasmid DNA (~0.3 g/  l) 
-  Big Dye Terminator Ready Reaction Mix – 4.0 l (½ unit) 
-  ½ Sequencing Buffer – 4.0 l (½ unit) 
-  Sequencing Primer – 3.2pmol 
-  Deionised Water – made up to 20 l 
  The  following  sequencing  reaction  programme  was  employed  for  all  sequencing 
reactions (on a ‘PTC DNA Engine Tetrad’ (gradient cycler) – MJ Research):- 
96° C for 10 secs 
50° C for 5 secs 
60° C for 4 mins 
END 
2.1.5.5 Ethanol Precipitation Protocol 
  Ethanol  allows  the  precipitation  of  DNA  at  low  temperatures,  which  can  then  be 
recovered by centrifugation and redissolved in appropriate buffer. This method was employed 
to clean the single stranded DNA from the sequencing reaction (refer to section 2.1.5.4). 
  The following protocol was employed for the ethanol precipitation of all sequencing 
reactions:- 
-  16 l  deionised  water  and  64 l  ice  cold  95%  ethanol  (Fisher)  was  added  to  the  20 l 
sequencing reaction, which was then vortexed and left at -20° C for 15 minutes. 
- The tubes were then centrifuged at 13,500 revolutions per minute (rpm) for 20 minutes. 
-  The  supernatants  were  then  carefully  aspirated  and  250 l  of  70%  ethanol  (diluted  with 
deionised water from Fisher stock) was added to the tubes which were then vortexed. 
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- The tubes were then centrifuged at 13,500rpm for 10 minutes. 
- The supernatants were then carefully aspirated, and the samples were placed in a 90° C 
heat block for 1 minute. Dried samples were then stored at -20° C. 
2.1.5.6 Sequencing Gel Preparation 
  The following protocol was employed for the preparation of all sequencing gels used 
in this study:- 
-  Sequencing  plates  were  cleaned  thoroughly  using  Alconox  (Aldrich),  and  rinsed  with 
deionised water. 
- The plates and spacers were then assembled in the gel frame as shown in Figure 20 (gel 
frame clips were rotated to lock assembly in place). 
 
Figure 20 – Diagram outlining the assembly of the sequencing plates and spacers within the 
gel frame. 
-  The  gel  mixture  –  30ml  10%  6M  Urea  (Amresco),  300 l  10%  ammonium  persulphate 
solution  (APS  –  refer  to  appendices)  and  30 l  100%  N,  N,  N',  N'-Tetramethyl-1-,  2-
diaminomethane (TEMED) (Sigma) – was poured, once mixed, from the top centre using a 
25ml syringe. 
- The continuous edge of the comb was then inserted at the top, and a pressure device was 
fixed. 
- Polymerisation of the gel was allowed to take place - ~2 hours. 
- After polymerisation, the outside of the plates were cleaned using deionised water, with 
particular attention to the scan region (lower eighth).   98
-  Pressure  device  was  then  removed,  as  was  the  comb,  and  any  loose  acrylamide  was 
cleaned off using deionised water and white tissue. 
- The comb was then reinserted teeth down, ensuring only 1½mm of the teeth entered the 
upper gel surface. 
2.1.5.6.1 Plate Check (to check scan region cleanliness) 
- The lower reservoir was placed in the ABI 377 sequencer (Applied Biosystems), as was the 
frame/ gel assembly which was clipped in place with four clips. Door was then closed. 
- Once the software (‘ABI Prism 377 DNA Sequencer Data Collection’ – Applied Biosystems) 
had been initialised, ‘Plate Check’ was selected. 
- A scan window with flat lines in each of the four colours was desired as an indicator of a 
clean laser scan region. If any peaks were seen, the gel cassette was removed and the scan 
region was cleaned using deionised water and white tissue until the peaks were no longer 
visible. 
- Once flat lines had been realised the plate check was terminated. 
2.1.5.6.2 Pre Run  
(to equilibrate gel running conditions prior to sample loading) 
- The upper reservoir was locked into place at the top of the gel, and both reservoirs were 
filled  with  1xTBE  (refer  to  appendices;  10xTBE  was  diluted  by  a  further  factor  of  ten  in 
deionised water). The heat plate was also clipped in place. Door was then closed. 
- The desired ‘pre run module’ was chosen within the software options – ‘PR 36E 1200’. Pre 
run was left for 10 minutes. 
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2.1.5.7 Sample Preparation/ Loading 
  The following procedure was carried out to prepare all dry DNA samples from the 
ethanol precipitation step (above) for DNA sequencing:- 
- 6 l of loading buffer – 1 part 25mM ethylenediaminetetraacetic acid disodium salt (EDTA) 
blue dextran (Applied Biosystems) + 5 parts deionised 100% formamide (Sigma) was added 
to each DNA pellet. Samples were then vortexed and briefly centrifuged. 
-  Samples  were  then  denatured  by  heating  them  at  96°C for  2 minutes  in  a  heat  block. 
Samples were then immediately placed on ice to prevent re-annealing. 
2.1.5.8 Sequence Run 
- Once the 10 minute pre run had been completed, the wells were flushed using a syringe. 
- 1.5 l of the prepared samples were then loaded into the required wells. 
- The upper reservoir lid was then clipped in to avoid buffer evaporation, and the required ‘run 
module’ was selected within the software options – ‘Seq Run 36E 1200’. 
- The required ‘sample sheet’ was then imported into the run software, and the sequencing 
run was initialised. 
  Once the sequencing run had been completed, analysis of the sequencing results 
took place on a separate computer connected to the ABI 377 sequencer, and employed ‘ABI 
Sequencing Analysis’ software (Applied Biosystems) to convert the gel image realised into 
individual electropherograms displayed in the results section. 
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2.2.2 PCR Product Endonuclease Digestion 
  The basic quantities indicated below were used in preparation for all endonuclease 
digests carried out on PCR products in this  study (the bovine serum albumin (BSA) and 
relevant buffers were sourced from the manufacturers of the respective enzyme - detailed in 
section 2.2.1):- 
-  DNA – 1.0-3.0 l (~100ng), 
-  10x BSA – 1.0 l 
-  10x relevant buffer – 1.0 l 
-  Restriction Endonuclease(s) (10units/ l) – 0.5 l or 0.4 l (for two in combination) 
-  Deionised water – made up to 10 l 
2.2.3 Primer-Introduced Restriction Analysis-Polymerase Chain Reaction 
2.2.3.1 Theory 
  Primer-introduced restriction analysis (PIRA-PCR) was used in an attempt to detect 
SNPs. It was used to create artificial RFLP, where a mismatch was introduced near the 3’ end 
of the sense or anti-sense primer that was close to the relevant SNP. Computer software (Ke 
et al. (2001)) was used to screen for suitable mismatches, design the required primers and list 
the relevant restriction enzymes. 
2.2.3.2 Protocol 
  Once the PIRA-PCR strategy had been chosen, the required PIRA-PCR primers were 
used as normal primers in a PCR reaction (refer to section 2.1.3.2). 
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2.2.4.4 C54A (S18Y) SNP Genotyping 
   Rsa 1 does not have a restriction site within the amplified reference homozygote 
exon  3  region,  however,  a  restriction  site  is  created  in  DNA  harbouring  the  polymorphic 
adenine allele. Rsa 1’s restriction site is thus:- 
GT↓    AC 
GT    ↑TG 
- Relevant corresponding SNP region:- 
GCTGTCCCGG 
  C54A 
  The endonuclease cleaves the amplified polymorphic exon 3 sequence at 180bp, no 
cut is realised in the amplified exon 3 region harbouring the reference homozygote C allele.  
                                                                       180bp  
▄                                                                        ↓                                                                      ▄ 
                                                             A allele Rsa 1 cut                                                  363bp 
Figure 24 - Linear representation of the amplified exon 3 sequence and the Rsa 1 restriction 
site. 
Thence, reference homozygote C allele DNA realises just one band - the undigested 
363bp  fragment. Whereas  DNA  harbouring  the  polymorphic  A  allele  realise  the  180  and 
183bp bands. 
2.2.4.5 A-24G SNP Genotyping 
  The A-24G SNP region did not present a viable restriction endonuclease site in its 
reference  homozygote  or  polymorphic  sequence  that  would  have  allowed  straightforward 
RFLP genotyping to be carried out. 
  An alternative option was to introduce a novel restriction site into the 5’ UTR SNP 
region by way of ‘primer-introduced restriction analysis (PIRA) PCR’ (refer to section 2.2.3). 
  Using computer software specially constructed for this purpose (Ke et al. (2001)), a 
pair of PCR primers were designed which would amplify the required region, and at the same 
time incorporate a base mismatch in the required region (brought about by the sense primer)   108 
- How the primers should adhere to the required UCH-L1 sequence flanking the A-306G SNP 
region is displayed:- 
TCAAATGCTTCAGAGACTCGAGC > 
TCAAATGCTTCAGAGACTCGAGCTTTAGAGTAATTGGGATGGTGAAAGGATGGGTTTC 
                                                                               A-306G 
CAGAAACTTCGCCCAAAATTAAAGACTCCATCAAAAGGACTGCTCCATACACTCAAGGAA 
 <TTTATGACGAGGTATGTGAGTTCCTT 
- The mismatch brought about by the anti-sense primer is highlighted (above and below) in 
green, the A-306G SNP is also highlighted. 
- The restriction endonuclease site to be created for Mbo II is thus:-- 
.GAAGA....NNN(8)..↓       . 
CTTCT....NNN(7)..↑…  . 
- Relevant corresponding SNP region (after successful mismatch):- 
TCAAAAAGACT 
A-306G… .  
  With  a  successful  mismatch  introduced,  Mbo  II  does  not  cleave  the  reference 
sequence, however, a 12bp cut should be realised in sequences harbouring the polymorphic 
G allele.  
                                                                                                                    12bp 
▄                                                                                                                    ↓                          ▄ 
                                                                                                         G allele Mbo II cut     118bp 
Figure 26 - Linear representation of the specified A-306G mismatch PCR region and Mbo II’s 
restriction site. 
- Thence, reference homozygote DNA should realise just one band - the undigested 118bp 
DNA fragment. Whereas DNA harbouring the polymorphic G allele should realise a 12bp 
band and another of 106bp. 
  A-306G mismatch region/ Mbo II endonuclease digestion products were then run on a 
ten percent polyacrylamide gel. However, as with the previous strategy, no Mbo II digestions 
were realised. Positive controls known to harbour the polymorphic G allele also came out 
negative. It was thus determined that this mismatch PCR/ endonuclease digestion strategy   109 
was once again failing for an unknown reason (again, the required mismatch was confirmed 
through DNA sequencing analysis). 
 
2.3 Cloning Methodologies 
2.3.1 Plasmid DNA Vectors 
2.3.1.1 pGEM-T Easy Theory 
  The pGEM-T Easy vector (Promega) (Figure 51) was chosen as it is a convenient 
system for the cloning of PCR products – in this study the UCH-L1 promoter haplotypes. The 
pGEM-T Easy vector has an insertion site which is flanked by single 3’-T overhangs which 
greatly improve the efficiency of PCR product ligation into the plasmid. This is achieved by the 
T overhangs preventing recircularisation of the vector, and providing compatible overhangs 
for PCR products generated by certain thermostable Taq polymerases (as used in this study) 
that add a single deoxyadenosine, in a template-independent fashion, to the 3’-ends of the 
amplified PCR fragment. 
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Figure  27  –  Schematic  representation  of  the  pGEM-T  Easy  vector  showing  the  gene 
conferring ampicillin resistance in E.coli (Amp
r), the origin of replication in E.coli (ori), the 
origin of replication derived from filamentous phage (f1 ori), the lac operator (lacZ – start 
codon),  the  T7  RNA  polymerase  transcription  site  (T7),  and  the  SP6  RNA  polymerase 
promoter (SP6). (www.Promega.com). 
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2.3.1.2 pGL3-Basic Vector 
 
Figure 28 – Schematic representation of the pGL3-Basic vector showing the cDNA encoding 
the modified firefly luciferase (luc+), the gene conferring ampicillin resistance in E.coli (Amp
r), 
the origin of replication in E.coli (ori), the origin of replication derived from filamentous phage 
(f1 ori), and its endonuclease restriction sites; those between nucleotide sequences 1 and 58 
make  up  the  ‘multiple  cloning  region’.  Other  components  are  described  in  diagram. 
(www.Promega.com). 
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2.3.1.3 pGL3-Eco RI Construction 
  The pGL3-Eco RI vector used in this study was customly engineered from Promega’s 
pGL3-Basic and pBluescript SK vectors to create a cloning vector with an expanded range of 
restriction endonuclease sites within the cloning region. The construction strategy is indicated 
in the figure below:- 
 
Figure 29 – pGL3-Eco RI construction strategy. pGL3-Basic (Promega) was firstly digested 
with Hind III and Sac 1 restriction endonucleases to remove a segment of the multiple cloning 
region. The pBluescript SK cloning vector was then also digested with Hind III and Sac 1. The 
pBluescript SK’s cleaved multiple cloning region was then ligated into the digested pGL3-
Basic vector, producing the modified pGL3-Eco RI vector with the expanded multiple cloning 
site.   114 
2.3.2 Agarose Gels 
  In this study, endonuclease digested minipreped plasmid DNA (including digested 
and  PCR  amplified  promoter  inserts)  were  visualised  on,  and  if  required  extracted  from, 
agarose gels. The agarose gels were prepared using the following protocol:- 
- 0.5g of agarose powder (GibcoBRL) was added to 50ml of 1xTAE (refer to appendices). 
(If  the  DNA  was  to  be  extracted  for  further  use  –  ‘Modified  TAE’  was  used  (refer  to 
appendices). 
- This was then boiled in a microwave to dissolve the agarose. 
- Once the solution had cooled adequately, the solution was poured into the gel former. The 
well former (comb) was also inserted. The assembly was then left for 20 minutes to set.  
2.3.2.1 Gel Loading and Running 
- Once set, the comb was removed and the gel was transferred into the ‘gel running pack’, 
where it was submerged in 1xTAE. 
- 5 l of Orange G loading dye (diluted to x1 from x5 stock solution) (refer to appendices) was 
added to 10 l of mini/ midipreped DNA and mixed well. 
- 12 l of the required samples were then loaded into the agarose gel wells. 
-  The  lid  of  the  gel  running  pack  was  then  attached  securing  the  anode  and  cathode 
connections. 
- Gels were typically run at 150 volts for 30 minutes to resolve 1-4 kb bands. 
- Once gels had been run, the gel was then soaked in ethidium bromide solution (20 l per 
200ml 1xTAE) for 20 minutes. 
- After staining, the gels were visualised in the Fluorimager 595 using ultra-violet light to 
elucidate required DNA bands.  
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2.3.3 Plasmid DNA Endonuclease Digestion 
  The basic quantities indicated below were used in preparation for all endonuclease 
digests  carried  out  on  plasmid  DNA  in  this  study  (the  bovine  serum  albumin  (BSA)  and 
relevant buffers were sourced from the manufacturers of the respective enzyme - detailed in 
section 2.2.1):- 
-  DNA – 1.0-10.0 l (3 g for ligation prep, otherwise »300ng), 
-  10x BSA – 2.0 l 
-  10x relevant buffer – 2.0 l 
-  Restriction Endonuclease(s) – 1.0 l or 0.8 l (for two in combination or sequentially) 
-  Calf Intestinal Alkaline Phosphatase (1unit/ l) (CIAP) – 5.0 l (if used)  
-  Deionised water – made up to 20 l 
2.3.4 General DNA Isolation/ Purification Protocols 
2.3.4.1 DNA Isolation from Agarose Gels 
  DNA extraction from agarose gels was carried out using the ‘Ultrafree-DA Centrifugal 
Filter Device’ (Millipore). 
2.3.4.1.1 Theory 
  The Ultrafree-DA device from Millipore was designed to recover 100 to 10,000 bp 
DNA from agarose gel slices in one ten-minute spin. It consists of a pre-assembled sample 
filter cup with agarose  ‘Gel Nebulizer’, and a microcentrifuge vial. The device utilises gel 
compression to extract DNA from the agarose. Centrifugal force collapses the gel structure, 
drives the agarose through a small orifice in the ‘Gel Nebulizer’ and the resultant gel slurry is 
sprayed into the sample filter cup. As the agarose is compressed at 5,000xg, DNA is extruded 
from the gel's pores. The gel matrix is retained by the microporous membrane, and the DNA 
passes freely through the membrane. DNA can then be recovered in the filtrate vial. 
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2.3.4.1.2 Protocol 
- Required DNA product was first electrophoresed through a modified TAE agarose gel (refer 
to section 2.3.2). 
- Band of interest was located using a long wavelength UV lamp, and the slice of agarose that 
contained the DNA was carefully excised from the gel (any excess agarose was also then 
trimmed away). 
- The gel slice was then placed into the ‘Gel Nebulizer’ sample cup assembly device and 
sealed, so that the cap was attached to the vial. 
- The ‘Gel Nebulizer’ and vial were then centrifuged at 5000xg fro 10 minutes. 
- DNA was now present in the filtrate. The filter cup and ‘Gel Nebulizer’ were then discarded, 
allowing the DNA to be stored in the capped filtrate vial. 
2.3.4.2 Miniprep Protocol (QIAgen Spin Miniprep Kit – Qiagen) 
  The ‘QIAgen Spin Miniprep Kit’ was used to isolate all the plasmid DNA screened for 
the required UCH-L1 promoter inserts. The protocol is described below (all buffers were part 
of the Qiagen kit):- 
- 0.5ml of the overnight culture (above) was centrifuged at 13,500rpm for 45 minutes. 
- The bacterial cells were resuspended in 250 l of Buffer P1 (+ RNase A) until no cell clumps 
were visible. 
- 250 l of Buffer P2 was then added. Tubes were inverted 4-6 times to mix. 
- 350 l of Buffer N3 was added, and tubes were inverted until the solution became cloudy. 
- Tubes were then centrifuged at 13,500 rpm for 10 mins.  
- Supernatants from the above step were decanted into the ‘QIAprep columns’ which were 
then centrifuged at 13,500rpm for 1 minute. The flowthrough was discarded. 
- The QIAprep spin column was then washed by adding 0.5ml Buffer PB, and the centrifuge 
step at 13,500rpm for 1 minute was repeated. The flowthrough was again discarded.   118 
 
2.3.4.3.2 DNA Purification by Centrifugation 
- A ‘PureYield Clearing Column’ was first placed into a new 50ml disposable plastic tube. 
- The lysate (from stage 1 above) was then poured in and left to stand for 2 minutes, so as to 
allow any cellular debris to rise to the top. 
- The ‘PureYield Clearing Column’ was then centrifuged at 3000 x g for 5 minutes to filter the 
lysate through (the centrifugation step was repeated if deemed necessary). 
- A ‘PureYield Binding Column’ was then placed into a new 50ml disposable plastic tube. 
- The filtered lysate was then poured in and centrifuged for 3 minutes at 1500 x g. 
- 5ml of ‘Endotoxin Removal Wash Solution’ (+ Isopropanol) was then added to the ‘PureYield 
Binding  Column’  and  centrifuged  at  1500  x  g  for  3  minutes.  The  flowthrough  was  then 
discarded, and the column reinserted into the tube. 
-  20ml  of  ‘Column Wash  Solution’  (+  ethanol)  was  then  added  to  the  ‘PureYield  Binding 
Column’, and centrifuged at 1500 x g for 5 minutes. The flowthrough was then once again 
discarded,  and  the  column  reinserted into the  tube. Centrifugation  at  1500 x  g  was  then 
carried out for an additional 10 minutes to ensure complete ethanol removal from the column 
(the tip of the column was also tapped on a paper towel to remove any final traces). 
- The DNA was then eluted by placing the binding column into a new 50ml disposable plastic 
tube, and adding 600µl of ‘Nuclease-Free Water’ to the binding membrane of the ‘PureYield 
Binding Column’. 
- The ‘PureYield Binding Column’ was then centrifuged for 5 minutes at 1500 x g. The filtrate 
was then finally transferred into a new 1.5ml tube. 
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2.3.7 Preparation of Competent Cells – Calcium Chloride Method 
  The following protocol was used in the preparation of all competent cells used in the 
cloning section of this study:- 
-  An  overnight  culture  was  grown  in  Luria-Bertoni  (LB)  broth  from  a fresh  ‘picked’  E.coli 
JM109 colony grown overnight on a LB plate. 
- 1ml of the overnight culture was diluted in 100ml of fresh LB broth. 
- Cells were then grown in a 37° C  shaking incubator until the culture reached an optical 
density (O.D.) between 0.4-0.6 at a wavelength of 600nm (~2-3 hours). 
- Cells were centrifuged at 4000rpm at 4° C for 10 mi ns.  
- Once centrifuged they were resuspended in 10ml of 0.1M ice-cold calcium chloride (CaCl2) 
solution, and left on ice for 30 minutes. 
- Cells were then again centrifuged at 3000rpm for 5 minutes at 4° C.  
- A second resuspension step in 4ml of CaCl2 was then carried out, before leaving the cells on 
ice for two hours before use. 
For Long Term Storage 
-  After  the  second  resuspension  step,  140 l  Dimethyl  sulfoxide  (1%)    (DMSO  –  BDH 
Laboratory Supplies) was added. Cells were then gently mixed and left on ice for 15 mins. 
- A further 140 l DMSO was then added, and the cells were gently mixed, before being 
aliquoted into microcentrifuge tubes and frozen in liquid nitrogen (for long term storage at -
80° C). 
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2.3.8 Ligations Using the pGEM-T Easy Vector 
  The following quantities were used in the preparation of all pGEM-T Easy ligation 
reactions carried out in this study:- 
  Standard 
Reaction 
Positive 
Control 
Background 
Control 
2 x Rapid Ligation Buffer -  5 l  5 l  5 l 
pGEM-T Easy Vector (50ng/  l) -  1 l  1 l  1 l 
PCR Product -  * l  -  - 
Control Insert DNA (4ng/  l) -  -  2 l  - 
T4 DNA Ligase (3 Weiss units/  l) -  1 l  1 l  1 l 
Deionised Water -  -  1 l  3 l 
*  -  The  amount  of  PCR  product  used  in  the  reaction  was  calculated  using  the  following 
equation:- 
ng of vector x kb size of insert 
kb size of vector 
x     insert: vector molar ratio   =   ng of insert to be used 
- A 3:1 molar to vector ratio was desired. 
-  ng  of  PCR  product  used  was  quantified  on  an  agarose  gel  in  comparison  to  a  known 
concentration of DNA. ng of vector was quantified using a Spectrophotometer (Beckman DU-
7000) to measure the light absorption of the (suitably diluted) solution at 260nm (absorption at 
280nm was also measured so that DNA purity could be ascertained and thus regulated). 
- All reactions were then left at 4° C for 15 hours. 
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2.3.10 Transformations Using the pGEM-T Easy Vector Ligation System 
  The  following  protocol  was  used  to  transform  all  pGEM-T  Easy  ligation  products 
(quantities in brackets were those used to calculate the transformation efficiency (TE) of the 
procedure):- 
- 2 l (TE - 0.1ng) of each ligation reaction was added to 50 l (TE - 100 l) of thawed E.coli 
JM109 calcium chloride prepared competent cells (refer to section 2.3.7). 
- The cells were then gently mixed and placed on ice for 20 minutes.  
- The cells were then ‘heat-shocked’ for 45 seconds in a 42° C water bath. 
- The tubes were immediately returned to ice for 2 mins. 
- 950 l (TE - 900 l) of SOC recovery medium (Promega) was added to the transformed cells. 
- Incubation then took place in a 37° C shaking incubator (150rpm) for 1.5 hours. 
- Each transformation culture then had 100 l (TE - 100 l of a 1:10 dilution) plated out (in 
duplicate) onto LB + ampicillin plates (refer to appendices) which were then incubated for 24 
hours at 37°
C. 
- Those E.coli colonies realised on the ampicillin LB agar plates after the 24 hour incubation 
contained  the  pGEM-T  Easy  vector  (ampicillin  resistance  gene),  and  those  colonies 
corresponding to the ‘standard reaction’ were thus potential harbourers of the required pGEM-
T Easy/ insert recombinant plasmid. 
- Those colonies were then screened for the required insert DNA (UCH-L1 promoter). 
- In preparation for the isolation of the pGEM-T Easy plasmid DNA by way of miniprep (refer 
to  section  2.3.4.2),  the  ampicillin  resistant  E.coli  colonies  (harbouring  the  pGEM-T  Easy 
vector)  were  ‘picked  off’  the  plate  and  grown  up  overnight  at  37° C  in  10mls  LB  broth  + 
ampicillin (refer to appendices).   124 
N.B. – Performed in parallel during each transformation procedure; 1 l of plasmid PUC 19 
DNA (which is a high copy number E. coli plasmid cloning vector) was transfected into the 
same batch of JM109 cells undergoing the same protocol as detailed above, as an extra 
positive control. 
2.3.11 Transformations Using the pGL3 Vector Ligation Products 
  The following protocol was used to transform all pGL3 ligation products (quantities in 
brackets were those used to calculate the transformation efficiency (TE) of the procedure):- 
- 5 l (TE - 0.1ng) of each ligation reaction was added to 50 l (TE - 100 l) of thawed E.coli 
JM109 calcium chloride prepared competent cells (refer to section 2.3.7). 
- The cells were then gently mixed and placed on ice for 5 minutes.  
- The cells were then ‘heat-shocked’ for 45 seconds in a 42° C water bath. 
- The tubes were immediately returned to ice for 2 mins. 
- 450 l (TE - 900 l) of SOC recovery medium (Promega) was added to the transformed cells. 
- Incubation then took place in a 37° C shaking incubator (150rpm) for 1.5 hours. 
- The cells were then centrifuged for 10 minutes at 4000rpm (1000 x G), and resuspended in 
200 l of SOC recovery medium. 
- Each transformation culture then had 100 l (TE - 100 l of a 1:10 dilution) plated out (in 
duplicate) onto LB + ampicillin plates (refer to appendices) which were then incubated for 24 
hours at 37° C. 
- Those E.coli colonies realised on the ampicillin LB agar plates after the 24 hour incubation 
contained the pGL3 vector (ampicillin resistance gene), and those colonies corresponding to 
the  ‘standard  reaction’  were  thus  potential  harbourers  of  the  required  pGL3/  insert 
recombinant plasmid. 
- Those colonies were then screened for the required insert DNA (UCH-L1 promoter). 
- In preparation for the isolation of the pGL3 plasmid DNA by way of miniprep (refer to section 
2.3.4.2), the ampicillin resistant E.coli colonies (harbouring the pGL3 vector) were ‘picked off’   125 
the plate and grown up overnight at 37° C in 10mls LB broth + ampicillin (refer to section 
6.5.8.2.1).  
N.B. – Performed in parallel during each transformation procedure; 1 l of plasmid PUC 19 
DNA was transfected into the same batch of JM109 cells undergoing the same protocol as 
detailed above, as an extra positive control.  
2.4 Cell Culture Protocols 
2.4.1 Mammalian Cell Lines and Required Growth Media 
2.4.1.1 - A2058 (Human Skin Melanoma) (ATCC Number – CRL-11147) 
-  Description  -  organism:  Homo  sapiens;  organ:  skin;  disease:  melanoma;  derived  from 
metastatic site: lymph node; morphology: epithelial; ethnicity: Caucasian; growth properties: 
adherent.  
- Concordant Growth Media - Dulbecco's Modified Eagle's Medium with 4 mM L-Glutamine, 
3.7 g/L Sodium Bicarbonate and 1.0 g/L Glucose, 90%; Fetal Bovine Serum, 10%. (ATCC). 
2.4.1.2 – MCF-7 (Human Breast Adenocarcinoma) (ATCC Number – HTB-22) 
- Description - organism: Homo sapiens; organ: mammary gland, breast; cell type: epithelial; 
disease:  adenocarcinoma;  morphology:  epithelial;  ethnicity:  Caucasian;  growth  properties: 
adherent. 
- Concordant Growth Medium - Minimum Essential Eagle’s Medium with 2 mM L-Glutamine 
and  Earle's  BSS  adjusted  to  contain  1.5  g/L  Sodium  Bicarbonate,  0.1  mM  non-essential 
amino acids and 1 mM Sodium Pyruvate and supplemented with 0.01 mg/ml Bovine Insulin, 
90%; Fetal Bovine Serum, 10%. (ATCC). 
2.4.1.3  –  ND-7  (Mouse  Neuroblastoma/  Rat  Basal  Ganglia  Neuron  Hybrid) 
(ATCC Number – HTB-22) 
- Description - organism: Mus musculus/ Rattus rattus hybrid; organ: brain; cell type (rat): 
dorsal  root  ganglion  neurone;  disease  (mouse):  neuroblastoma;  morphology:  neuronal; 
ethnicity: Caucasian; growth properties: adherent.   127 
2.4.2.2 Subculturing Protocol (Passage/ Cell Splitting) 
  This outlines the basic handling procedure of how cell lines were subcultured when 
they had reached 90% confluence. The subcultivation ratio was typically 1:3, and took place 
in 75cm
2 flasks. (All cell lines used in this study were adherent). 
- The culture medium was initially discarded. 
 The cell layer was then briefly rinsed with a 0.25% (w/v) Trypsin-0.53mM EDTA solution 
(refer to appendices) in order to remove all traces trypsin inhibitor-containing serum. 
- 3.0ml of Trypsin-EDTA solution was added to the flask, and then cell layer dispersion was 
observed under a microscope. Cells typically took 10 minutes to fully disperse. 
- 8ml of complete growth medium was then added, and the cells were aspirated by gentle 
pipetting. 
- The cell suspension was then transferred to a centrifuge tube and spun at 125 x g for 5 
mins. 
- The supernatant was then discarded to remove any trypsin-EDTA solution. The cell pellet 
was resuspended in fresh growth medium, and added to new a culture vessel containing 15-
minute pre-incubated growth medium. 
- The culture vessel was then placed in a 37°C incubator with a 5% CO2 air atmosphere. 
- (Media renewal typically took place twice per week.) 
2.4.3 Vector Transfection into Adherent Mammalian Cells 
2.4.3.1 Transfection Related Chemicals 
- Serum free medium – animal free protein, without L-glutamine (Sigma – 14591C) 
- GeneJuice Transfection agent (Merck Biosciences) 
2.4.3.1.1 GeneJuice Theory 
Whereas many available transfection reagents are based on cationic lipid formulation, 
GeneJuice  Transfection  Reagent  is  composed  of  a  nontoxic  cellular  protein  and  a  small   128 
amount of a novel polyamine. GeneJuice Transfection Reagent provides highly efficient DNA 
transfer in both stable and transient transfection of eukaryotic cells. The unique chemistry 
provides the advantage of compatibility with both serum-containing and serum-free media, 
and makes media changes unnecessary.  
2.4.3.2 Transfection Preparation 
- One day prior to transfection 1-3 x 10
5 cells were plated into 35mm dishes in the required 
complete growth medium. 
- The cells were then incubated overnight at 37°C in a 5% CO2 air atmosphere. 
- Cells were ensured to be 50-80% confluent prior to transfection.  
2.4.3.3 Transfection Procedure 
- For each 35mm dish that was to be transfected, 100ml of serum free medium (refer to 
section 2.4.3.1) was added into a sterile tube. To this, 3-6ml of ‘GeneJuice’ transfection agent 
(refer to section 2.4.3.1.1) was added drop-wise, and mixed thoroughly by vortexing (actual 
volume of GeneJuice added was determined through initial optimisation reactions carried out 
for each cell line). 
- Mixtures were incubated at room temperature for 5 minutes. 
- 1mg of desired vector DNA was then added to each GeneJuice/ serum free medium mixture 
and gently mixed in by pipetting. 
- The GeneJuice/ DNA mixtures were then incubated at room temperature for a further 15 
minutes. 
-  The  entire  volume  of  each  GeneJuice/  DNA  mixture  was  then  added  drop-wise  to  the 
prepared 35mm dishes containing the required cells in complete growth medium. The drops 
were distributed evenly over the entire surface of each dish, and the dish was then gently 
rocked to ensure even distribution.   129 
- Cells were incubated for 24 hours at 37°C in a 5% CO2 air atmosphere. (After 8 hours, the 
transfection mixture was removed from each dish and replaced with complete growth mixture 
for the remainder of the incubation.)  
2.4.4 Dual-Luciferase Reporter Assay (Promega) 
2.4.4.1 Dual-Luciferase Reporter Assay Theory 
  In  the  Dual-Luciferase  Reporter  (DLR
TM)  Assay  System  the  activities  of  firefly 
(Phontinus pyralis) and Renilla (Renilla reniforms) luciferases are sequentially measured from 
a single sample. The activity of the firefly luciferase experimental reporter is thus normalised 
to  the  activity  of  the  Renilla  luciferase  internal  control,  thence  minimising  experimental 
variability caused by differences in cell viability and/ or transfection efficiency.  
  Firstly,  recombinant  firefly  luciferase  is  measured  through  the  addition  of  Beetle 
luciferin  which  is  oxidised  in  the  presence  of  ATP,  Mg
2+  and  O2  (and  coenzyme  A). 
Immediately after firefly luciferase quantification, a ‘Stop & Glo’ reagent is added to quench 
firefly luciferase luminescence – it also activates the Renilla luciferase through the addition of 
Coelenterazine (in the presence of O2) – which produces a stabilised luminescent signal that 
decays slowly. 
  Thence, the integrated format of the DLR
TM Assay allows rapid quantification of the 
experimental reporter luciferase relative to the internal control Renilla luciferase in transfected 
mammalian cells. 
The procedures below outline the protocol used to prepare and perform the Dual-
Luciferase Reporter Assays  on all of the cell lines investigated in this study. (All buffers, 
substrates and reagents detailed were supplied by Promega.) 
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2.4.4.2 Dual-Luciferase Reporter Assay Buffer Preparation (Promega) 
- Passive Lysis Buffer 
  -  4 volumes  of  Distilled Water  to  1 volume  of the  Buffer  of  Phosphate  Buffered  Saline 
(Promega). 
- Luciferase Assay Buffer II 
  - The lyophilised Luciferase Assay Substrate powder (Promega) was added to the 10ml of 
supplied Luciferase Assay Buffer II (Promega).  
- Stop and Glo Buffer  
  -  1  volume  of  Stop  and  Glo  Substrate  (x50  concentrate)  (Promega)  was  added  to  50 
volumes of the supplied Stop and Glo Buffer (Promega). 
2.4.4.3 Assay Preparation – Lysis of Cultured Cells 
- The initial step in the preparation was to dilute a sufficient quantity of the Passive Lysis 
Buffer, which was supplied at x 5 concentrate, by adding 4 volumes of distilled water to 1 
volume of the buffer. The solution was then mixed well. 
- The growth medium was removed from each of the 35mm dishes, and then a sufficient 
volume of phosphate buffered saline was gently added. The culture vessel was then briefly 
swirled to remove any detached cells and residual growth medium. 
- Once all the rinse solution had been removed, 500ml of diluted (1x) Passive Lysis Buffer was 
dispensed into each 35mm dish so that the cellular monolayer was completely covered. 
- The culture plates were then gently rocked (on a rocking platform) for 15 minutes at room 
temperature to ensure complete and even coverage of the Passive Lysis Buffer within each 
35mm dish. 
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2.4.4.4 Luciferase Assay Protocol 
- Initial preparation of the Luciferase Assay Reagent II was required by resuspending the 
provided lyophilised Luciferase Assay Substrate in 10ml of the supplied Luciferase Assay 
Buffer II. 
- An adequate volume of Stop and Glo Reagent also required preparation - 100ml required per 
sample to be assayed. 1 volume of the Stop and Glo Substrate (supplied at x50 concentrate) 
was added to 50 volumes of Stop and Glo Buffer in a new siliconised polypropylene tube. 
- 100ml of Luciferase Assay Reagent II was predispensed into the appropriate number of 
luminometer tubes required to complete the desired number of dual luciferase assays. 
-  The luminometer  was  then  programmed to  perform  a  2-second  premeasurement  delay, 
followed by a 10-second measurement period for each reporter assay. 
- 20ml of the cell lysate from the required 35mm dish prepared in section 2.4.4.3 above, was 
then carefully transferred into a luminometer tube containing the Luciferase Assay Reagent. 
The solution was then mixed by pipetting 2 or 3 times. 
- The firefly luciferase activity reading was then measured. 
- The sample tube was then removed from the luminometer, and 100ml of Stop and Glo 
Reagent was then added and vortexed to mix. The sample was replaced in the luminometer, 
and a second reading initiated. 
- The Renilla luciferase activity reading was then measured. 
- The reaction tube was then discarded, and the next dual luciferase reporter assay  was 
carried out.  
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3 Results 
3.1 Results I – Mutation Screening 
  The  overall  aim  of  this  section  was  to  elucidate  any  common  mutations  or 
polymorphisms within UCH-L1’s promoter, 5’-UTR and exon regions. 
  dHPLC was initially employed as a rapid detection method to indicate which regions 
of the UCH-L1 gene harbour any common sequence variations. (As discussed in section 
2.1.3.4, for optimal dHPLC analysis, relevant UCH-L1 nucleotide sequence was divided into 
regions between 150-450bp in length (with one exception – Exon 9). 
  Once  regions  harbouring  any  common  mutations/  polymorphisms  had  been 
elucidated through dHPLC, the nature of these sequence variations were established through 
direct DNA sequencing of the samples that displayed dHPLC heteroduplexes, with reference 
to  the  homoduplex  samples,  to  clearly  determine  the  specific  nature  and  location  of  the 
sequence variations. 
  Once  these  sequence  variations  had  been  classified,  RFLP  genotyping  strategies 
could then be devised (please see section 2.2.4), which allowed concordant genotyping data 
to be uncovered from the two control DNA arrays (n=31, and n=480). From this data, common 
haplotypes within the Caucasian population were able to be elucidated, which would form the 
basis of the functional studies that were carried out in the next stage of the investigation. 
3.1.1 dHPLC Analysis 
  The initial stage of this project involved mutation/ polymorphism scanning of the UCH-
L1  gene  through  dHPLC  analysis.  Sequence  variations  within  the  UCH-L1  gene  were 
identified using genomic DNA from 26 unrelated healthy individuals (refer to section 2.1.1.1). 
  Once these UCH-L1 regions had been successfully amplified by Polymerase Chain 
Reaction (PCR - refer to section 2.1.3) for each of the 26 genomic DNA samples in the array, 
the samples were then subjected to dHPLC mutation scanning (refer to section 2.1.4.2).   136 
3.1.1.1 dHPLC Analysis of Promoter Region A 
A 
 
 
B 
 
Figure 31 – Comparative dHPLC scans for Promoter Region A (UCH-L1 nucleotide sequence 
+158 → -105) showing (A) a sample exhibiting potential heteroduplexes, and (B) a sample 
displaying only homoduplex species. Samples were eluted at an ‘oven temperature’ of 64ºC.  
- The y-axis indicates the absorbance intensity in millivolts (mV), whilst the x-axis displays the 
retention (elution) time in minutes (mins).  
- The initial vertical peak at a retention time ≈1 min was the elution of excess PCR primer, the 
observed shallow peak ≈1 min before hetero/ homoduplex peak elution was non-specific PCR 
product, and the final peak at ≈7 mins retention time was genomic DNA. 
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3.1.1.2 dHPLC Analysis of Promoter Region B 
A 
 
 
B 
 
Figure 32 – Comparative dHPLC scans for Promoter Region B (UCH-L1 nucleotide sequence  
-31 → -311) showing (A) a sample exhibiting potential heteroduplexes, and (B) a sample 
displaying only homoduplex species. Samples were eluted at an ‘oven temperature’ of 65ºC.  
- The y-axis indicates the absorbance intensity in millivolts (mV), whilst the x-axis displays the 
retention (elution) time in minutes (mins).  
- The initial vertical peak at a retention time ≈1 minute was the elution of excess PCR primer, 
the observed peak at ≈2.75 minutes  was non-specific PCR product elution, and the final 
shallow peak immediately after hetero/ homoduplex peak elution was genomic DNA. 
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3.1.1.3 dHPLC Analysis of Promoter Region C 
A 
 
 
B 
 
Figure  33  –  Comparative  dHPLC  scans  for  Promoter  Region  C  (UCH-L1  nucleotide 
sequence  -235 → -549) showing (A) a sample exhibiting potential heteroduplexes, and (B) a 
sample displaying only homoduplex species. Samples were eluted at an ‘oven temperature’ of 
57ºC. 
- The y-axis indicates the absorbance intensity in millivolts (mV), whilst the x-axis displays the 
retention (elution) time in minutes (mins).  
- The initial vertical peak at a retention time ≈1 minute was the elution of excess PCR primer, 
and the final peak(s) at ≈6.75 minutes retention time was genomic DNA elution. 
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3.1.1.4 dHPLC Analysis of Promoter Region D 
A 
 
 
B 
 
Figure  34  –  Comparative  dHPLC  scans  for  Promoter  Region  D  (UCH-L1  nucleotide 
sequence  -475 → -802) showing (A) a sample exhibiting potential heteroduplexes, and (B) a 
sample displaying only homoduplex species. Samples were eluted at an ‘oven temperature’ of 
58ºC.  
- The y-axis indicates the absorbance intensity in millivolts (mV), whilst the x-axis displays the 
retention (elution) time in minutes (mins).  
- The initial vertical peak at a retention time ≈1 minute was the elution of excess PCR primer, 
and the final peak at ≈6.75 mins retention time was genomic DNA elution. 
 
 Potential 
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3.1.1.5 Interpretation of dHPLC Analysis 
  Promoter regions A, B, C and D have exhibited potential heteroduplexes, and thus 
possible  sequence  mutations  or  polymorphisms.  These  samples  were  then  directly 
sequenced,  along  with  four  samples  displaying  only  homoduplex  species  for  nucleotide 
sequence  comparison,  to  confirm  the  presence  and  elucidate  the  exact  nature  of  these 
sequence variations. 
  The  following  regions  did  not  realise  any  potential heteroduplexes  during  dHPLC 
mutation scanning: promoter region E, exons 1 & 2, exon 4, exons 5 & 6, exon 7, exon 8 and 
exon 9. 
  Exon  3  was  unable  to  be  mutation  scanned  using  dHPLC  as  the  PCR  amplicon 
attained for this coding region required the use of betaine. Betaine is a substance  which 
cannot  be  used  within  Transgenomic’s  dHPLC  apparatus  (Transgenomic  dHPLC  User 
Manual). 
  As  described  in  section  1.3.2,  UCH-L1  exon  3  harbours  a  cytosine  to  adenine 
substitution at nucleotide position +54 – corresponding to a serine to tyrosine polymorphism 
at amino acid position 18 (Ser18Tyr) - which has been hypothesised to confer protection 
against Parkinson’s disease in certain populations. To identify samples which harbour this 
allele, a viable Restriction Fragment Length Polymorphism (RFLP) genotyping strategy will be 
utilised, followed by direct DNA sequencing to confirm the presence of this single nucleotide 
polymorphism (SNP) in this study. 
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3.1.1.6 Confirming the Presence of Exon 3’s Polymorphic +54A allele 
  A documented RFLP genotyping strategy utilising the restriction endonuclease Rsa I 
(Mellick & Silburn (2000)) was employed to identify samples harbouring the +54A allele (refer 
to section 2.2.4.4 for details of C54A RFLP genotyping strategy). 
UCH-L1 exon 3 region/ Rsa 1 restriction enzyme digestion was set up on a set of 16 
control DNA samples:- 
 
Figure 35 – A 5% polyacrylamide gel (refer to section 2.1.2) displaying UCH-L1 exon 3 Rsa I 
RFLP analysis of x16 control DNA samples (arbitrarily labelled B1-5,.and L23-33). The nine 
circled  lanes  indicate  exon  3  PCR  products  which  realised  partial  Rsa  I  restriction 
endonuclease  digestion,  and  are  thus  heterozygous  for  the  polymorphic  +54A  allele.  No 
homozygotes for the polymorphic A allele were seen to be evident, as no complete Rsa I 
digestion was realised (refer to section 2.2.4.4 for relevant RFLP genotyping strategy details). 
DNA sample nomenclature are annotated above each brace of polyacrylamide wells; right 
hand wells are undigested exon 3 PCR controls. 
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3.1.1.6.1 RFLP of Exon 3’s +54A Allele - Interpretation 
  Nine out of the sixteen samples realised partial Rsa I digestion and thus displayed 
heterozygosity for the polymorphic A allele. In order to confirm the presence and exact nature 
of  the  C54A SNP in  this  study, four  of  the  samples  which  exhibited  heterozygosity  were 
directly  DNA  sequenced,  along  with  three  samples  which  did  not  realise  cleavage  for 
nucleotide sequence comparison. 
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3.1.2.1 DNA Sequencing of Promoter Region A 
  As shown in the electropherograms below, promoter region A revealed four novel 
SNPs - two in the 5’ UTR: an adenine to guanine substitution at position -24, and a cytosine 
to thymine base substitution at position -16; and two located in the coding region of exon 1: 
both novel guanine to adenine nucleotide substitutions at positions +12 and +21. 
- Shown here are the relevant nucleotide sequences (sense and anti-sense) corresponding to 
the  electropherograms  displayed  for  promoter  region  A  in  this  section.  (Sequences  were 
cross  referenced  with  the  NCBI  website  database).  The  positions  of  the  four  observed 
nucleotide variations are highlighted and denoted in red:- 
                                                                                 A-24G        C-16T 
Sense (5’ → 3’):-                TTCGTCTTCCCAAGGCTATTTCTGCCGGGCGCTCCGCGAAGA 
Anti-sense (3’ ← 5’):-        AAGCAGAAGGGTTCCGATAAAGACGGCCCGCGAGGCGCTTCT 
                                                                                 T-24C          G-16A 
Anti-sense (5’ → 3’):-        TCTTCGCGGAGCGCCCGGCAGAAATAGCCTTGGGAAGACGAA 
                                                                                G-16A           T-24C 
                                                                                G+12A           G+21A 
Sense (5’ → 3’):-                    GAAGATGCAGCTCAAGCCGATGGAGATCAACCCCGAGGTG 
Anti-sense (3’ ← 5’):-               CTTCTACGTCGAGTTCGGCTACCTCTAGTTGGGGCTCCAC 
                                                                                 C+12T            C+21T 
Anti-sense (5’ → 3’):-              CACCTCGGGGTTGATCTCCATCGGCTTGAGCTGCATCTTC 
                                                                                 C+21T            C+12T 
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A (Anti-sense) 
                            G/A SNP -16                                          T/C SNP -24 
 
 
B (Anti-sense) 
                                             -16                                                -24 
 
Figure  36  –  Comparative  DNA  sequencing  scans  for  the  UCH-L1  anti-sense  nucleotide 
sequence -11 to -30 of promoter region A (relative to the ATG start codon of exon 1). 
(A) Heterozygous sample exhibiting an anti-sense guanine to adenine SNP at position -16 
(G/A SNP -16) and an anti-sense thymine to cytosine SNP at position -24 (T/C SNP -24), 
corresponding to sense strand SNPs C-16T and A-24G respectively.  
(B) Homozygous sample harbouring no nucleotide sequence variation (corresponding base 
pair positions are indicated).  
-  SNPs  are  identifiable from  significant  sequencing  peaks  of  different  colours  (nucleotide 
bases – see below) being realised at the same base pair position. (Smaller peaks are caused 
by background non-specific PCR products). 
- Nucleotide bases are colour coded accordingly: blue – cytosine(C), black – guanine(G), 
green – adenine(A), and red – thymine (T). 
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A (Anti-sense) 
                                       C/T SNP +21                                  C/T SNP +12 
 
 
B (Anti-sense) 
                                            +21                                                  +12 
 
Figure  37  –  Comparative  DNA  sequencing  scans  for  the  UCH-L1  anti-sense  nucleotide 
sequence +28 to +5 of promoter region A (relative to the ATG start codon of exon 1). 
(A) Heterozygous sample exhibiting two anti-sense cytosine to thymine SNPs at positions +21 
(C/T SNP +21) and +12 (C/T SNP +12), corresponding to sense strand SNPs G+21A and 
G+12A respectively.  
(B) Homozygous sample harbouring no nucleotide sequence variation (corresponding base 
pair positions are indicated). 
-  SNPs  are  identifiable from  significant  sequencing  peaks  of  different  colours  (nucleotide 
bases – see below) being realised at the same base pair position. (Smaller peaks are caused 
by background non-specific PCR products). 
- Nucleotide bases are colour coded accordingly: blue – cytosine(C), black – guanine(G), 
green – adenine(A), and red – thymine (T). 
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3.1.2.2 Sequencing Analysis of Promoter Region B 
  As shown in the electropherograms below, promoter region B revealed one novel 
SNP;  a  guanine  to  adenine  nucleotide  substitution  at  position  -234  (relative  to  the  ATG 
translation start codon of exon 1). 
- Shown here are the relevant nucleotide sequences (sense and anti-sense) corresponding to 
the  electropherograms  displayed  for  promoter  region  B  in  this  section.  (Sequences  were 
cross  referenced  with the  NCBI  website  database).  The  position  of the  observed  SNP is 
highlighted and denoted in red:- 
                                                                                          G-234A 
Sense (5’ → 3’):-                   AACACCAGATTATCTCACCGGCGAGTGAGACTGCAAGGTTT 
Anti-sense (3’ ← 5’):-            TTGTGGTCTAATAGAGTGGCCGCTCACTCTGACGTTCCAAA 
                                                                                          C-234T 
Anti-sense (5’ → 3’)):-           AAACCTTGCAGTCTCACTCGCCGGTGAGATAATCTGGTGTT 
                                                                                          C-234T 
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A (Anti-sense) 
  C/T SNP -234 
 
 
B (Anti-sense) 
-234 
 
Figure  38  –  Comparative  DNA  sequencing  scans  for  the  UCH-L1  anti-sense  nucleotide 
sequence -223 to -245 of promoter region B (relative to the ATG start codon of exon 1).  
(A) Heterozygous sample exhibiting an anti sense cytosine to thymine SNP at position -234 
(C/T SNP -234), corresponding to a G-234A sense strand SNP. 
(B) Homozygous sample harbouring no nucleotide sequence variation (corresponding base 
pair position is indicated).  
-  SNPs  are  identifiable from  significant  sequencing  peaks  of  different  colours  (nucleotide 
bases – see below) being realised at the same base pair position. (Smaller peaks are caused 
by background non-specific PCR products). 
- Nucleotide bases are colour coded accordingly: blue – cytosine(C), black – guanine(G), 
green – adenine(A), and red – thymine (T). 
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3.1.2.3 Sequencing Analysis of Promoter Region C 
  As shown in the electropherograms below, promoter region C revealed two novel 
SNPs; both adenine to guanine nucleotide substitutions, at positions -307 and -306 (relative 
to the ATG translation start codon of exon 1). 
-  Shown  here  is  the  relevant  nucleotide  sequence  (sense  strand)  corresponding  to  the 
electropherograms displayed for promoter region C in this section. (Sequences were cross 
referenced with the NCBI website database). The positions of the two observed SNPs are 
highlighted and denoted in red:- 
(Sense strand (5’ → 3’) 
CCAAAATTAAAGACTCCATCAAAAGGACTGCTCCATACACT 
 A-307/6G  . 
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A (Sense) 
A/G SNP -307  . 
 
 
B (Sense) 
    -307/6 
 
Figure 39 – Comparative DNA sequencing scans for the UCH-L1 sense nucleotide sequence   
-318 to -296 of promoter region C (relative to the ATG start codon of exon 1). 
(A) Heterozygous sample exhibiting an adenine to guanine SNP at position -307 (A/G SNP    
-307); thus a A-307G sense strand SNP.  
(B) Homozygous sample harbouring no nucleotide sequence variation (corresponding base 
pair positions are indicated).  
-  SNPs  are  identifiable from  significant  sequencing  peaks  of  different  colours  (nucleotide 
bases – see below) being realised at the same base pair position. (Smaller peaks are caused 
by background non-specific PCR products). 
- Nucleotide bases are colour coded accordingly: blue – cytosine(C), black – guanine(G), 
green – adenine(A), and red – thymine (T). 
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A (Sense) 
        A/G SNP -306   
 
 
B (Sense) 
      -307/6 
 
Figure 40 – Comparative DNA sequencing scans for the UCH-L1 sense nucleotide sequence   
-318 to -296 of promoter region C (relative to the ATG start codon of exon 1). 
(A) Heterozygous sample exhibiting an adenine to guanine SNP at position -306 (A/G SNP    
-306); thus a A-306G sense strand SNP.  
(B) Homozygous sample harbouring no nucleotide sequence variation (corresponding base 
pair positions are indicated).  
-  SNPs  are  identifiable from  significant  sequencing  peaks  of  different  colours  (nucleotide 
bases – see below) being realised at the same base pair position. (Smaller peaks are caused 
by background non-specific PCR products). 
- Nucleotide bases are colour coded accordingly: blue – cytosine(C), black – guanine(G), 
green – adenine(A), and red – thymine (T). 
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3.1.2.4 Exon 3 (C54A) Sequencing Results 
  As shown in the electropherograms below, Exon 3 revealed one previously described 
SNP  (Farrer  et  al.  (1999));  a  cytosine  to  adenine  nucleotide  substitution  at  position  +54 
(relative to the ATG translation start codon of exon 1). 
- Shown here are the relevant nucleotide sequences (sense and anti-sense) corresponding to 
the  electropherograms  displayed  for  exon  3  in  this  section.  (Sequences  were  cross 
referenced with the NCBI website database). The position of the documented C54A SNP is 
highlighted and denoted in red:- 
                                                                                           C+54A 
Sense (5’ → 3’):-                  CTCCTCTCCGCAGGTGCTGTCCCGGCTGGGGGTCGCCGGC 
Anti-sense (3’ ← 5’):-          GAGGAGAGGCGTCCACGACAGGGCCGACCCCCAGCGGCCG 
                                                                                           G+54T 
Anti-sense (5’ → 3’):-          GCCGGCGACCCCCAGCCGGGACAGCACCTGCGGAGAGGAG 
                                                                                           G+54T 
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A (Anti-sense) 
G/T SNP +54 
 
 
B (Anti-sense) 
+54 
 
Figure  41  –  Comparative  DNA  sequencing  scans  for  the  UCH-L1  anti-sense  nucleotide 
sequence +65 to +45 of exon 3 (relative to the ATG start codon of exon 1). 
(A) Heterozygous sample exhibiting an anti-sense guanine to thymine SNP at position +54 
(G/T SNP +54), corresponding to the C+54A documented sense strand SNP. 
(B) Homozygous sample harbouring no nucleotide sequence variation (corresponding base 
pair position is indicated).  
-  SNPs  are  identifiable from  significant  sequencing  peaks  of  different  colours  (nucleotide 
bases – see below) being realised at the same base pair position. (Smaller peaks are caused 
by background non-specific PCR products). 
- Nucleotide bases are colour coded accordingly: blue – cytosine(C), black – guanine(G), 
green – adenine(A), and red – thymine (T). 
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3.1.2.5 Interpretation of DNA Sequencing 
  DNA sequencing of the four UCH-L1 promoter regions exhibiting potential dHPLC 
heteroduplexes (refer to section 3.1.1) has elucidated a total of seven SNPs - G21A, G12A, 
C-16T,  A-24G,  G-234A,  A-306G  and  A-307G  (relative  to  the  translation  start  site).  DNA 
sequencing has also confirmed the position and nature of the documented exon 3 SNP – 
C54A – whilst corroborating the Rsa I RFLP genotyping methodology used to initially identify 
those samples harbouring the polymorphic A allele. 
  UCH-L1 promoter region D, though it exhibited potential heteroduplex dHPLC scans 
(refer to section 3.1.1.4), did not elucidate any nucleotide sequence variations through DNA 
sequencing.  This  seems  to  indicate  that  the  dHPLC  scans  displaying  potential  promoter 
region  D  heteroduplexes,  were  perhaps  contaminated  with  non-specific  PCR  sequences 
which mimicked heteroduplex peaks. 
  In addition to the previously documented C54A SNP, two novel coding region SNPs 
have also been elucidated through DNA sequencing; both are present within UCH-L1’s exon 
1 nucleotide sequence. However, unlike the C54A SNP, the polymorphic alleles of the G12A 
and G21A SNPs do not effect a change in UCH-L1’s amino acid sequence, i.e. the primary 
protein  structure  of  UCH-L1  remains  unchanged.  This  is  depicted  below  (polymorphic 
nucleotide and amino acid changes are indicated in red):- 
UCH-L1’s exon 1 nucleotide sequence 
                      ATG  CAG  CTC  AAG/A CCG ATG GAG/A ATC AAC               . 
                                   Met   Gln   Leu   Lys/Lys  Pro  Met  Glu/Glu  Ile   Asn. 
UCH-L1’s corresponding amino acid sequence 
  Owing to the fact that neither the 12A and 21A polymorphic alleles bring about a 
variation in UCH-L1’s primary structure, led to the cessation of investigative work into these 
exon 1 SNPs. 
  The five novel SNPs elucidated within UCH-L1’s 5’ UTR/ promoter region and the 
confirmed exon 3 documented SNP, were then genotyped in Caucasian sample arrays to 
ascertain  the  most  frequent  haplotypes  governing  the  distribution  of  the  alleles  in  the 
Caucasian population.   156 
 
Figure  42  –  C-16T  SNP  RFLP Genotyping Gel Output  (visualised  under  UV  light  after 
staining with ethidium bromide). A 5% polyacrylamide gel displaying UCH-L1 promoter region 
A  Nci  I  RFLP  analysis  of x96  samples  (from x480 DNA  sample  set). The  18  red circled 
samples  indicate  those  PCR  samples  which  realised  partial  double  Nci  I  restriction 
endonuclease digestion, which can be deduced from the presence of both the 162bp DNA 
band and the 72, 90 & 100bp fragment cluster (e.g. well H5), and are thus heterozygous for 
the polymorphic -16T allele. No homozygotes for the polymorphic T allele were seen to be 
evident, as no purely single Nci I digestion was realised, i.e. the 72, 90 & 100bp DNA band 
cluster is visible in all other viable wells, indicating dual Nci I digestion, and thence reference 
homozygote (C allele) DNA. (Refer to section 2.2.4.1 for C-16T RFLP genotyping strategy 
details). Sample nomenclature runs in well rows from A to H, and in well columns from 1 to 
12.  Samples  D2  and  C4  did  not  elucidate  any  results  owed  to  sample  genomic  DNA 
concentration deficiency. 
  A. 
  H. 
  1
  12 
162bp 
72,90  
& 100bp 
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Figure 44 – A-307G SNP RFLP Genotyping Gel Output (visualised under UV light after 
staining with ethidium bromide). A 5% polyacrylamide gel displaying UCH-L1 promoter region 
C Taq I RFLP analysis of x96 samples (from x480 DNA sample set). The 19 red circled 
samples  indicate  those  PCR  samples  which  realised  partial  double  Taq  I  restriction 
endonuclease digestion, which can be deduced from the presence of both the 172 & 143bp 
fragments and the 71 & 72bp DNA bands (e.g. well H6), and are thus heterozygous for the 
polymorphic -307G allele. The gold circled digest indicates a sample which realised complete 
Taq  1  digestion  –  as  only  three  bands  are  evident  (i.e.  no  143bp  band)  -  and  is  thus 
homozygous for the polymorphic G allele. All other viable wells display homozygosity for the 
reference A allele as no 71 & 72bp fragments are seen. (Refer to section 2.2.4.3 for A-307G 
RFLP genotyping strategy details). Sample nomenclature runs in well rows from A to H, and 
in well columns from 1 to 12. Samples E5, C8, C9 and D9 did not elucidate any results owed 
to sample genomic DNA concentration deficiency. 
   A. 
 H. 
  1  
  12 
172 & 
143bp 
 
71 & 72bp 
bands 
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  As indicated above, owed to the lack of results obtained from both the A-24G and    
A-307G PIRA-RFLP genotyping strategies, RFLP methodology had to be supplemented. For 
the x64 DNA sample set, this took the form of supplemental DNA sequencing data. 
  Direct DNA sequencing was utilised to further investigate the linkage between the      
-16T  and  -24G  alleles.  All  the  x64  DNA  samples  that  exhibited  heterozygosity  for  the 
polymorphic  -16T  allele,  through  RFLP  methodology,  were  sequenced  to  elucidate  the 
potential presence of the -24 G allele.  
  Sequencing of UCH-L1 promoter region A elucidated the -24G allele in all the DNA 
samples that had exhibited the polymorphic T allele through RFLP analysis. 
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A (Anti-sense) 
                            -16TA (Sense -16T)                                   -24C (Sense -24G) 
 
 
B (Anti-sense) 
                                             -16                                                -24 
 
Figure  46  –  Comparative  DNA  sequencing  scans  for  the  UCH-L1  anti-sense  nucleotide 
sequence -11 to -30 of promoter region A (relative to the ATG start codon of exon 1). 
(A)  Sample  that  previously  exhibited  heterozygosity  for  the  polymorphic  -16T  allele 
(corresponds  to  anti-sense  -16A  allele  above)  through  RFLP  methodology,  also  displays 
heterozygosity for the anti-sense -24C allele (sense strand -24G allele). 
(B)  Homozygous  sample  harbouring  no  polymorphic  alleles  (corresponding  base  pair 
positions are indicated).  
- The polymorphic alleles are identifiable in the heterozygous sample above (A) by way of 
significant peaks of different colours (nucleotide bases – see below) being realised at the 
same  base  pair  position.  (Smaller  peaks  are  caused  by  background  non-specific  PCR 
products). 
- Nucleotide bases are colour coded accordingly: blue – cytosine(C), black – guanine(G), 
green – adenine(A), and red – thymine (T). 
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RFLP analysis also indicated that all the samples in the x64 DNA sample set that 
exhibited heterozygosity for the -16T allele, and thus also the -24G allele (refer above), were 
correspondingly heterozygous for the -307G allele. 
  DNA sequencing was employed to investigate the linkage between the -306/ -307 
polymorphic G alleles and the -234A allele. All the samples in the x64 DNA sample set that 
exhibited  homozygosity/  heterozygosity  for  the  polymorphic  -234A  allele  through  RFLP 
analysis, were accordingly sequenced to elucidate the potential presence of either the -306 or 
-307 G allele. 
  Sequencing  of  promoter  region  C  elucidated  the  -306G  allele  (in  a  homozygous/ 
heterozygous dependent manner) in all the DNA samples that had exhibited the polymorphic  
-234A allele through RFLP analysis. The -307G allele was not seen to be present. 
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A (Sense) 
           -306G 
 
 
B (Sense) 
                                                                           -306 . 
 
Figure 47 – Comparative DNA sequencing scans for the UCH-L1 sense nucleotide sequence   
-318 to -296 of promoter region C (relative to the ATG start codon of exon 1). 
(A) Sample that previously exhibited homozygosity for the polymorphic -234A allele through 
RFLP analysis, also displays homozygosity for the -306G allele. 
(B) Homozygous sample harbouring no polymorphic alleles (corresponding base pair position 
is indicated).  
-  The  polymorphic  allele  is  identifiable  in  the  homozygous  sample  above  (A)  by  way  of 
comparison with the non-polymorphic sample (B), which exhibits a different coloured peak 
(different  nucleotide  base  –  see  below)  at  the  corresponding  base  pair  position.  (Smaller 
peaks are caused by background non-specific PCR products). 
- Nucleotide bases are colour coded accordingly: blue – cytosine(C), black – guanine(G), 
green – adenine(A), and red – thymine (T). 
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A (Sense) 
        -306G 
 
 
B (Sense) 
                                                                            -306 . 
 
Figure 48 – Comparative DNA sequencing scans for the UCH-L1 sense nucleotide sequence   
-318 to -296 of promoter region C (relative to the ATG start codon of exon 1). 
(A) Sample that previously exhibited heterozygosity for the polymorphic -234A allele through 
RFLP analysis, also displays heterozygosity for the -306G allele. 
(B) Homozygous sample harbouring no polymorphic alleles (corresponding base pair position 
is indicated).  
-  The  polymorphic  allele  is  identifiable  in  the  heterozygous  sample  above  (A)  by  way  of 
significant peaks of different colours (nucleotide bases – see below) being realised at the 
same  base  pair  position.  (Smaller  peaks  are  caused  by  background  non-specific  PCR 
products). 
- Nucleotide bases are colour coded accordingly: blue – cytosine(C), black – guanine(G), 
green – adenine(A), and red – thymine (T). 
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  For the x480 DNA sample set, owed to the lack of results attained from both the A-
24G and A-307G PIRA-RFLP genotyping strategies, RFLP methodology was supplemented 
with allele frequency data supplied by Kbiosciences Ltd. 
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3.1.3.2 x64 DNA Sample Set (62 Chromosomes) Genotyping Results and 
Analysis 
3.1.3.2.1 Variant Allele Frequency Table 
RFLP Analysis 
Allele  Frequency  
-307 G  8.1% 
-234 A  25.8% 
-16 T  8.1% 
+54 A  8.1% 
 
Sequencing Analysis 
Allele  Frequency  
-306 G  25.8% 
-24 G  8.1% 
Table 9 –Displays the frequency of variant alleles obtained from the x 31 DNA sample set 
through both RFLP and sequencing analysis (refer above). The variant alleles are listed on 
the left, with their respective allelic frequencies within the sample set indicated on the right.  
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3.1.3.2.2 Genotype Frequency Table 
Nucleotide Position of Allele   
-307  -306  -234  -24  -16  +54  Genotype Freq. 
A  A  G  A  C  C  36 
A  G  A  A  C  C  16 
G  A  G  G  T  C  5 
A  A  G  A  C  A  5 
Table  10  –  Collation  of  the  RFLP  and  sequencing  results  with  respect  to  the  genotypes 
exhibited  by  each  of the x31  individuals  within  the x64  DNA  sample  set. The  genotypes 
elucidated are indicated by A (adenine), G (guanine), C (cytosine) and T (thymine) under the 
relevant nucleotide position (displayed downstream from left to right). Their frequencies are 
indicated in the far right hand column. (Variant alleles are denoted in Red). 
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3.1.3.2.3 Hardy-Weinberg Equilibrium Consistency of Genotype Frequencies 
(The Hardy-Weinberg equilibrium concept is introduced in section 1.7.2.1) 
  Single Nucleotide Polymorphism 
  A-307G, A-24G, C-16T & C+54A  G-234A & A-306G 
Genotypes  Observed  Expected  Observed  Expected 
Homozygotes - Reference  26  26.2  17  17.1 
Heterozygotes  5  4.6  12  11.9 
Homozygotes - Variant  0  0.2  2  2.1 
Variant Allele Frequency  0.08  0.26 
Chi-Squared Test p Value  0.8876  0.9982 
(p value < 0.05 indicates inconsistency with Hardy-Weinberg Equation). 
Table 11 – Exhibits the genotype frequencies for the six UCH-L1 SNPs investigated for this 
sample set with the Hardy-Weinberg formula (equation) applied. Both the actual frequencies 
(‘Observed’),  and  the  Hardy-Weinberg  Equation  theoretically  ‘Expected’  frequencies  are 
displayed.  The variant  allele frequency  is  also  indicated,  with  the final  row  exhibiting the 
probability (p value) of consistency between the ‘Observed’ and ‘Expected’ figures, calculated 
through Chi-Squared statistical analysis. 
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3.1.3.2.4 Haplotype Frequency Diagrams 
Reference Homozygote 
▄                                                                                                                        ▼                    ▄ 
Haplotype 1                                                                                                                       (58%) 
                      -306G                          -234A 
▄                      ↓                                   ↓                                                           ▼                     ▄ 
Haplotype 2                                                                                                                    (25.8%) 
                -307G                                                                    -24G        -16T 
▄                 ↓                                                                           ↓               ↓        ▼                    ▄ 
Haplotype 3                                                                                                                      (8.1%) 
                                                                                                                                   +54A 
▄                                                                                                                        ▼        ↓           ▄ 
Haplotype 4                                                                                                                      (8.1%) 
Figure 49 - The four UCH-L1 haplotypes are diagrammatically represented with reference to 
the  distribution  of  the  six  polymorphic  alleles,  elucidated  through  RFLP  and  sequencing 
genotyping analysis of the x64 sample set (allelic positions not to scale). Their haplotypic 
frequency within the 62 chromosomes studied is indicated in brackets. (▼ – indicates the 
translation start site (+1)). 
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3.1.3.2.5 Interpretation of x64 DNA Sample Set Genotyping Analysis 
  Through  restriction  fragment  length  polymorphism  and  sequencing  analysis  the 
frequencies of the six UCH-L1 variant alleles were ascertained (Table 9), and once collated 
with respect to the genotypes exhibited by each of the 31 individuals in the x64 DNA sample 
(Table 10), haplotype frequencies were able to be determined (Figure 49). 
  Four  distinct  haplotypes  were  elucidated:  the  reference  haplotype  (AAGACC) 
displayed a frequency of 58%, the polymorphic AGAACC haplotype displayed a frequency of 
25.8%, whilst both variant GAGGTC and AAGACA haplotypes realised a frequency of 8.1%. 
  The fact that the genotype frequencies for each of the six UCH-L1 SNPs investigated 
were consistent with the Hardy-Weinberg formula lends credence to these results – see Table 
9 (the genotype frequencies for each of the SNPs correlated well with those predicted by the 
Hardy-Weinberg equation). 
  These  results  from  the  31  individuals  (x62  chromosomes)  investigated  did  not 
elucidate the +54A allele in linkage disequilibrium with any of the promoter/ 5’ UTR alleles. 
Thence,  this  polymorphism  was  removed  from  any  proceeding  experimental  work  in  this 
study, as the investigation concentrated on the promoter/ 5’ UTR region of UCH-L1.  
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3.1.3.3 x480 DNA Sample Set (960 Chromosomes) Genotyping Results and 
Analysis 
3.1.3.3.1 Variant Allele Frequency Table 
Allele  Frequency  
-307 G  9.7% 
-306 G  17.3% 
-234 A  17.6% 
-24 G  9.9% 
-16 T  9.7% 
Table 12 – Displays the frequency of variant alleles obtained from the x 480 DNA sample set. 
The variant alleles are listed on the left, with their respective allelic frequencies within the 
sample set indicated on the right. 
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3.1.3.3.2 Genotype Frequency Table 
Nucleotide Position of Allele   
-307  -306  -234  -24  -16  Genotype Freq. 
A  A  G  A  C  577 
A  G  A  A  C  148 
G  A  G  G  T  74 
G  G  A  G  T  16 
A  A  A  A  C  3 
A  G  A  G  C  2 
G  A  G  G  C  2 
A  A  G  A  T  2 
G  A  G  A  T  1 
A  A  G  G  C  1 
(N.B. – 134 Indeterminable alleles) 
Table 13 – Collation of the results with respect to the (determinable) genotypes exhibited 
within the x480 DNA sample set (960 chromosomes). The genotypes elucidated are indicated 
by  A  (adenine), G  (guanine),  C  (cytosine)  and  T  (thymine)  under  the  relevant  nucleotide 
position (displayed downstream from left to right). Their frequencies are indicated in the far 
right hand column. (Variant alleles are denoted in Red). 
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3.1.3.3.3 Hardy-Weinberg Equilibrium Consistency of Genotype Frequencies 
(The Hardy-Weinberg equilibrium concept is introduced in section 1.7.2.1) 
  Single Nucleotide Polymorphism 
  A-307G  A-306G  G-234A  A-24G  C-16T 
Genotypes  O  E  O  E  O  E  O  E  O  E 
Homozygotes 
(Reference)  376.  377.6  275.  275.2  317.  312.3  367.  368.9  376.  377.6 
Heterozygotes  87  83.7  134  133.6  129  138.4  89  85.2  87  83.7 
Homozygotes  
(Variant)  3  4.6  16  16.2  20  15.3  3  4.9  3  4.6 
Variant Allele 
Frequency  0.10  0.20  0.18  0.10  0.10 
Chi-Squared Test     
p Value  0.6993  0.9979  0.3446  0.6285  0.6993 
(p value < 0.05 indicates inconsistency with Hardy-Weinberg Equation). 
Table14 – Exhibits the genotype frequencies for the five UCH-L1 SNPs investigated for this 
sample set with the Hardy-Weinberg formula (equation) applied. Both the actual frequencies 
(‘O’  for  ‘Observed’),  and  the  Hardy-Weinberg  Equation  theoretically  ‘Expected’  (‘E’) 
frequencies are displayed. The variant allele frequency is also indicated, with the final row 
exhibiting the  probability  (p value)  of consistency  between  the  ‘Observed’  and  ‘Expected’ 
figures, calculated through Chi-Squared statistical analysis. 
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3.1.3.3.4 Haplotype Frequency Diagrams 
Reference Homozygote 
▄                                                                                                                                                ▄ 
Haplotype 1                                                                                                                  (60.1%) 
                                   -306G                            -234A 
▄                                    ↓                                    ↓                                                                    ▄ 
Haplotype 2                                                                                                                  (15.4%) 
                         -307G                                                                                 -24G         -16T 
▄                          ↓                                                                                        ↓                ↓        ▄ 
Haplotype 3                                                                                                                    (7.7%) 
(For continuation of less common UCH-L1 promoter haplotypes, please continue overleaf) 
 
 
 
 
 
 
 
 
 
   175 
 
 
 
                      -307G     -306G                           -234A                               -24G           -16T 
▄                       ↓             ↓                                   ↓                                       ↓                 ↓        ▄ 
Haplotype 4                                                                                                                      (1.7%) 
                                                                         -234A 
▄                                                                          ↓                                                                    ▄ 
Haplotype 5                                                                                                                      (0.3%) 
                                    -306G                           -234A                                  -24G 
▄                                    ↓                                    ↓                                          ↓                        ▄ 
Haplotype 6                                                                                                                      (0.2%) 
                         -307G                                                                                   -24G     
▄                          ↓                                                                                          ↓                        ▄ 
Haplotype 8                                                                                                                      (0.2%) 
                                                                                                                                  -16T 
▄                                                                                                                                   ↓           ▄ 
Haplotype 7                                                                                                                      (0.2%) 
                         -307G                                                                                              -16T 
▄                          ↓                                                                                                      ↓            ▄ 
Haplotype 8                                                                                                                      (0.1%) 
                                                                                                                    -24G   
▄                                                                                                                    ↓                          ▄ 
Haplotype 10                                                                                                                    (0.1%) 
Figure  50  -  The  ten  UCH-L1  promoter  haplotypes  are  indicated  with  reference  to  the 
distribution of the five promoter/ 5’ UTR polymorphic alleles elucidated in this study (allelic 
positions not to scale). Their haplotypic frequency within the 960 chromosomes studied in this 
sample set is indicated in brackets. 
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3.1.3.3.5 Interpretation of x480 DNA Sample Set Genotyping Analysis 
  Through restriction fragment length polymorphism and supplemental allele frequency 
data,  the  frequencies  of  the  five  UCH-L1  promoter  polymorphic  alleles  were  ascertained 
(Table 12), and once collated with respect to the genotypes exhibited by each of the 480 
individuals  (x480  DNA  sample  set)  (Table  13),  haplotype  frequencies  were  able  to  be 
determined (Figure 50). 
  Ten haplotypes were elucidated; three displayed a frequency of greater than 5%, with 
seven others displaying a total frequency of 2.8% (Figure 50). With reference to the three 
haplotypes  elucidated  from  the  x64  DNA  sample  set  (refer  to  section  3.1.3.2),  a  good 
correlation was observed with the three most common haplotypes uncovered from the x480 
DNA  sample  set.  The  AAGAC  promoter  haplotype being  the most  common  (60.1%),  the 
AGAAC haplotype being the next frequent (15.4%), and the GAGGT haplotype exhibiting a 
frequency of 7.7%. This promoter haplotype order, with respect to frequency, was the same in 
both DNA sample sets investigated. 
  As  previously  discussed,  this  study’s  main  focus  was  on  potential  changes  in 
expression that common UCH-L1 Caucasian promoter haplotypes could bring about on UCH-
L1 levels within mammalian cells. Thus, only those haplotypes with a frequency of over 5% 
were  deemed  relevant  to  the  next  stage  of this  study,  which  was  to  insert  the  promoter 
haplotypes within suitable vectors, to allow expression studies within mammalian cell lines to 
be carried out. 
N.B. – UCH-L1 promoter haplotype nomenclature:- 
  AAGAC – UCH-L1 reference haplotype. 
  AGAAC – Haplotype exhibiting –306G and –234A polymorphic alleles. 
  GAGGT – Haplotype exhibiting –307G, -24G and –16T polymorphic alleles. 
 
 
   177 
3.1.4 Discussion of Mutation Screening 
  From the mutation screening carried out above, three common promoter haplotypes 
have  emerged  which  govern  the  distribution  of  five  novel  SNPs  within  the  Caucasian 
population. 
  As  with  all  biallelic  polymorphisms  of  Mendelian  inheritance,  it  was  important  to 
ascertain whether the genotype distribution of the promoter/ 5’-UTR SNP alleles uncovered in 
this study (upon which the next stage of this study was to be based) were consistent with the 
Hardy-Weinberg principle – the qualifying law in population genetics to ensure a population is 
panmictic  and  in  evolutionary  stasis.  The  Hardy-Weinberg  law  was  used  to  test  the  null 
hypothesis in both DNA sample sets (refer to sections 3.1.3.2.3 and 3.1.3.3.3), and both 
populations displayed a high level of consistency – thus ensuring that downstream analysis 
was sound. 
  What the mutation screening in this section also elucidates is that the previously cited 
S18Y (C54A) variant allele is not in linkage disequilibrium with any of the promoter variant 
alleles uncovered in this study. In a recent large, case-control study (n=3023) (Healy et al. 
(2006)), this previously reported polymorphism was seen to have no significant association 
with sporadic Parkinson’s disease (previous studies had reported the S18Y polymorphism as 
having  a  protective  effect  against  Parkinson’s  disease  –  please  refer to  section  1.3.2 for 
further discussion). This lends credence to the fact that this polymorphism will not be studied 
further in this investigation, and also sustains the objective to concentrate the focus of this 
study on the promoter haplotypes, the polymorphic variants of which, are not in haplotypic 
linkage with the S18Y variant allele. 
  Within this same study (Healy et al. (2006)), the authors also provide frequency data 
for  an  array  of  SNPs  within  the  UCH-L1  gene  (resequencing  data  from  128  control 
chromosomes), only one of which relates to the promoter polymorphisms elucidated in this 
study – designated C-16T in this study (rs9321, clone position (NT_006238) 960944) – they 
report a frequency of 10.0% (0.32 HW), which supports the allele frequency observed in this 
study  within both control arrays of 9.7 and 8.1%. This SNP also has population diversity 
information within the NCBI database (Entrez SNP (dbSNP)); frequency from two populations   178 
have been uploaded – one reports a 15% frequency of the variant allele in a Japanese control 
array (n=100), and the second reports a frequency of 4% for the polymorphic T allele in a 
mixed  ethnicity control  array  (n=92)  – though  owing  to  both  populations  not  being  100% 
Caucasian, it is difficult to draw any direct conclusion from this data. One other SNP that has 
been elucidated in this study within UCH-L1’s promoter region also has been designated on 
the NCBI database – A-307G: rs13129604 – but has no population diversity frequency data 
associated with it. 
  The five polymorphisms that this study elucidates within the promoter were analysed 
for  their  predicted  effect  on  transcription  factor  binding.  The  ‘TFSEARCH’  program  was 
utilised (at http://www.rwcp.or.jp/lab/pdappl/papia.html (Akiyama, Y. (1995))), which searches 
highly  correlated  sequence  fragments versus  ‘TFMATRIX’  transcription factor  binding  site 
profile database in ‘TRANSFAC’ databases developed at GBF – Braunschweigh, Germany, 
and then carries out a simple correlation calculation with required inputted sequence data – 
its use has been designated suitable in publications (Heinemeyer et al. (1998)). 
  Any significant alterations to predicted transcription factor binding, in contrast to the 
reference alleles (Wt alleles), that the TFSEARCH software uncovered for the five UCH-L1 
promoter SNPs elucidated in this study, are outlined in Table 15 below. 
Owed to the predictive nature of the TFSEARCH software, it is difficult to draw any 
specific conclusions from the analysis carried out, although Table 15 does describe significant 
changes in predicted transcription factor binding (compared to that of the reference alleles) for 
three  of  the  variant  alleles  –  with  at  least  one  harboured  on  each  of  the  two  UCH-L1 
polymorphic  promoter  haplotypes.  This  supports  the  necessity  to  study  these  haplotypic 
sequence variants further in functional analyses, which were to be carried out in the next 
stage of this project. 
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Variant Allele(s) 
Change in Predicted 
Transcription Factor Binding 
from that of Reference Allele 
Species (if applicable) 
-307G 
-306G 
-234A 
-24G/ -16T 
No Predicted Change  
Novel GATA-binding factor-1 
No Predicted Change 
Novel SRY site (Sex-
Determining region Y gene 
product) 
Lost 2x CdxA sites 
- 
Mus musculus (Mouse) 
- 
Homo sapiens (Human) 
Gallus gallus (Chick) 
Table  15  –  Outlines  the  predicted  changes  in  transcription  factor  binding  that  the  five 
promoter UCH-L1 SNP variant alleles realised from that of the reference alleles utilising the 
‘TFSEARCH’ software (Akiyama, Y. (1995)) (at default settings, for Vertebrate classification). 
–  The  –24G  and  –16T  polymorphic  alleles  were  analysed  together  owed  to  their  close 
proximity, and the fact that they reside on the same polymorphic haplotypes. 
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       ↓                5’                                       ¬1007bp®                                        3’                 ↓ 
GAAGATCTTC▄                      3 x UCH-L1 Promoter Haplotypes                       ▄GGGGTACC 
    Kpn I Site                                                                                                                Bgl II Site 
Figure  51  –  Diagrammatic  representation  of  required  UCH-L1  promoter  sequences  (↓  = 
specific ‘cutting’ site of restriction endonuclease). 
Primer Design Considerations 
Anti-sense Primer:-  
-  5’ end had to begin upstream of ATG translation start site, as only 5’ UTR/ promoter 
sequences were required (ATG start codon was present in pGL3’s luc+ gene). 
-  3’ end had to end downstream of the C-16T SNP to encompass its interhaplotypic 
variation. 
Sense Primer:- 
-  3’ end had to encompass/ be upstream of all identified regulatory sequence elements 
(with reference to Mann et al. (1996)). 
All three UCH-L1 promoter/ 5’UTR haplotypes were successfully amplified by PCR and 
the respective nucleotide sequence fidelities were confirmed through DNA sequencing. Kpn I/ 
Bgl II double restriction digest  was then carried out on the three UCH-L1 PCR amplified 
haplotypes and the pGL3 vector, to allow ligation reactions to be employed to allow promoter 
insertion into the vector. 
Interpretation 
  Through reasons that remain unclear, despite many modifications in time, 
temperature and quantities being made to each segment of the cloning strategy (post initial 
sequence confirmation), including Kpn I/ Bgl II restriction digestion, the ligation reaction and 
E.coli transformation and recovery, no pGL3/ UCH-L1 promoter constructs were identified. 
This particular cloning strategy was thus suspended in search of a more successful approach.  
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3.2.1.2 Revised Cloning Strategy – pGL3 via pGEM-T Easy holding vector 
3.2.1.2.1 Incorporation of Haplotypes into pGEM-T Easy 
The basic outline of this first phase of the revised cloning strategy was to incorporate 
the individual UCH-L1 promoter haplotypes into an initial transient holding vector - pGEM-T 
Easy (Promega) (Figure 27) – before incorporating the promoter sequence into pGL3. The 
pGEM-T Easy system was chosen as PCR products could be inserted directly into the vector 
without any post-modification (refer to section 2.3.1.1). It was also chosen as it contained 
several restriction sites flanking the PCR insertion (cloning) site which were not realised within 
the UCH-L1 promoter haplotype sequences (refer to appendices for ‘Lasergene’ output of 
non-cutting  endonucleases),  which  were  then  able  to  be  used  to  remove  the  UCH-L1 
promoter sequences with a single restriction digest protocol. 
As for the ‘Initial Cloning Strategy’ (refer to section 3.2.1.1), the same region of the 
UCH-L1  promoter  was  amplified  by  PCR  (the  primers  were  only  modified  to  remove  the 
restriction sites and further reduce any DNA secondary structure). Once amplified through 
PCR and the respective nucleotide sequence fidelity confirmed, all three UCH-L1 promoter 
haplotypes were inserted into pGEM-T Easy through specific pGEM-T Easy ligation reactions 
(see section 2.3.8). Their incorporation was then confirmed through E.coli subcloning protocol 
and subsequent Eco RI restriction digest of the relevant plasmid DNA to display the pGEM-T 
Easy vector and UCH-L1 promoter inserts.   186 
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Figure 53 – Basic outline of the ultimately successful ‘Revised Cloning Strategy’. 
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Orientation  of  the  UCH-L1  promoter  inserts  in  pGEM-T  Easy  were  of  critical 
importance. As seen in Figure 27 (section 2.3.1.1), pGEM-T Easy harbours Eco RI restriction 
sites either side of its ‘PCR insertion site’, and on the ‘SP6 branch’ of its ‘multiple cloning 
region’ the Spe I restriction site is located closer to the ‘PCR insertion site’ than Eco RI. This 
then allowed, if done sequentially (i.e. not at the same time), the UCH-L1 promoter inserts in 
pGEM-T Easy to be extracted with ‘sticky ends’ for Eco RI at one end and Spe I at the other. 
Though for this to be done correctly Spe I would have to be utilised first, then followed by Eco 
RI.  
pGL3-Eco RI contains these two restriction sites within its modified ‘multiple cloning 
region’, however Spe I is 5’ and Eco RI is 3’ in respect to the luc+ gene (the correct control of 
which is fundamental to the next stage of this investigation). This meant that pGEM-T Easy/ 
UCH-L1 inserts had to be identified in the 5’ to 3’ orientation in respect to the lac operator, so 
that  they  could  then  be  transferred  to  the  pGL3-Eco  RI vector  in  the  correct  orientation. 
(Referring  back  to  the  sequencing  electropherograms  for  the  pGEM-T  Easy/  UCH-L1 
promoter  constructs  obtained  in  section  3.2.1.2.1,  one  construct  for  each  haplotype  that 
incorporated the UCH-L1 insert in the correct orientation (lacZ 5’ to 3’) was identified). 
Spe I followed by Eco RI restriction endonuclease digestion of these pGEM-T Easy 
constructs and of the pGL3/ Eco RI vector was then carried out, and three pGL3-Eco RI/ 
UCH-L1  promoter  constructs  were  then  formed  through  three  separate  ligation  reactions 
using the purified digestion products, followed by transformations and selective ampicillin agar 
plating as normal.   189 
 
Figure 55 - Agarose gel identifying three pGL3-Eco RI constructs harbouring the UCH-L1 
promoter inserts (+ve) for all three promoter haplotypes (denoted in white). The upper bands 
are the linear pGL3-Eco RI vectors. The lower bands are the Spe I/ Eco RI ‘cleaved’ promoter 
inserts. The 1 Kb band of the DNA ladder confirmed the inserts were of the required size (~1 
Kb) (denoted and marked in red). 
-  One  insert  for  each  UCH-L1  haplotype  represented  within  the  pGL3-Eco  RI/  UCH-L1 
promoter  constructs  elucidated  were  DNA  sequenced  to  confirm  their  respective  100% 
sequence fidelity (electropherograms not shown). 
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Interpretation 
  All three UCH-L1 promoter haplotypes had been successfully incorporated 
into  the  modified  pGL3-Eco  RI  vector,  which  allowed  the  next  stage  of  this  study  to  be 
initialised;  in  which  the  transcriptional  activities  of  the  UCH-L1  promoters  could  now  be 
investigated within mammalian cell lines to elucidate any potential differences between the 
haplotypes. 
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graph, as are the respective p-values – which were calculated by way of ‘Two Way Analysis 
of Variance’ (ANOVA) of all luciferase data. 
- The mean ratio, standard error of mean and p-values were derived form all the data from 6 
separate assays (in which measurements were taken in duplicate).  
-  The  x-axis  indicates  the  mean  firefly/  renilla  luciferase  activity  ratios  in  an  arbitrary 
luminescence scale. The y-axis indicates the pGL3 construct.  
- The standard error of means are graphically indicated as (+/-) error lines at the top of each 
separate bar. 
- Prior to cell lysis and dual-luciferase reporter assay methodology – 1-3x10
5 cells were grown 
to 50-80% confluence at 37° C (5% C0 2) in full growth medium; 1mg of vector together with 
‘GeneJuice’ transfection agent were then added, and cells were incubated for 24 hours at 
37° C (5% C0 2). 
N.B. – Raw data from each of the dual-luciferase assays carried out for the A2058 cell line is 
detailed in the relevant section of the appendix. 
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below the graph, as are the respective p-values – which were calculated by way of ‘Two Way 
Analysis of Variance’ (ANOVA) of all luciferase data. 
- The mean ratio, standard error of mean and p-values were derived form all the data from 3 
separate assays (in which measurements were taken in triplicate).  
- The x-axis indicates 2 x the mean firefly/ renilla luciferase activity ratios in an arbitrary 
luminescence scale. The y-axis indicates the pGL3 construct.  
-The standard error of means are graphically indicated as (+/-) error lines at the top of each 
separate bar. 
- Arbitrary luminescence values for each pGL3 construct were multiplied by a factor of 2 for 
clearer graph comparison purposes between the cell lines. 
- Prior to cell lysis and dual-luciferase reporter assay methodology – 1-3x10
5 cells were grown 
to 50-80% confluence at 37° C (5% C0 2) in full growth medium; 1mg of vector together with 
‘GeneJuice’ transfection agent were then added, and cells were incubated for 24 hours at 
37° C (5% C0 2). 
N.B. – Raw data from each of the dual-luciferase assays carried out for the MCF-7 cell line is 
detailed in the relevant section of the appendix. 
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data is also detailed below the graph, as are the respective p-values – which were calculated 
by way of ‘Two Way Analysis of Variance’ (ANOVA) of all luciferase data. 
- The mean ratio, standard error of mean and p-values were derived form all the data from 3 
separate assays (in which measurements were taken in quadruplicate).  
- The x-axis indicates the mean firefly/ renilla luciferase  activity ratios divided by 2 in an 
arbitrary luminescence scale. The y-axis indicates the pGL3 construct.  
-The standard error of means are graphically indicated as (+/-) error lines at the top of each 
separate bar. 
- Arbitrary luminescence values for each pGL3 construct were divided by a factor of 2 for 
clearer graph comparison purposes between the cell lines. 
- Prior to cell lysis and dual-luciferase reporter assay methodology – 1-3x10
5 cells were grown 
to 50-80% confluence at 37° C (5% C0 2) in full growth medium; 1mg of vector together with 
‘GeneJuice’ transfection agent were then added, and cells were incubated for 24 hours at 
37° C (5% C0 2). 
N.B. – Raw data from each of the dual-luciferase assays carried out for the ND-7 cell line is 
detailed in the relevant section of the appendix. 
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below the graph, as are the respective p-values – which were calculated by way of ‘Two Way 
Analysis of Variance’ (ANOVA) of all luciferase data. 
- The mean ratio, standard error of mean and p-values were derived form all the data from 3 
separate assays (in which measurements were taken in triplicate).  
-  The  x-axis  indicates  the  mean  firefly/  renilla  luciferase  activity  ratios  in  an  arbitrary 
luminescence scale. The y-axis indicates the pGL3 construct.  
-The standard error of means are graphically indicated as (+/-) error lines at the top of each 
separate bar. 
- Prior to cell lysis and dual-luciferase reporter assay methodology – 1-3x10
5 cells were grown 
to 50-80% confluence at 37° C (5% C0 2) in full growth medium; 1mg of vector together with 
‘GeneJuice’ transfection agent were then added, and cells were incubated for 24 hours at 
37° C (5% C0 2). 
N.B. – Raw data from each of the dual-luciferase assays carried out for the HCN-1A cell line 
is detailed in the relevant section of the appendix. 
3.2.2.5 Interpretation of Luciferase Reporter Assays 
  From the four dual-luciferase reporter assays carried out, it can be seen that in ND-7 
cells  (mouse  neuroblastoma/  rat  basal  ganglia  neuron  hybrid)  no  statistically  significant 
variation in mean firefly/ renilla luciferase activity ratios between the promoter haplotypes was 
realised (Figure 58). However, in all three of the human call lines investigated, the GAGGT 
promoter haplotype realised a significant increase in mean luciferase activity ratios (Figures 
56, 57 & 59), compared with the other two UCH-L1 haplotypes. 
  The increase in mean GAGGT luciferase activity ratios varied between cell types – a 
44.4% increase was realised in the A2058 (Human Skin Melanoma) cells, whilst in the MCF-7 
(Human Breast Carcinoma) cells a 40.2% increase was exhibited, and the HCN-1A (Human 
Brain Cortical Neuron) cells displayed a 129.9% increase for the GAGGT promoter haplotype 
– relative to the average of the mean activity ratios obtained for the AAGAC and AGAAC 
haplotype constructs.   200 
3.2.3 Discussion of Functional Studies 
  The  dual-luciferase  reporter  assays  carried  out  in  section  3.2.2  have  thence 
elucidated a significant increase in the transcriptional activity of GAGGT polymorphic UCH-L1 
promoter in human cells; Figure 60 illustrates these increases relative to the mean of the 
other two haplotypes in all the cell lines tested. 
Mean Increase in Transcriptional Activity of the GAGGT UCH-L1 Gene 
Promoter Haplotype in Relation to the AAGAC and AGAAC Haplotypes
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Figure  60  –  A  bar  graph  displaying  the  mean  increase  in  firefly/  renilla  luciferase  mean 
activity ratios (which is directly related to transcriptional activity of promoter insert, of the 
GAGGT UCH-L1 gene promoter haplotype, in relation to the AAGAC (reference homozygote) 
and AGAAC gene promoter haplotypes, in the four mammalian cell lines assayed. 
  These  results  suggest  that  the  –16T,  -24G  and  –307G  polymorphic  alleles 
significantly  effect  the  UCH-L1  promoter’s  transcriptional  activity  in  human  cells  in  vitro, 
especially in neuronal cells (please refer to section 4 for further discussion with regards to the 
differences in transcriptional activity elucidated between the promoter haplotypes and cell 
lines tested). 
  To support the use of the Dual-Luciferase Reporter Assay (Promega), and thence 
any downstream conclusions/ inferences made, a recent functional study on the parkin gene 
promoter  (UCS  related  neuron-specific  gene  –  refer  to  section  1.4.2)  with  reference  to   201 
sporadic Parkinson’s disease, which also employed the dual-luciferase system, will now be 
discussed (West et al. (2002)). 
  In this study, the group investigated two SNPs within the parkin core promoter and 
assayed  their  respective  promoter  activities  using  the  dual luciferase  system. The  results 
elucidated one allele (-258G) that reduced luciferase activity by the order of 25% in human 
neuroblastoma  cells,  compared  to  that  of  the  reference  allele  (-258T).  The  group  then 
subsequently  indicate,  in  a  large  population-based  series  of  cases  (n=319)  and  controls 
(n=196), that this polymorphism was associated with sporadic Parkinson’s disease. Further 
supporting functional work (EMSA) showed that the polymorphic G allele did not bind protein 
from  the  human  substantia  nigra  as  well  as  the  reference  T  allele, indicating  a  potential 
transcription factor binding deficiency. 
  This study has shown that interhaplotypic variations in the transcriptional activity of 
promoters, elucidated through the use of the dual-luciferase reporter assay, can certainly help 
uncover polymorphic alleles that are associated with disease. With particular applicability to 
UCH-L1, the target gene in this work was also a neuron-specific enzyme intricately involved in 
the UCS, and was found to have association with a neurodegenerative disease (Parkinson’s 
disease – lending considerable credence to the experimental rationale in this investigation. 
  The  next  stage  in  this  investigation  will  attempt  to  uncover  any  potential 
neurodegenerative disease association of the UCH-L1 promoter SNP alleles in an elderly 
population with associated cognitive function data. 
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3.3 Results III – Population Studies 
  The overall aim of this final result’s section was to identify if any of the reference or 
polymorphic  SNP  alleles  elucidated  in  this  study  were  associated  with  any  variation  in 
cognitive function that could be attributed to a neurodegenerative phenotype. 
The x480 MRC DNA sample set genotyped for the five UCH-L1 promoter/ 5’UTR 
SNPs that were elucidated in this study, had supplemental cognitive function data on the 
respective individuals whose DNA it included. This allowed the collated genotyping results for 
each of the SNPs to be correlated with the cognitive function data held for each individual, to 
identify  –  through  simple  statistical  analysis  –  if  any  variation  in  cognitive  function  was 
associated. 
The cohort comprised of 480 unrelated Caucasian men and women aged between 
66-75 years old, and the concordant cognitive function tests were administered in the field 
through interview. Four cognitive function tests were administered to each individual (refer to 
section 2.5.2 for further details on each of the specific tests), though two tests which were of 
particular/ increased value to this investigation were the AH4 cognitive function test which 
measured fluid intelligence - which declines with age - and the Mill Hill cognitive function test 
which measured ‘crystallised intelligence’ - which importantly does not decline with age; as a 
simple regression of the AH4 scores onto those of the Mill Hill test would allow an indication 
of cognitive decline to be ascertained. 
Alzheimer’s disease, Huntington’s disease and dementia with Lewy bodies have all 
been associated with UCH-L1 SNP alleles (section 1.3) and all realise cognitive decline as a 
main  disabling  feature  (Tang-Wai  et  al.  (2005),  Chua  &  Chiu  (2005),  Bryne  (2005)). 
Parkinson’s  disease  has  been  most  strongly  associated  with  UCH-L1  (section  1.3),  and 
although  not  regarded  as  a  major  clinical  symptom,  cognitive  decline/  dysfunction  in 
Parkinson’s disease patients is high, and has recently received much more attention in the 
field as a feature of the disease (Pai & Chan (2001)). Thence, any variation uncovered in 
cognitive decline that is associated with any of the UCH-L1 promoter SNPs elucidated in this 
study, must be seen as a potential genetic risk factor in neurodegeneration, especially when   203 
the very high risk age range (66-75 years old) of the cohort is borne in mind, in relation to age 
of onset in the vast majority of neurodegenerative disease cases.  
The cognitive function data comprises of scores attained by each individual in the four 
separate cognitive function tests, plus the AH4/ Mill Hill regression analysis. For each test/ 
analysis in cognitive function, the mean test scores for each genotype of a particular allele 
(i.e. reference homozygote, heterozygote and variant homozygote) was statistically analysed 
by two-way Analysis of Variance (ANOVA) to uncover any significant differences between 
them, which would indicate associated cognitive function variation. If any nominally significant 
differences were uncovered in any of the tests through ANOVA, a post-hoc test that would be 
applied is a Bonferroni correction (refer to section 2.5.2.6). Furthermore, confounders – such 
as smoking for example – would not be taken into account in the first instance; if nominally 
significant/ significant results were  elucidated from the initial analysis, further multi-variate 
tests  would  be  applied  to  take  such  confounders  into  consideration  (age  was  not  a 
confounder  in  this  analysis,  as  it  was  taken  into  account  by  way  of  the  AH4/  Mill  Hill 
regression analysis described above). 
  Statistical  analysis  revealed  no  significant  correlative  differences  between  the 
cognitive function mean test scores and any of the UCH-L1 allele genotypes. 
  Statistical analysis in this section was carried out by Dr Catherine Gale (MRC 
Epidemiological Centre, Southampton General Hospital). 
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Interpretation of the Statistical Analysis 
  Statistical  analysis  of  the  mean  test  scores  from  each  of  (or  indeed  part  of)  the 
cognitive function tests which had been carried out on the individuals whose DNA made up 
the x480 DNA array (and the regression work there of), indicated no significant relationships 
with  respect  to  the  five  UCH-L1  promoter  SNPs  and  the  concordant  reference/  variant 
homozygote and heterozygote genotypes. 
3.3.1 Population Genetics Discussion 
  Thence,  none  of  the  UCH-L1  promoter  SNP  alleles  investigated, in  the  statistical 
based  population  study  above,  was  seen  to  be  associated  with  any variation/  decline  in 
cognitive function.  Decline in  cognitive function  is  a  major feature  of  the  dementias,  and 
although  cognitive  dysfunction  is  also  a  feature  of  Parkinson’s  disease,  the  motor 
abnormalities – which have their pathophysiological basis in the dopaminergic neurons of the 
substantia nigra – are still the defining characteristics of Parkinson’s disease. Furthermore, of 
all  the  neurodegenerative  diseases  which  UCH-L1  is  associated,  Parkinson’s  disease 
certainly  has  the  strongest  association  in  the  literature  –  with  particular  reference  to  the 
Ile93Met  mutation  (Leroy  et  al.  (1998b))  and  the  protective  Ser18Tyr  polymorphic  allele 
(Maraganore  et  al.  (1999),  Gasser  et  al.  (1999), Wintermeyer  et  al.  (2000), Zhang  et  al. 
(2000)). Thence, despite these seemingly negative statistical results within this cohort, UCH-
L1  still  remains  a  good  candidate  gene  to  investigate  a  potential  genetic  risk  factor  for 
Parkinson’s disease. 
  Using  data  which  is  available  from  the  ‘International  HapMap  Project’ 
(www.hapmap.org),  the  linkage  disequilibrium  (LD)  blocks  that  span  the  UCH-L1  gene  in 
Caucasians could be ascertained. Analysis of these LD blocks indicates that there is some LD 
across the whole gene, though there is also some division after UCH-L1’s exon 2. Thence, 
the five promoter SNPs elucidated in this study are in a LD block with exons 1 and 2, but 
show less LD with exons 3-9, meaning that the promoter SNPs would not mark any SNPs 
downstream of exon 2 very well, which was seen to be the case with the previously reported 
exon 3 C54A SNP (Ser18Tyr polymorphism) (refer to section 3.1 above).   210 
  With particular reference to Parkinson’s disease, SNP association data from whole 
genome studies are also available from the National Institute of Neurological Disorders and 
Stroke  (NINDS)  Repository  Parkinson’s  Disease  Collection 
(http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?id=phs000003), which allowed the 
UCH-L1 region to be analysed for SNPs that were associated with the disease. From the 
analysis of the data (using Ensembl – www.ensembl.org), the one UCH-L1 SNP (rs6848261) 
that was most strongly associated with Parkinson’s disease in the UCH-L1 expanded region 
was only very weakly associated, was 15.7Mb downstream, and was thence not on the same 
LD block as the promoter SNPs elucidated in this study. 
  Data with regards to the five promoter SNPs elucidated is still lacking in these SNP 
databases available in the public domain; only the C-16T and A-307G SNPs are present on 
the  dbSNP  database,  and  the  associated  data  in  relatively  scarce  (see  section  3.1.4). 
Thence, the analysis of these SNPs as Parkinson’s disease risk alleles cannot be completed 
with the data that is currently available. However, the UCH-L1 promoter SNPs elucidated 
have been investigated with reference to the more general area of neurodegeneration and 
dementia,  with  focus  on  the  main  cognitive  decline  phenotype,  and  the  results  of  these 
analyses  have  now  focused  future  work  on  these  SNPs  toward  the  motor  dysfunction 
phenotypes associated with Parkinson’s disease – to augment the significant transcriptional 
effects that have been found in vitro and elucidate the concordant effects in vivo. 
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     A-307/6G                                    A-24G                                       C-16T              G-234A 
Figure 61 – Comparison of the nucleotide sequences at the 5’ end of the human (H) and 
Monodelphis  domestica  (M)  UCH-L1  genes  by  optimal  sequence  alignment.  Those 
nucleotides seen to be conserved are highlighted (*), and all relevant promoter architecture is 
also shown (Mann et al. (1996) – refer to Figure 10 for further description). Adapted above to 
show the positions of the five novel promoter/ 5’ UTR SNPs elucidated in this study (positions 
in relation to ATG translation start site).   213 
The adenine to guanine substitution at positions -307 and -306 (A-307G, A-306G) 
were located in a highly conserved tetra-adenine sequence, and similarly the two 5’ UTR 
SNPs – an adenine to guanine substitution at position -24 (A-24G) and a cytosine to thymine 
nucleotide change at position -16 (C-16T) – were also realised within short highly conserved 
sequences. The guanine to adenine SNP at position -234 (G-234A), though not conserved 
across species, was positioned one base pair upstream of a 59bp region of critical importance 
to the promoter’s activity (between nucleotides -233 and -147 – refer to section 1.8 for further 
explanation), and one base pair downstream of a highly conserved transcriptional motif that 
contains an inverted GATA factor binding sequence, and the ATTA core of the homeobox 
binding sites (Mann et al. (1996)), which indicates a high potential for transcription factor 
binding. The positioning of the five novel SNPs elucidated in UCH-L1’s promoter/ 5’ UTR 
indicated the potential to affect a variation in transcriptional activity, and were thus deemed 
suitable for further investigation. The three SNPs - A-307G, A-306G and G-234A - that were 
located  in  UCH-L1’s  promoter  region  (upstream  of  the  transcription  start  site),  have  the 
potential  to  effect  transcription  by  effecting  the  formation  of  the  Transcription  Initiation 
Complex  (see  Section  1.7.1.2)  by  altering  transcription  factor  recruitment  to  at  least  two 
upstream regulatory elements. The G-234A SNP could also have an impact on the critical 
59bp ‘minimal active promoter’ identified by Mann et al. (1996). The two 5’ UTR SNPs – A-
24G and C-16T – could effect the assembly of components of the TFIID complex (see Section 
1.7.1.1), which would also have an impact on UCH-L1 transcription rates. 
  The next phase of the study required information on the haplotypic distribution of the 
five  novel  SNPs,  so  that  the  common  Caucasian  haplotypes  incorporating  them  could 
ultimately be investigated for any differences in transcriptional activity realised between them. 
  Genotyping implemented through Restriction Fragment Length Polymorphism (RFLP) 
theory  and  direct  DNA  sequencing  of  the  two  DNA  sample  sets  of  unrelated  healthy 
Caucasian individuals, identified two UCH-L1 gene haplotypes governing the distribution of 
the five novel promoter/ 5’ UTR SNPs elucidated in this study. Thence, it was able to be 
concluded  that  three  common  UCH-L1  gene  promoter  haplotypes  exist  in  the  Caucasian 
population (Figure 62).   214 
Reference Homozygote 
▄                                                                                                                                                ▄ 
Haplotype 1                                                                                                                 (AAGAC) 
                        -306G                              -234A 
▄                         ↓                                       ↓                                                                            ▄ 
Haplotype 2                                                                                                                 (AGAAC) 
                 -307G                                                                                 -24G      -16T 
▄                  ↓                                                                                         ↓            ↓                    ▄ 
Haplotype 3                                                                                                                 (GAGGT) 
Figure 62 - The three UCH-L1 promoter haplotypes are diagrammatically represented with 
reference to the distribution of the five novel promoter/ 5’ UTR polymorphic alleles elucidated 
from  the  genotyping  analysis  in  this  study  (allelic  positions  not  to  scale).  Haplotype 
designations are indicated in brackets underneath and right. 
Initial genotyping results in the smaller sample set (x62 chromosomes) were also 
confirmed in the larger Caucasian DNA sample set of 480 individuals (960 chromosomes), in 
which the three promoter haplotypes elucidated above (Figure 62), were the only haplotypes 
to be realised at frequencies above 5%. In this study, 5% was designated the threshold to 
determine  a  ‘common’  haplotype  with  the  potential  to  confer  genetic  susceptibility  for 
multifactorial neurodegenerative disease prevalence (refer to section 1.6) in the Caucasian 
population. The respective haplotype frequencies were: AAGAC (reference homozygote) – 
60.1%,  AGAAC  –  15.4%,  and  GAGGT  –  7.7%  (seven  other  less  common  promoter 
haplotypes realised a combined frequency of 2.8%). 
As discussed in section 3.3.1, there is linkage disequilibrium across the promoter 
region, though there is an indication from the data available in the public domain (HapMap), 
that after exon 2 there is a division in LD blocks, which support the results obtained in section 
3.1  that  the  previously  reported  C54A  SNP  (protective  Ser18Tyr  allele)  is  not  in  linkage 
disequilibrium with the promoter SNPs associated. 
  Once the common Caucasian UCH-L1 promoter haplotypes had been identified, they 
were  incorporated  into  the  mammalian  cloning vector  pGL3  (slightly modified  to increase 
cloning strategy options) via pGEM-T Easy as a ‘holding vector’. Through (dual) luciferase   215 
reporter  assays  conducted  on  transfected  mammalian  cells,  the  pGL3  luciferase  reporter 
vector  allowed  the  transcriptional  activity  of the  three  inserted  UCH-L1  promoter/  5’  UTR 
haplotype sequences to be quantitatively compared. 
  The  transcriptional  activity  of  the  three  UCH-L1  promoter  haplotype  inserts  were 
analysed in four different mammalian cell lines – three of human origin. The only non-human 
cell line investigated was a mouse neuroblastoma/ rat basal ganglia neuron hybrid – ND-7 – 
which realised no significant differences in the transcriptional activities of the three promoter 
haplotypes. Assays conducted in human cell lines however, elucidated a significant difference 
in  the  transcriptional  activity  of  the  GAGGT  UCH-L1  promoter  (Figure  60).  In  the  A2058 
human skin melanoma cell line and the MCF-7 human breast adenocarcinoma cell line, the 
GAGGT  haplotype  realised  a  mean  increase  in  transcriptional  activity  of  44%  and  40% 
respectively,  compared  to  the  AAGAC  and  AGAAC  haplotypes.  This  increase  in 
transcriptional activity of the GAGGT haplotype was even more pronounced in human cortical 
neuronal cells (HCN-1A cell line), which unveiled a 130% increase compared to the other 
UCH-L1 promoters. Statistical analysis (employing two-way ANOVA) consistently supported 
these findings as significant.  
  These results clearly demonstrate that the -16T, -24G and -307G polymorphic alleles 
have a significant impact on the UCH-L1 promoter’s transcriptional activity in human cells in 
vitro. Furthermore, the effect of the GAGGT haplotype on transcriptional activity became more 
pronounced the closer the cell type investigated corresponded to the cells in which UCH-L1 is 
expressed in vivo, i.e. human neuronal cells. No effect was observed in the rat/ mouse ND-7 
hybrid cell line, human skin (A2058) and breast cancer (MCF-7) cell lines realised comparable 
effects  of  around  a  forty  percent  increase  in  transcriptional  activity,  whilst  the  GAGGT 
promoter haplotype brought about an increase in transcriptional activity around three times 
this in the human neuronal cell line - HCN-1A. 
  The  marked  increase  in  transcriptional  activity  brought  about  by  the  GAGGT 
haplotype’s three constituent polymorphic alleles in neuronal cells would seem to suggest that 
their effect on transcriptional activity is brought about by cis-acting sequence motif alteration, 
as trans-acting gene specific transcriptional binding factors often have a cell-type specific 
expression pattern which could well account for this large variation in transcriptional activity   216 
between the cell lines (Weinzier (1999)). This would be especially true for UCH-L1, whose 
protein  has  been  observed  to  be  completely  absent  in  non-neuronal  cell  lines  due  to 
regulation of expression at the transcriptional level (Mann et al. (1996)). Moreover, if the 
SNPs  had  affected  the  secondary  structure  or  DNA  methylation  state  of  the  UCH-L1 
promoter,  a  more  general,  cell  line  non-specific  transcriptional  effect  would  have  been 
realised, and should thus be discounted as the underlying mechanism of the observed inter-
cell-type  transcriptional  variation.  (It  should  be  noted  that  this  analysis  in  view  of  DNA 
methylation was in particular reference to the C-16T and C-24G SNPs, as the A-307G SNP is 
not located in the CpG island region identified by Mann et al. (1996) – refer to section 1.8). 
  Thence, it is proposed that the -16T, -24G and -307G polymorphic alleles effect the 
transcriptional activity of the UCH-L1 promoter by positively effecting the efficiency of the 
Transcription Initiation Complex (TIC) assembly and/ or its initiation by modifying (or indeed 
creating  new)  specific  RNA/  protein  interactions  in  view  of  transcription  binding  factor 
recruitment.  
  In  reference  to  UCH-L1’s  well  documented  association  to  Parkinson’s  disease, 
together with the novel role I have proposed for UCH-L1 at the synapse with α-synuclein 
(refer to section 1.3.6 for a discussion on UCH-L1 and review of recent literature), an increase 
in UCH-L1 transcription could be a potential route in the disease pathogenesis – through 
proportionally increasing UCH-L1 expression in neuronal cells. UCH-L1’s hypothesised role 
as an α-synuclein regulator (through its E3-like ligase activity) in the ‘SNARE protein cycle’ of 
neurotransmitter  release/  vesicle  recycling,  suggests  a  potential  pathogenic  route  for 
Parkinson’s  disease;  an  increase  in  UCH-L1  expression  would  cause  an  increase  in  α-
synuclein ubiquitination/ activation throughout life, which could ultimately lead to the ‘critical 
concentration of α-synuclein’ being exceeded (Rochet and Lansbury (2000)) when protein 
turnover  and  degradation  pathways  become  less  efficient  in  later  life,  giving  rise  to  the 
resultant protein aggregation and related cytoplasmic stresses which seem to be the acute 
pathophysiological cause of Parkinson’s disease. 
  This can basically be seen as the inverse of the biochemical route hypothesised for 
UCH-L1’s  Ser  18Tyr  variant’s  protective  effect  (in  certain  populations),  with  reduced 
ubiquitination/ activation of α-synuclein leading to a reduced build up of associated protein   217 
aggregates in later life. Concordantly with this observation, UCH-L1’s 54A polymorphic allele 
which  codes  for  the  Ser18Tyr  variant  was  also  genotyped  in  this  study  through  RFLP 
analysis, and though it was detected at a frequency of 8.1% (within a DNA sample set of 31 
unrelated healthy Caucasian individuals), it was not seen to be distributed with any of the 
UCH-L1 promoter haplotypes harbouring the novel SNPs elucidated in this study, i.e. the -
16T,  -24G  and  -307G  alleles  were  not  haplotypically  associated  with  the  ‘protective’  54A 
polymorphic allele. 
  A  further  objective  of  this  study  was  to  investigate  any  possible  association  the 
polymorphic  alleles  potentially  had  in  relation  to  neurodegenerative  symptoms.  This  was 
achieved through analysing the data obtained from the RFLP genotyping that was carried out 
on the DNA sample set composed of 480 individuals that had supplemental cognitive function 
data on each individual. Such analysis allowed each polymorphic allele to be analysed with 
respect  to  the  scores  attained  by  the  individuals  in  four  separate  tests,  each  examining 
specific areas of cognitive function. Furthermore, score comparisons from two of the cognitive 
function tests – the AH4 and Mill Hill tests – allowed any potential cognitive decline (with age) 
associated with any of the promoter polymorphic alleles to be uncovered. Cognitive decline 
with age is a symptom heavily associated with dementia, i.e. Alzheimer’s disease, Dementia 
with Lewy Bodies and Huntington’s disease – all of which have been associated with UCH-L1 
(see Section 1.6). Ergo, this phase of the study attempted to uncover any evidence that the 
UCH-L1 promoter SNPs were associated with dementia pathogenesis. Ultimately, none of the 
five  novel  UCH-L1  promoter/  5’  UTR  SNPs  elucidated  in  this  study  were  seen  to  be 
associated with any variation in cognitive function. These results suggest that the increased 
transcriptional activity observed for the GAGGT promoter haplotype does not seem to have 
any obvious, highly penetrant detrimental effects in reference to cognitive function/ decline 
with age, which indicates that this haplotype may not play a pathogenic role in dementia 
onset.  
  The cohort investigated in this study, in an attempt to elucidate any cognitive variation 
with respect to the UCH-L1 promoter SNPs, varied from those cohorts that initially identified 
UCH-L1 as an important gene in neurodegenerative diseases (refer to section 1.3), by way of 
not  having  disease  phenotypes.  The  rationale for  this  was  to  potentially  uncover  a more   218 
general association with neurodegenerative disease that would be signified by an association 
with cognitive decline; thence potentially uncovering a broader link with dementia. The cohort 
was large (n = 480) in comparison to much of the work that has already been done on UCH-
L1 with regards to more specific neurodegenerative disease investigation, and thence should 
be treated as a useful insight into the potential neuropathogenic role that UCH-L1 may play in 
the Caucasian population, as this study has certainly refocused UCH-L1 towards the more 
motor dysfunctional side of neurodegeneration – with which it has been most consistently 
associated  since  Leroy  et  al.’s  work  in  1998.  One  would  have  certainly  expected  a  well 
established  genetic  risk  factor  for  a  common  dementia  to  have  been  associated  with  a 
variation  in  cognitive  decline  in  the  cohort  studied  -  ApoE4  as  a  genetic  risk  factor  for 
Alzheimer’s for instance. 
  One of the limitations of this study was that the UCH-L1 promoter SNPs were not 
evaluated as Parkinson’s disease risk alleles, and although this would have provided a much 
clearer picture into UCH-L1’s potential pathophysiological role in the brain, especially bearing 
in mind the increased transcriptional activity uncovered in one of the promoter haplotypes, the 
fact that its association with cognitive decline has been investigated should still be regarded 
as very useful insight into one of the most abundant proteins in the brain (1-5% of total 
soluble protein). 
  The rationale that the GAGGT UCH-L1 promoter haplotype could have a pathogenic 
association with Parkinson’s disease and not dementia, can be explained by the fact that 
although  the  proposed  pathogenic  transcriptional  effect  (which  leads  to  a  hypothesised 
increase in UCH-L1 expression) would be felt throughout the neuronal cells of the brain, it 
would be more pronounced in the neurons of the substantia nigra – where UCH-L1 is already 
transcribed at higher levels (Leroy et al. (1992)). Thence, owed to a lifetime of increased α-
synuclein  ubiquitination/  activation  at  the  synapse,  any  damaging  neuronal  effects  of  α-
synuclein/ protein aggregation brought about by this hypothesised pathogenic model in later 
life, would be realised in the neurons of the substantia nigra before they made an impact 
anywhere else in the brain – thus effecting the control of voluntary movement (which this 
region of the brain facilitates) in the first instance - as seen in Parkinson’s disease.   219 
  This  thesis  has  outlined  the  pathogenic  models  in  which  both  coding  region  and 
promoter/ 5’ UTR sequence variations could potentially give rise to the cytoplasmic stresses 
upon the neurons of the substantia nigra, which in turn bring about the symptoms seen in 
Parkinson’s disease. The effect of coding region polymorphisms are easy to track through the 
processes of transcription and translation, as the change in UCH-L1’s amino acid sequence 
allows one a straightforward insight. The effects of polymorphic variations within the promoter 
region/ 5’ UTR of a gene however, are not so easy to determine in vivo owed to the different 
levels of post-transcriptional control available to a cell. The pathogenic model for the –307G, -
24G and –16T polymorphic promoter/ 5’ UTR alleles described in this thesis, relies upon the 
increase in transcription – which they certainly bring about in vitro – to be mirrored with an 
increase in the protein’s translation in vivo. 
  Transcriptional control is by far the most basic and thus effective form of control a cell 
can  have  on  the  production  of  a  particular  protein  –  and  is  concordantly  also  the  most 
common (Mata et al. (2005)) – for without the mRNA transcript no protein can be synthesised, 
and  inversely,  more  transcript  generally  gives  rise  to  more  protein  (Beyer  et  al.  (2004)). 
However,  eukaryotic  cells  have  evolved  a  variety  of  methods  that  can  regulate  gene 
expression post transcription-rate regulation. These all centre around the processing, export, 
localisation,  turnover,  stability  and  translation  of  the  transcript  mRNAs  by  various 
combinations  of  RNA-binding  proteins,  which  add  substantial  complexity to  the  control  of 
gene expression (Mata et al. (2005)).  
  Regulation of mRNA stability is one widespread and common method of controlling 
transcript levels via several different exonucleolytic or endonucleolytic pathways (Parker and 
Sang (2004)). Decay rates can be specified by control or AU-rich elements that are usually 
located  within  the  3’  UnTranslated  Regions  (UTR)  and  are  recognised  by  various  RNA-
binding proteins (Parker and Sang (2004)). Though it is possible that UCH-L1’s 3’ UTR region 
could contain a control element that would effect its mRNA pre-translation stability, work done 
by Yang et al. (2003) does seem to suggest that transcripts encoding vital proteins – such as 
UCH-L1 – would have long half lives; making it markedly stable, when its relatively short 
nucleotide length is borne in mind.    220 
  Another level of post-transcriptional control takes place during translation, specifically 
the  multi-step,  rate-limiting  process  of  translation  initiation.  Transcript-specific  regulation 
involves  RNA-binding  proteins  that  associate  with  particular  structural  features  in  target 
transcript UTRs (Mata et al. (2005)) – in much the same way as outlined for mRNA decay. 
UCH-L1’s  3’  UTR may  well  harbour  such  control  elements,  and is  certainly  worth further 
investigation, though its relatively short UTR nucleotide length does make the chances of any 
critical control mechanism being present in this capacity more unlikely. The same rationale 
would also be applied to other control processes involving RNA-binding proteins that could 
alter UCH-L1 mRNA through its potential processing, export or localisation. Length of mRNA 
also  effects  more  ‘global’  regulation  of  translation,  by  inversely  effecting  the  density  of 
ribosomes,  i.e.  it  has  been  shown  that  long  transcripts  seem  to  have  reduced  ribosome 
density, which seems to be caused by less efficient translation initiation – though the reason 
for this remains unclear (Arava et al. (2005)). Ergo, this finding seems to suggest that shorter 
transcripts – such  as UCH-L1 mRNA – would be less likely to be effected by translation 
initiation limitations owed to a reduction in ribosomal density. 
  Though  post-transcriptional  regulation  is  an  established  multi-level  route  whereby 
cells  can  control the  expression  of  certain  genes,  a  wide-ranging  recent  report  does  still 
suggest  that  there  is  a  significant  whole  genome  correlation  between  absolute  transcript 
abundance, and translational efficiency in steady state conditions (Beyer et al. (2004)).  
It is my contention that although post transcriptional regulation of UCH-L1 should not 
to be discounted, neither should it be overstated in view of theoretically negating any increase 
in the UCH-L1 protein. 
In summary, it is my contention that, the increased transcriptional activity of UCH-L1’s 
GAGGT  promoter  haplotype  ascertained from  the  (dual) luciferase  expression  analysis  in 
human cell lines, interpreted with reference to the novel pathogenic model of Parkinson’s 
disease proposed in this thesis, certainly warrants further investigation as a potential genetic 
risk factor for sporadic Parkinson’s disease. 
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5 Future Work 
In view of the potential pathogenic route towards Parkinson’s disease elucidated in 
this study, with reference to the increased transcriptional activity brought about by the -16T, -
24G and -307G polymorphic alleles upon UCH-L1’s promoter, potential association of these 
SNPs with Parkinson’s disease must be investigated. The methodology employed could take 
the form of the RFLP genotyping strategies outlined in this investigation within DNA sample 
sets of sporadic Parkinson’s disease suffers. 
This study seemed to indicate that the increased transcriptional activity of the UCH-
L1 GAGGT promoter haplotype was caused by one or more alterations in the binding of 
transcription  factors,  which  positively  effected  the  efficiency  of  the  Transcription  Initiation 
Complex (TIC) assembly/ initiation. Investigative work should now be carried out to confirm 
any change in UCH-L1 promoter/ protein binding which would support this hypothesis. An 
Electrophoretic Mobility Shift Assay (EMSA) could not only uncover any variations in protein 
binding between the haplotypes, it could also specifically examine any changes in protein 
binding  realised  between  the  reference  homozygote  and  polymorphic  alleles  for  each 
individual SNP. DNase 1 Footprinting could also be similarly used to elucidate any differences 
in DNA-protein interaction between the haplotypes. 
  Furthermore, whether or not an increase in UCH-L1 mRNA transcript brings about 
concordant increases in UCH-L1 protein within neuronal cells has not yet been confirmed, as 
post-transcriptional  regulation  could  somehow  stabilise  intracellular  UCH-L1  at  a  certain 
concentration  -  buffering  any  increase  in  transcriptional  rate.  The  influence  of  post-
transcriptional  gene  regulation  could  be  established  through  post  mortem  neuronal  tissue 
analysis  of  UCH-L1  protein  levels  in  those  individuals  harbouring  the  GAGGT  promoter 
haplotype,  compared  to  those  individuals  carrying  the  AGAAC  or  reference  homozygote 
UCH-L1  haplotypes.  This  would  thus  confirm  that  the  increase  in  transcriptional  activity 
brought about by the GAGGT haplotype, gives rise to an increase in UCH-L1 protein in vivo. 
  Though the investigation discussed above would be a very effective route to directly 
determine the role of post-transcriptional regulation for UCH-L1 in vivo, the reality of securing   222 
the  methodology’s  required  resources  may  prove  difficult.  Thence,  simpler,  less  resource 
consuming in vitro methodologies must be discussed. UCH-L1 protein expression analysis 
from neuronal tissue culture could provide an effective in vitro route to determine whether the 
GAGGT haplotype brings about an increase in UCH-L1 protein compared to the two other 
promoter haplotypes elucidated in this study.  
The presence of any 3’UTR control elements in post-transcriptional regulation (most 
likely region in which these control elements would  be present – refer to section 4 for a 
discussion)  of  UCH-L1  could  also  be  investigated.  UCH-L1  sequence  could  be  cross-
referenced for known post-transcriptional control elements, and if present, UCH-L1 sequence 
mutants could be constructed that lack these elements, which could then be investigated to 
determine  whether  any  change  in  protein  expression  results,  compared  to  that  of  the 
reference homozygote 3’UTR sequence. 
Moreover, similar to the approach and methodology used in this thesis, further SNP 
screening  work  could  take  place  in  UCH-L1’s  3’UTR,  in  which  any  polymorphic  alleles 
elucidated could be genotyped within Parkinson’s disease DNA sample sets, to establish any 
association. This, in addition to the RFLP genotyping work for the –16T, -24G and –307G 
polymorphic alleles within Parkinson’s disease sample sets already set out in this section, 
would give a more complete overview of any potential association of the UCH-L1 gene in 
Parkinson’s disease. 
With  the  transcription  of  UCH-L1  still  in  mind,  the  fact  that  its  13kb  transcript  is 
present in the substantia nigra at higher levels than else where in the brain (Leroy et al. 
(1992)),  indicates  that the  neurons  of  the  substantia  nigra  would  be  a  good investigative 
target to uncover the route by which increased UCH-L1 transcription is actually brought about 
in vivo. Elucidation of such in vivo methods of increasing UCH-L1’s transcription rate, would 
not only provide a clearer understanding of UCH-L1 transcriptional regulation, but it may also 
impart valuable information for any potential future putative therapy that involved targeting 
neuronal  UCH-L1  levels  in  the  control  of  neurodegeneration  in  Parkinson’s  disease  (see 
below).   223 
The true role of UCH-L1 in neurons is far from clear. Further in vitro work in neuronal 
cells  is  required  to  confirm  its  potential  role  as  an  E3-like  ‘ubiquitinator’/  activator  of  α-
synuclein at the synapse. What would be of immediate interest, in view of the hypothesised 
pathogenic model of Parkinson’s disease onset put forward in this study, is whether synaptic 
α-synuclein levels proportionally rise as UCH-L1 expression levels are increased in human 
neuronal cells. 
Furthermore, with reference to the hypothesised basis put forward in this thesis (refer 
to section 1.3.6) of the documented protective effect brought about by the Ser18Tyr UCH-L1 
mutant in certain populations, it would also be important to establish whether carriers of the 
polymorphic allele do actually realise a decreased level of SNARE complex associated neural 
activity throughout life. 
From what has been discussed and put forward in this thesis regarding Parkinson’s 
disease pathogenesis involving UCH-L1, a theoretically valid and potentially effective target 
for Parkinson’s disease therapy becomes apparent. It has been shown that a polymorphic 
variation  in  UCH-L1’s  coding  region  can  protect  against  Parkinson’s  disease  in  certain 
populations  (Maraganore  et  al.  (1999),  Zhang  et  al.  (2000),  Satoh  et  al.  (2001)  & 
(Wintermeyer et al. (2000) – refer to section 1.3.2), and this seems to be associated with the 
polymorphic  protein’s  reduced  ligase  activity  (Liu  et  al.  (2002)).  Thence,  any  therapeutic 
strategy that can effect a similar change in UCH-L1’s ligase enzyme kinetics, would have a 
good theoretical basis of providing a similar protective effect to an individual. Potential targets 
for such a therapeutic strategy, could take the form of repressing UCH-L1’s transcription – if 
indeed elevated UCH-L1 levels are found to be a major risk factor. Though, as discussed 
above,  the  specifics  of  neuronal  UCH-L1  transcriptional  regulation  need  to  be  more  fully 
elucidated before this can be attempted. Therapeutic strategies could also potentially target 
UCH-L1’s  as  yet  unknown  post-transcriptional  regulatory  mechanisms  (if  any  are  indeed 
present),  i.e.  investigations  outlined  above  could  uncover  3’UTR  translational  control 
elements within the UCH-L1 gene, which could thus be biochemically targeted. 
However, before such potential therapies can be administered, genetic predisposition 
to Parkinson’s disease must be identified and confirmed, so that those individuals at risk can   224 
be  quickly  and  easily  identified  through  genetic  screening;  the  outcome  of  any  further 
research investigating the association of UCH-L1’s GAGGT gene promoter haplotype will be 
eagerly anticipated. 
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              Exon 1>                         
CTCCGCGAAGATGCAGCTCAAGCCGATGGAGATCAACCCCGAGGTGAGCGCCAGGTGC
ACCGCTACCCGGAGAGCGCGAGGCCGAGGGAGGGGGAGCCGAGTCGCTGATCGGTTC 
                                                                    Exon 2> 
GGTTTTGCCTTTTTCTTTGCATTTGCCTTTCAGATGCTGAACAAAGTGAGTGGCGTCTCG 
                                                                           <CTACGACTTGT TTCACTCACC<P1 
CGCCGTCTCTGGCCCCCTCCCCCGCGAGCGCCGAGGCGGGGGCGCCCACCGGTTCCG 
                                                                                                                                      <AAGGC 
GCTGCTGGCAGGGACCAAGCCGCCCGCTGCGAGCACCGGAGACGGCCGGGCTGGGG 
CGACGACCGTCCCTG<E1/2b 
CGTGGGCTGGGCGCAGCACAGACTCGGCTGCACGGGCTTCGCGGGCGCCACGTGTGG 
GCCGCGCTTTGTGCTGTGTCATTGCGCCGGCCCGGGTGGGGGTGGCAGGGCGGGACT 
     E3a>GCTTTGTGCTGTGTCATTGC> 
GGGGCTCCTCCCAGGCTCGGGTGCGGGCGCGGAGGGCGCGCGCCTCCTGGCCCCGC
CCCCTGGCAGGTGCCCGCGACCCGCGTGTCCCCGTGCGCCTGGCCGCCTTGTCTCCTC 
 Exon 3> 
TCCGCAGGTGCTGTCCCGGCTGGGGGTCGCCGGCCAGTGGCGCTTCGTGGACGTGCT 
                           C54A (S18Y) 
GGGGCTGGAAGAGGAGTCTCTGGGCTCGGTGCCAGCGCCTGCCTGCGCGCTGCTGCT
GCTGTTTCCCCTCACGGCCCAGGTAGGGCGTGGGGCCCAGGATGCGCCGGCCGCCGG
CAGTGCACGCCGCTCCCCAGCTTGAGTCCTCGGGGTAGTTGGTAGAACTCATGTGCTG 
                  <CGGCGAGGGGTCGAACTC<E3b                                           Exon 4> 
CCATCTGTTCTTTGCACTTTCATTCTGAGATGTAAAAACGCTTTTTACATTCGCAGCATGA 
                    E4a>TGCACTTTCATTCTGAGATG> 
GAACTTCAGGAAAAAGCAGATTGAAGAGCTGAAGGGACAAGAAGTTAGTCCTAAAGTGT
ACTTCATGAAGCAGACCATTGGGAATTCCTGTGGCACAATCGGACTTATTCACGCAGTG
GCCAATAATCAAGACAAACTGGGATTTGGTAGGTGTGGGTTTTGAGGCCAGCCATCCTA 
            C277G (I93M)                                                          <CAAAACTCCGGTCGGTAG<E4b 
AGCTTGAACTTGAAACATGGAGTTCAGAAACAGCTGTTTATCCACAACCCTGGAGGCAGT 
ATTAAAGATTCAGGTTGCTCAGCATGTTCAGCAAAGGCTTAAGTCAACAATAAATATGTAC 
               E5/6a>AGGTTGCTCAGCATGTTCAG>     Exon 5> 
CCACTTGTATTATTTTACCTATACTAACACATCCATTTTTTTTTTAAGAGGATGGATCAGTT 
CTGAAACAGTTTCTTTCTGAAACAGAGAAAATGTCCCCTGAAGACAGAGCAAAATGCTTT 
GAAAAGAATGAGGTAAGAGAACTTACAGAGCATGGCCTTTAAATAACTCTAGAGATTTTT 
                                                Exon 6> 
GTGCTAATTATTTTCTTTTTTCCGCAGGCCATACAGGCAGCCCATGATGCCGTGGCACAG
GAAGGCCAATGTCGGGTAAATGCAAATACAAATCGGAGCCAGGCTGCCTGGGTGCCAT 
                                                                                                                                    <CGGTA 
CTGTGTTTCTACTGAAATTGTGCAGGAATCTCTTACTGGAACCTCATAGAGTTGTTCTGA 
GACACAAAGATGAC<E5/6b 
CAGTTAACAGTATATTTACCTTAGTGGGCTTAGAATAGGGCTTAATGTAAGACATACATTA 
                                     E7a>CTTAGTGGGCTTAGAATAGG>  
AATATTAGCTATAATTTCTAAAAATCAAGTCAGTTCAAGCACATTTCACTTGAATTGCAAG 
                                                                                                                   Exon 7> 
ATAATTTTTAAAATACAGCTTACACTCATTTTCAAAAATTTCTTGACTTTCTTTAGGTAGAT 
GACAAGGTGAATTTCCATTTTATTCTGTTTAACAACGTGGATGGCCACCTCTATGAACTTG
GTATGTTTTACTCCATTTTTGGAACCCAGTGTAGTTTCATGTGTTCTTTCAGACTGAATTT
CTCTTGATATATTGTGTGACTTTATGGCACTTGGCATATCATTGTTTATAAAGCCACAATA
ACAAAGTATTCTCATGAGGGCACTTAACCCCTTATCTGTGGGTTTGGCAGTGGTTTTTGG 
          <CATAAGAGTACTCCCGTGAA<E7b 
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AAGAATCTAAAACTTCCATCTAGGCTAGGTAAGCACGGTAGCCAGAAAACATGCAGAGA 
                                E8a>ATCTAGGCTAGGTAAGCACG> 
                                                        Exon 8> 
AAATTGACATGCCTGGCTTCTTTGTTACAGATGGACGAATGCCTTTTCCGGTGAACCATG
GCGCCAGTTCAGAGGACACCCTGCTGAAGGTCATCTTTGGAATGCATCTCTTCTTAATGT
GCCTCACAATTCTTTGGCTAAATTTTCTATTCTAAAGTGCTAACACTCTTCCAGTATAGCC 
                                                                                                          <GAGAAGGTCATATCGG 
AGCATCAGTTGCCTGGGTTAATAGCAGTCTTTAGGGTGAACTTTGAGCATTAATAGACCT 
TCGT<E8b 
TGGAGCCTTTCCCTATGTGACTTTCATTTTGAGCTCTTGCTGTTTGGATTTTAATGACATT 
>GGAGCCTTTCCCTATGTGAC>E9a 
            Exon 9> 
TCTCCTTTCCAGGACGCTGCCAAGGTCTGCAGAGAATTCACCGAGCGTGAGCAAGGAGA
AGTCCGCTTCTCTGCCGTGGCTCTCTGCAAGGCAGCCTAATGCTCTGTGGGAGGGACTT
TGCTGATTTCCCCTCTTCCCTTCAACATGAAAATATATACCCCCCCATGCAGTCTAAAATG
CTTCAGTACTTGTGAAACACAGCTGTTCTTCTGTTCTGCAGACACGCCTTCCCCTCAGCC
ACACCCAGGCACTTAAGCACAAGCAGAGTGCACAGCTGTCCACTGGGCCATTGTGGTGT
GAGCTTCAGATGGTGAAGCATTCTCCCCAGTGTATGTCTTGTATCCGATATCTAACGCTT
TAAATGGCTACTTTGGTTTCTGTCTGTAAGTTAAGACCTTGGATGTGGTTTAATTGTTTGT 
                                                                    <CAATTCTGGAACCTACACCA<E9b 
CCTCAAAAGGAATAAAACTTTTCTGCTGATAAGATAGCCACAGCTGATTCTCATTTTCTTT 
TACCCTCTCCTCAATATGTCAGG………...... 
Figure 63 – Displays UCH-L1’s promoter and coding regions with PCR primer sequences 
adhered (primer sequences are indicated directly below the relevant UCH-L1 sequence – 
sense primers in >blue>, and anti-sense primers in <green< (refer to section 2.1). UCH-L1 
exons are underlined and labelled above the 5’ end. Sequences not relevant to UCH-L1’s 
promoter or coding regions, i.e. intronic regions, are not represented. Major sites within the 
sequence are indicated in larger, bold font; UCH-L1’s TATA box, transcription start site (a 
guanine residue), ATG start codon (Exon 1) and TAA stop codon (Exon 9). Also, documented 
UCH-L1 single nucleotide polymorphisms (SNPs) are highlighted in red, with their sequence 
position and base change displayed immediately below.  
- Intronic nucleotide distances for UCH-L1 are as follows: intron 1 – 105bp, intron 2 – 463bp, 
intron 3 – 2700bp, intron 4 – 950bp, intron 5 - 75bp, intron 6 – 1300bp, intron 7 800bp and 
intron 8 - >200bp. 
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6.3 Initial Cloning Strategy Results 
- All three UCH-L1 promoter/ 5’ UTR haplotype PCR bands were successfully amplified:- 
 
Figure 66 – MADGE gel clearly showing all three haplotype PCR bands at the required size 
(~1 Kb). Alternate wells display 1 Kb DNA ladders (refer to section 3.4.1.2), with the 1 Kb 
band clearly marked and denoted in red. 
*(The  KPN  I  and  Bgl  II  restriction  sites  were  also  confirmed  through  DNA  sequencing 
(electropherograms not shown)). 
 
 
 
 
 
      ←1 
Kb 
    1 Kb 
→ 
AAGAC 
GAGGT 
AGAAC   236 
6.5 Stock Solutions/ Preparations 
6.5.1 PCR 
- PCR Buffer (x 10, 200mM Tris-HCl, 500mM KCl) (Invitrogen) 
- dNTPs (8 mM) (Invitrogen) 
- MgCl2 (25 mM) (Invitrogen) 
- DNA Taq Polymerase (5 units/  l) (Invitrogen) 
- Betaine (5M) - 5.86g Betaine (Sigma) in 10ml deionised water. 
6.5.2 Polyacrylamide Gel Related 
6.5.2.1 Gel Plate Preparation  
- Methanol (BDH Laboratory Supplies) 
- Sticky Silane – 495ml Ethanol (Fisher) 
                         - 2.5ml Glacial acetic acid (BDH Laboratory Supplies) 
                         - 2.5ml Methacryloxypropylthimethoxy-silane (Fisher) 
6.5.2.2 Gel Preparation 
30% Acrylamide (Severn Biotech)  
- TBE (10x) - 108g Tris Base (Sigma) 
                    - 55g Orthaboric acid (BDH Laboratory Supplies) 
                    - 93g EDTA (BDH Laboratory Supplies) 
   (Made up to 1000ml with deionised water.) 
- Ammonium Persulphate Solution 25% (25% APS) 
- 2.5g Ammonium persulphate powder (Fisher) in 10ml deionised water. 
- Ethidium bromide (Sigma)  
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6.5.2.3 Gel Running 
- MADGE Loading Dye - 980 l Deionised formamide (Sigma) 
                                           - 200 l 0.5M Ethylenediaminetetraacetic acid disodium salt 
                                                     - 186.12g EDTA (BDH Laboratory Supplies) in 1000ml diH20 
                                           - 0.025% Xlene cyanol ff (Sigma) – as required. 
                                           - 0.025% Bromophenol blue (Sigma) – as required.  
                                                              (Made up to 10ml with deionised water.) 
6.5.3 dHPLC Buffers 
- Buffer A (0.1M Triethylammonium acetate (TEAA) - 50ml TEAA (2M – Transgenomic) 
                                                                                       - 250 l Acetonitrile (Aldrich) 
                                                                                       - Made up to 1000ml with HPLC diH20 
- Buffer B (0.1M TEAA and 250ml acetonitrile (25%)) - 50ml TEAA (2M – Transgenomic) 
                                                                                         - 250ml Acetonitrile (Aldrich) 
                                                                                        - Made up to 1000ml with HPLC diH20 
- Buffer C (75% Acetonitrile cleaning solution) - 750ml Acetonitrile (Aldrich) 
                                                                               - Made up to 1000ml with HPLC diH20 
- Buffer D (Syringe wash solution – 8% Acetonitrile) - 80ml Acetonitrile (Aldrich)  
                                                                                        - Made up to 1000ml with HPLC diH20 
6.5.4 DNA Sequencing Related 
- Shrimp Alkaline Phosphatase (SAP) (Promega) 
- SAP Buffer (Promega) 
- Exonuclease I (Exo I) (Promega) 
- Big Dye Terminator Ready Reaction Mix (ABI) 
- Sequencing Buffer (ABI) 
- 95% Ethanol (Fisher) 
- 70% Ethanol (diluted with deionised water from Fisher stock) 
- Alconox (Aldrich) 
- Additional Chemicals Used in the Preparation of the Gel Mixture: 
- 10% 6M Urea (Amresco)    238 
- Ammonium Persulphate Solution 10% (10% APS) 
- 1.0g Ammonium persulphate powder (Fisher) in 10ml deionised water. 
- N, N, N', N'-Tetramethyl-1-, 2-diaminomethane (TEMED) (Sigma) 
- Sequencing Loading Buffer 
- 1 part 25mM Ethylenediaminetetraacetic acid disodium salt (EDTA) (BDH Lab Supplies) 
- 5 parts deionised Formamide (Sigma) 
-  Blue Dextran (Applied Biosystems) – as required 
 
- Other Restriction Digest Related Chemicals: 
- 10 x Bovine Serum Albumin (BSA) (Invitrogen) 
- Calf Intestinal Alkaline Phosphatase (CIAP) (Promega) 
6.5.5 Agarose Gel Related 
6.5.5.1 Gel Preparation 
- Agarose powder (GibcoBRL) 
- TAE (1x) - 242g Tris base (Sigma) 
                 - 57.1ml Glacial acetic acid (BDH Laboratory Supplies) 
                 - 100ml 0.5M EDTA (see above) 
                            (Made up to 1000ml with deionised water.)  
- Modified TAE (1x) - 48.25g Tris base (Sigma) 
                                 - 11.42ml Glacial acetic acid (BDH Laboratory Supplies) 
                                 - 0.372g EDTA (BDH Laboratory Supplies) 
                                      (Made up to 500ml with deionised water) 
6.5.5.2 Gel Running 
- Orange G Loading Dye – 5ml Glycerol (BDH Laboratory Supplies) 
                                           - 1ml 0.5M EDTA (see above) 
                                           - 1ml 2% Orange G (Sigma) 
                                           - 0.1ml 10% Lauryl sulfate sodium salt (SDS) (BDH Lab. Supplies) 
                                                               (Made up to 10ml with deionised water.)  
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6.5.9.3 Additional Post Ligation Media 
- SOC recovery medium (Promega)  
6.5.10 Mammalian Cell Culture 
6.5.10.1 Solutions Related to Propagation Methodology (Passaging) 
- 0.25% (w/v) Trypsin-0.53mM EDTA solution (Sigma) 
- 70% Ethanol (diluted with deionised water from 95% Fisher stock) 
6.5.10.2 Transfection Related Chemicals 
- Serum free medium – animal free protein, without L-glutamine (Sigma)  
GeneJuice (Merck Biosciences) – Theory: 
   Whereas many available transfection reagents are based on cationic lipid formulation, 
GeneJuice  Transfection  Reagent  is  composed  of  a  nontoxic  cellular  protein  and  a  small 
amount of a novel polyamine. GeneJuice Transfection Reagent provides highly efficient DNA 
transfer in both stable and transient transfection of eukaryotic cells. The unique chemistry 
provides the advantage of compatibility with both serum-containing and serum-free media, 
and makes media changes unnecessary. 
6.5.10.3 Dual Luciferase Reporter Assay Buffer Preparation (Promega) 
- Passive Lysis Buffer 
  -  4 volumes  of  Distilled Water  to  1 volume  of the  Buffer  of  Phosphate  Buffered  Saline 
(Promega). 
- Luciferase Assay Buffer II 
  - The lyophilised Luciferase Assay Substrate powder (Promega) was added to the 10ml of 
supplied Luciferase Assay Buffer II (Promega).  
- Stop and Glo Buffer  
  -  1  volume  of  Stop  and  Glo  Substrate  (x50  concentrate)  (Promega)  was  added  to  50 
volumes of the supplied Stop and Glo Buffer (Promega).   242 
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